Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

The registrant had ~~164,495,833~~165,163,689 shares of common stock, $0.01 par value, outstanding at ~~October 29, 2020.~~July 26, 2021.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019			2021			2020			2021			2020
Net sales	$	1,233		$	1,390		$	3,631		$	4,173		$	1,655		$	1,093		$	3,091		$	2,398
Cost of goods sold		976			1,096			2,877			3,260			1,391			894			2,530			1,901
Gross profit		257			294			754			913			264			199			561			497
Selling, general, and administrative expense		112			130			347			423			172			110			310			235
Research and development expense		22			20			67			61			27			20			51			44
Restructuring, asset-related, and other charges		9			34			37			49			5			17			0			28
Total other operating expenses		143			184			451			533			204			147			361			307
Equity in earnings of affiliates		4			9			19			25			10			7			20			14
Interest expense, net		(53	)		(53	)		(160	)		(156	)		(47	)		(53	)		(97	)		(107	)
Other (expense) income, net		(5	)		25			(6	)		81
Other income (expense), net														21			14			21			(1	)
Income before income taxes		60			91			156			330			44			20			144			96
(Benefit from) provision for income taxes		(16	)		15			(44	)		65
Benefit from income taxes														(22	)		(4	)		(17	)		(28	)
Net income		76			76			200			265			66			24			161			124
Net income attributable to Chemours	$	76		$	76		$	200		$	265		$	66		$	24		$	161		$	124
Per share data
Basic earnings per share of common stock	$	0.46		$	0.46		$	1.22		$	1.60		$	0.40		$	0.15		$	0.97		$	0.75
Diluted earnings per share of common stock		0.46			0.46			1.21			1.58			0.39			0.15			0.95			0.75

	Three Months Ended September 30,																		Three Months Ended June 30,
	2020									2019									2021									2020
	Pre-tax			Tax			After-tax			Pre-tax			Tax			After-tax			Pre-tax			Tax			After-tax			Pre-tax			Tax			After-tax
Net income	$	60		$	16		$	76		$	91		$	(15	)	$	76								$	66								$	24
Other comprehensive income (loss):
Hedging activities:
Unrealized (loss) gain on net investment hedge		(32	)		8			(24	)		33			(8	)		25
Unrealized (loss) gain on cash flow hedge		(2	)		0			(2	)		5			(1	)		4
Unrealized loss on net investment hedge																			$	(13	)	$	3			(10	)	$	(18	)	$	4			(14	)
Unrealized loss on cash flow hedge																				(1	)		—			(1	)		(4	)		1			(3	)
Reclassifications to net income - cash flow hedge		(1	)		0			(1	)		(2	)		0			(2	)		2			—			2			(2	)		—			(2	)
Hedging activities, net		(35	)		8			(27	)		36			(9	)		27			(12	)		3			(9	)		(24	)		5			(19	)
Cumulative translation adjustment		59			0			59			(68	)		0			(68	)		36			—			36			39			—			39
Defined benefit plans:
Additions to accumulated other comprehensive loss:
Net gain		1			0			1			—			0			0
Prior service cost		(1	)		0			(1	)		—			0			0
Curtailment gain		4			(1	)		3			—			0			0
Effect of foreign exchange rates		(3	)		0			(3	)		9			0			9			(2	)		—			(2	)		(2	)		—			(2	)
Reclassifications to net income:
Amortization of actuarial loss		2			(1	)		1			6			(1	)		5			2			—			2			2			(1	)		1
Amortization of prior service gain		(1	)		0			(1	)		(1	)		0			(1	)		(1	)		—			(1	)		(1	)		—			(1	)
Settlement loss		1			0			1			3			0			3
Defined benefit plans, net		3			(2	)		1			17			(1	)		16		$	(1	)	$	—			(1	)	$	(1	)	$	(1	)		(2	)
Other comprehensive income (loss)		27			6			33			(15	)		(10	)		(25	)
Other comprehensive income																										26									18
Comprehensive income		87			22			109			76			(25	)		51									92									42
Comprehensive income attributable to Chemours	$	87		$	22		$	109		$	76		$	(25	)	$	51								$	92								$	42


	Nine Months Ended September 30,																		Six Months Ended June 30,
	2020									2019									2021									2020
	Pre-tax			Tax			After-tax			Pre-tax			Tax			After-tax			Pre-tax			Tax			After-tax			Pre-tax			Tax			After-tax
Net income	$	156		$	44		$	200		$	330		$	(65	)	$	265								$	161								$	124
Other comprehensive income (loss):
Hedging activities:
Unrealized (loss) gain on net investment hedge		(40	)		10			(30	)		36			(9	)		27
Unrealized (loss) gain on cash flow hedge		(4	)		1			(3	)		7			(1	)		6
Unrealized gain (loss) on net investment hedge																			$	24		$	(6	)		18		$	(8	)	$	2			(6	)
Unrealized gain (loss) on cash flow hedge																				3			(1	)		2			(2	)		1			(1	)
Reclassifications to net income - cash flow hedge		(5	)		1			(4	)		(8	)		1			(7	)		4			(1	)		3			(3	)		—			(3	)
Hedging activities, net		(49	)		12			(37	)		35			(9	)		26			31			(8	)		23			(13	)		3			(10	)
Cumulative translation adjustment		(19	)		0			(19	)		(45	)		0			(45	)		(34	)		—			(34	)		(78	)		—			(78	)
Defined benefit plans:
Additions to accumulated other comprehensive loss:
Net gain (loss)		1			0			1			(3	)		0			(3	)
Prior service (cost) benefit		(1	)		0			(1	)		5			0			5
Curtailment gain		4			(1	)		3			—			0			0
Effect of foreign exchange rates		(4	)		0			(4	)		10			0			10			2			—			2			(1	)		—			(1	)
Reclassifications to net income:
Amortization of actuarial loss		6			(1	)		5			18			(4	)		14			4			(1	)		3			4			—			4
Amortization of prior service gain		(2	)		0			(2	)		(2	)		0			(2	)		(2	)		—			(2	)		(1	)		—			(1	)
Settlement loss		1			0			1			4			(1	)		3
Defined benefit plans, net		5			(2	)		3			32			(5	)		27		$	4		$	(1	)		3		$	2		$	—			2
Other comprehensive (loss) income		(63	)		10			(53	)		22			(14	)		8
Other comprehensive loss																										(8	)								(86	)
Comprehensive income		93			54			147			352			(79	)		273									153									38
Comprehensive income attributable to Chemours	$	93		$	54		$	147		$	352		$	(79	)	$	273								$	153								$	38

	September 30, 2020			December 31, 2019			June 30, 2021			December 31, 2020
Assets
Current assets:
Cash and cash equivalents	$	956		$	943		$	1,139		$	1,105
Accounts and notes receivable, net		572			674			802			511
Inventories		993			1,079			1,046			939
Prepaid expenses and other		84			81			60			78
Total current assets		2,605			2,777			3,047			2,633
Property, plant, and equipment		9,391			9,413			9,668			9,582
Less: Accumulated depreciation		(5,973	)		(5,854	)		(6,220	)		(6,108	)
Property, plant, and equipment, net		3,418			3,559			3,448			3,474
Operating lease right-of-use assets		264			294			230			236
Goodwill and other intangible assets, net		169			174
Goodwill, net								153			153
Other intangible assets, net								9			14
Investments in affiliates		182			162			178			167
Other assets		310			292			414			405
Total assets	$	6,948		$	7,258		$	7,479		$	7,082
Liabilities
Current liabilities:
Accounts payable	$	701		$	923		$	1,061		$	844
Compensation and other employee-related cost								113			107
Short-term and current maturities of long-term debt		32			134			25			21
Current environmental remediation								154			95
Other accrued liabilities		575			484			321			375
Total current liabilities		1,308			1,541			1,674			1,442
Long-term debt, net		4,063			4,026			3,964			4,005
Operating lease liabilities		213			245			188			194
Long-term environmental remediation								402			295
Deferred income taxes		34			118			55			36
Other liabilities		596			633			296			295
Total liabilities		6,214			6,563			6,579			6,267
Commitments and contingent liabilities
Equity
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 189,772,210 shares issued and 164,452,975 shares outstanding at September 30, 2020; 188,893,478 shares issued and 163,574,243 shares outstanding at December 31, 2019)		2			2
Treasury stock, at cost (25,319,235 shares at September 30, 2020 and December 31, 2019)		(1,072	)		(1,072	)
Common stock (par value $0.01 per share; 810,000,000 shares authorized; 191,115,609 shares issued and 165,373,101 shares outstanding at June 30, 2021; 190,239,883 shares issued and 164,920,648 shares outstanding at December 31, 2020)								2			2
Treasury stock, at cost (25,742,508 shares at June 30, 2021; 25,319,235 and December 31, 2020)								(1,087	)		(1,072	)
Additional paid-in capital		879			859			920			890
Retained earnings		1,325			1,249			1,381			1,303
Accumulated other comprehensive loss		(402	)		(349	)		(318	)		(310	)
Total Chemours stockholders’ equity		732			689			898			813
Non-controlling interests		2			6			2			2
Total equity		734			695			900			815
Total liabilities and equity	$	6,948		$	7,258		$	7,479		$	7,082

	Common Stock				Treasury Stock					Additional			Retained			Accumulated Other Comprehensive			Non-controlling						Common Stock				Treasury Stock					Additional Paid-in			Retained			Accumulated Other Comprehensive			Non-controlling
	Shares		Amount		Shares		Amount			Paid-in Capital			Earnings			(Loss) Income			Interests			Total Equity			Shares		Amount		Shares		Amount			Capital			Earnings			(Loss) Income			Interests			Total Equity
Balance at July 1, 2019		188,801,201	$	2		25,319,235	$	(1,072	)	$	853		$	1,571		$	(531	)	$	6		$	829
Balance at April 1, 2020																										189,537,718	$	2		25,319,235	$	(1,072	)	$	870		$	1,308		$	(453	)	$	6		$	661
Common stock issued - compensation plans		6,807		—		—		—			—			—			—			—			—			8,872	—		—		—				1			(1	)	—			—				—
Exercise of stock options, net		3,678		—		—		—			—			—			—			—			—			5,000	—		—		—				—		—			—			—				—
Stock-based compensation expense		—		—		—		—			4			—			—			—			4			—		—		—		—			1			—			—			—			1
Net income		—		—		—		—			—			76			—			—			76			—		—		—		—			—			24			—			—			24
Dividends declared on common shares ($0.25 per share)		—		—		—		—			—			(41	)		—			—			(41	)		—		—		—		—			—			(41	)		—			—			(41	)
Other comprehensive loss		—		—		—		—			—			—			(25	)		—			(25	)
Balance at September 30, 2019		188,811,686	$	2		25,319,235	$	(1,072	)	$	857		$	1,606		$	(556	)	$	6		$	843
Dividends to non-controlling interests																										—		—		—		—			—			—			—			(4	)		(4	)
Other comprehensive income																										—		—		—		—			—			—			18			—			18
Balance at June 30, 2020																										189,551,590	$	2		25,319,235	$	(1,072	)	$	872		$	1,290		$	(435	)	$	2		$	659

Balance at July 1, 2020		189,551,590	$	2		25,319,235	$	(1,072	)	$	872		$	1,290		$	(435	)	$	2		$	659
Common stock issued - compensation plans		2,578		—		—		—			—			—			—			—			—
Exercise of stock options, net		218,042		—		—		—			4			—			—			—			4
Stock-based compensation expense		—		—		—		—			3			—			—			—			3
Net income		—		—		—		—			—			76			—			—			76
Dividends declared on common shares ($0.25 per share)		—		—		—		—			—			(41	)		—			—			(41	)
Other comprehensive income		—		—		—		—			—			—			33			—			33
Balance at September 30, 2020		189,772,210	$	2		25,319,235	$	(1,072	)	$	879		$	1,325		$	(402	)	$	2		$	734


	Common Stock				Treasury Stock					Additional			Retained			Accumulated Other Comprehensive			Non-controlling
	Shares		Amount		Shares		Amount			Paid-in Capital			Earnings			(Loss) Income			Interests			Total Equity
Balance at January 1, 2019		187,204,567	$	2		16,424,093	$	(750	)	$	860		$	1,466		$	(564	)	$	6		$	1,020
Balance at April 1, 2021																										190,783,383	$	2		25,319,235	$	(1,072	)	$	907		$	1,357		$	(344	)	$	2		$	852
Common stock issued - compensation plans		1,098,346		—		—		—			1			(1	)		—			—			—			8,140		—		—		—			—			—			—			—			—
Exercise of stock options, net		508,773		—		—		—			8			—			—			—			8			324,086		—		—		—			5			—			—			—			5
Purchases of treasury stock, at cost		—		—		8,895,142		(322	)		—			—			—			—			(322	)		—		—		423,273		(15	)		—			—			—			—			(15	)
Stock-based compensation expense		—		—		—		—			18			—			—			—			18			—		—		—		—			8			—			—			—			8
Cancellation of unissued stock awards withheld to cover taxes		—		—		—		—			(30	)		—			—			—			(30	)		—		—		—		—			—			—			—			—			—
Net income		—		—		—		—			—			265			—			—			265			—		—		—		—			—			66			—			—			66
Dividends declared on common shares ($0.75 per share)		—		—		—		—			—			(124	)		—			—			(124	)
Dividends declared on common shares ($0.25 per share)																										—		—		—		—			—			(42	)		—			—			(42	)
Other comprehensive income		—		—		—		—			—			—			8			—			8			—		—		—		—			—			—			26			—			26
Balance at September 30, 2019		188,811,686	$	2		25,319,235	$	(1,072	)	$	857		$	1,606		$	(556	)	$	6		$	843
Balance at June 30, 2021																										191,115,609	$	2		25,742,508	$	(1,087	)	$	920		$	1,381		$	(318	)	$	2		$	900


																									Common Stock				Treasury Stock					Additional Paid-in			Retained			Accumulated Other Comprehensive			Non-controlling
																									Shares		Amount		Shares		Amount			Capital			Earnings			(Loss) Income			Interests			Total Equity
Balance at January 1, 2020		188,893,478	$	2		25,319,235	$	(1,072	)	$	859		$	1,249		$	(349	)	$	6		$	695			188,893,478	$	2		25,319,235	$	(1,072	)	$	859		$	1,249		$	(349	)	$	6		$	695
Common stock issued - compensation plans		222,207		—		—		—			1			(1	)		—			—			—			219,629		—		—		—			1			(1	)		—			—			—
Exercise of stock options, net		656,525		—		—		—			9			—			—			—			9			438,483		—		—		—			5			—			—			—			5
Stock-based compensation expense		—		—		—		—			12			—			—			—			12			—		—		—		—			9			—			—			—			9
Cancellation of unissued stock awards withheld to cover taxes		—		—		—		—			(2	)		—			—			—			(2	)		—		—		—		—			(2	)		—			—			—			(2	)
Net income		—		—		—		—			—			200			—			—			200			—		—		—		—			—			124			—			—			124
Dividends declared on common shares ($0.75 per share)		—		—		—		—			—			(123	)		—			—			(123	)
Dividends declared on common shares ($0.50 per share)																										—		—		—		—			—			(82	)		—			—			(82	)
Dividends to non-controlling interests		—		—		—		—			—			—			—			(4	)		(4	)		—		—		—		—			—			—			—			(4	)		(4	)
Other comprehensive loss		—		—		—		—			—			—			(53	)		—			(53	)		—		—		—		—			—			—			(86	)		—			(86	)
Balance at September 30, 2020		189,772,210	$	2		25,319,235	$	(1,072	)	$	879		$	1,325		$	(402	)	$	2		$	734
Balance at June 30, 2020																										189,551,590	$	2		25,319,235	$	(1,072	)	$	872		$	1,290		$	(435	)	$	2		$	659

Balance at January 1, 2021																										190,239,883	$	2		25,319,235	$	(1,072	)	$	890		$	1,303		$	(310	)	$	2		$	815
Common stock issued - compensation plans																										154,312		—		—		—			1			(1	)		—			—			—
Exercise of stock options, net																										721,414		—		—		—			11			—			—			—			11
Purchases of treasury stock, at cost																										—		—		423,273		(15	)		—			—			—			—			(15	)
Stock-based compensation expense																										—		—		—		—			20			—			—			—			20
Cancellation of unissued stock awards withheld to cover taxes																										—		—		—		—			(2	)		—			—			—			(2	)
Net income																										—		—		—		—			—			161			—			—			161
Dividends declared on common shares ($0.50 per share)																										—		—		—		—			—			(82	)		—			—			(82	)
Other comprehensive loss																										—		—		—		—			—			—			(8	)		—			(8	)
Balance at June 30, 2021																										191,115,609	$	2		25,742,508	$	(1,087	)	$	920		$	1,381		$	(318	)	$	2		$	900

	Nine Months Ended September 30,						Six Months Ended June 30,
	2020			2019			2021			2020
Cash flows from operating activities
Net income	$	200		$	265		$	161		$	124
Adjustments to reconcile net income to cash provided by (used for) operating activities:
Depreciation and amortization		240			232			163			160
Gain on sales of assets and businesses		0			(11	)		(2	)		0
Equity in earnings of affiliates, net		(16	)		(24	)		(19	)		(11	)
Amortization of debt issuance costs and issue discounts		7			7			4			5
Deferred tax benefit		(105	)		(17	)		(39	)		(70	)
Asset-related charges		16			12			0			11
Stock-based compensation expense		12			18			20			9
Net periodic pension cost		9			4			3			6
Defined benefit plan contributions		(17	)		(15	)		(8	)		(14	)
Other operating charges and credits, net		(11	)		(2	)		24			(3	)
Decrease (increase) in operating assets:
Accounts and notes receivable, net		97			32			(288	)		128
Inventories and other operating assets		111			(46	)		(60	)		33
(Decrease) increase in operating liabilities:
Accounts payable and other operating liabilities		(89	)		(205	)		336			(223	)
Cash provided by operating activities		454			250			295			155
Cash flows from investing activities
Purchases of property, plant, and equipment		(214	)		(385	)		(127	)		(167	)
Acquisition of business, net		(10	)		(10	)
Proceeds from sales of assets and businesses, net		0			7
Proceeds from life insurance policies		0			1
Foreign exchange contract settlements, net		14			0			(7	)		4
Cash used for investing activities		(210	)		(387	)		(134	)		(163	)
Cash flows from financing activities
Proceeds from accounts receivable securitization facility		12			125			0			12
Proceeds from revolving loan		300			150			0			300
Repayments on revolving loan		(300	)		(150	)
Debt repayments		(140	)		(15	)		(27	)		(134	)
Payments on finance leases		(4	)		(2	)		(5	)		(3	)
Purchases of treasury stock, at cost		0			(322	)		(13	)		0
Proceeds from exercised stock options, net		9			8			11			5
Payments related to tax withholdings on vested stock awards		(2	)		(30	)		(2	)		(2	)
Payments of dividends to the Company's common shareholders		(123	)		(124	)		(82	)		(82	)
Distributions to non-controlling interest shareholders		(4	)		0			0			(4	)
Cash used for financing activities		(252	)		(360	)
Cash (used for) provided by financing activities								(118	)		92
Effect of exchange rate changes on cash and cash equivalents		21			(10	)		(9	)		4
Increase (decrease) in cash and cash equivalents		13			(507	)
Increase in cash and cash equivalents								34			88
Cash and cash equivalents at January 1,		943			1,201			1,105			943
Cash and cash equivalents at September 30,	$	956		$	694
Cash and cash equivalents at June 30,							$	1,139		$	1,031

Supplemental cash flows information
Non-cash investing and financing activities:
Changes in property, plant, and equipment included in accounts payable	$	25		$	68
Obligations incurred under build-to-suit lease arrangement		0			35
Non-cash financing arrangements		15			11
Deferred payments related to acquisition of business		0			15
Purchases of property, plant, and equipment included in accounts payable							$	43		$	25
Treasury Stock repurchased, not settled								2			0

The Chemours Company (“Chemours”, or the “Company”) is a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. The Company delivers customized solutions with a wide range of industrial and specialty chemical products for markets, including coatings, plastics, ~~and coatings,~~ refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, ~~electronics,~~ mining, and oil ~~refining.~~and gas. The Company’s principal products include titanium dioxide (“TiO₂”) pigment, refrigerants, industrial fluoropolymer resins, sodium cyanide, and performance chemicals and ~~intermediates, and titanium dioxide (“TiO~~₂~~”) pigment.~~intermediates. Chemours manages and reports its operating results through 34 reportable segments: ~~Fluoroproducts,~~Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions, and Titanium Technologies. The Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications.Solutions. The Titanium Technologies segment is a leading, global provider of TiO₂ pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and ~~protection~~protections in a variety of applications. The Thermal & Specialized Solutions segment is a leading, global provider of refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment is a leading, global provider of high-end polymers and advanced materials. The Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications.

Chemours separated from E. I. du Pont de Nemours and Company (“~~DuPont”~~EID”) on July 1, 2015 (the “Separation”). On August 31, 2017, ~~DuPont~~EID completed a merger with The Dow Chemical Company (“Dow”). Following their merger, ~~DuPont~~EID and Dow engaged in a series of reorganization steps and, in 2019, separated into three publicly-traded companies named Dow Inc., DuPont de Nemours, Inc. (“DuPont”), and Corteva, Inc. (“Corteva”).

Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our Company”, “we”, “us”, and “our” refer to The Chemours Company and its consolidated subsidiaries. References to ~~“DuPont”~~“EID” refer to E. I. du Pont de Nemours and Company, which is now a subsidiary of Corteva.

The accompanying interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). In the opinion of management, all adjustments (consisting of normal, recurring adjustments) considered necessary for a fair statement of the Company’s results for interim periods have been included. The notes that follow are an integral part of the Company’s interim consolidated financial statements. The Company’s results for interim periods should not be considered indicative of its results for a full year, and the year-end consolidated balance sheet does not include all of the disclosures required by GAAP. As such, these interim consolidated financial statements should be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020.

Certain prior period amounts have been reclassified to conform to the current period presentation, the effect of which was not material to the Company’s interim consolidated financial statements.

During the fourth quarter of 2020, the Company changed the level of detail at which its Chief Operating Decision Maker (“CODM”) regularly reviews and manages certain of its businesses, resulting in the bifurcation of its former Fluoroproducts segment into two standalone reportable segments: Thermal & Specialized Solutions (formerly Fluorochemicals) and Advanced Performance Materials (formerly Fluoropolymers). The Company now manages and reports its operating results through four reportable segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. This change allows Chemours ~~Company~~

~~Notes~~to enhance its customer focus and better align its business models, resources, and cost structure to the ~~Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~specific current and future secular growth drivers of each business, while providing increased transparency to the Company’s shareholders. The historical segment information has been recast to conform to the current segment structure.

Considerations related to the current novel coronavirus disease (“COVID-19”)

~~In December 2019, an outbreak of illness caused by COVID-19 was identified in Wuhan, China, and the virus has since continued to spread globally.~~ In March 2020, the World Health Organization declared COVID-19 a global pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. Since the initial stages of the pandemic, certain economies in regions throughout the world have started to reopen; however, certain of these regions have also seen further spread and even resurgences in the number of positively identified infections. Particularly in the Americas and Europe, infections have continued to spread, leading to health-related concerns in regions where the Company has several key manufacturing facilities. In an attempt to minimize the transmission of COVID-19, significant social and economic restrictions have been imposed throughout the U.S. and abroad, including travel bans, quarantines, restrictions on public gatherings, shelter-in-place orders, and/or safer-at-home orders. These restrictions, while necessary and important for public health, have negative business-related implications for the Company and the U.S. and global economies. In consideration of the Company’s global customer base, the rates at which economies across the globe recover or worsen may drive varying levels of end-market demand for the various performance chemicals provided by the Company’s three segments. In turn, the magnitude and duration of the COVID-19 pandemic create significant uncertainties for the Company’s customer demand and financial results and, during the quarter ended September 30, 2020, have caused adverse impacts on the Company’s results of operations.

~~In response to the macroeconomic uncertainties driven by COVID-19, beginning in the second quarter of 2020, management~~ decided to take certain precautionary measures. On April 8, 2020, the Company drew $300 from its revolving credit facility, which was subsequently repaid during the third quarter of 2020 based on the Company’s liquidity position. Management also elected to accept tax relief provided by various taxing jurisdictions, resulting in the deferral of approximately $80 in tax payments, which are largely expected to be made in the first quarter of 2021. From a cost savings perspective, management implemented a range of actions aimed at reducing costs, inclusive of reducing all discretionary spend, freezing non-critical hiring, delaying external spend wherever possible, reducing structural plant fixed costs, and temporarily reducing base salaries where legally permissible. The temporary base salary reductions were discontinued in September 2020. ~~Management~~ ~~continues to expect that available cash, cash from operations, and existing debt financing arrangements will provide the Company with sufficient liquidity through at least November 2021.~~

In the preparation of these financial statements and related disclosures, management has assessed the impact of COVID-19 on its results, estimates, assumptions, forecasts, and accounting policies and made additional disclosures, as necessary. As the COVID-19 situation is unprecedented and ever evolving, future events and effects related to the illness cannot be determined with precision, and actual results could significantly differ from estimates or forecasts.

~~In December 2019, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2019-12,~~ ~~Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes~~. The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, as well as improve consistency of application by clarifying and amending existing guidance. For public entities, the amendments are effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years, and early adoption is permitted. The Company is currently evaluating the impacts of adopting this guidance on its financial position, results of operations, and cash flows.

~~In June 2016, the FASB issued ASU No. 2016-13,~~ ~~Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments~~ (“ASU No. 2016-13”). The amendments in this update affect loans, debt securities, trade receivables, and any other financial assets that have the contractual right to receive cash, which, for the Company, primarily consists of accounts and notes receivable, net. ASU No. 2016-13 requires an entity to recognize expected credit losses rather than incurred losses for financial assets. The Company adopted ASU No. 2016-13 on January 1, 2020 using the modified retrospective transition method, the effect of which was not material to its financial position, results of operations, and cash flows.

In March 2020, the ~~FASB~~Financial Accounting Standards Board (“FASB”) issued ASU No. 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting (“ASU No. 2020-04”). The amendments in this update provide optional guidance for a limited period of time to ease the potential burden associated with accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (“LIBOR”) or another reference rate expected to be discontinued due to reference rate reform. ASU No. 2020-04 is effective March 12, 2020 through December 31, 2022. The Company is currently evaluating the impacts this standard will have on its accounting for contracts and hedging relationships.

~~Acquisition of Southern Ionics Minerals, LLC~~Simplifying the Accounting for Income Taxes

In ~~August~~December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU No. 2019-12”). The amendments in this update simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740, as well as improve consistency of application by clarifying and amending existing guidance.The Company ~~through~~adopted ASU No. 2019-12 on January 1, 2021, the effect of which was not material on its wholly-owned subsidiary, The Chemours Company FC, LLC, entered into a Membership Interest Purchase Agreement to acquire all of the outstanding stock of Southern Ionics Minerals, LLC (“SIM”), a privately-held minerals exploration, mining, and manufacturing company headquartered in Jacksonville, Florida. The aggregate purchase price of $25 included an upfront payment of $10, an additional installment payment of $10, and contingent considerations with an estimated fair value of $5. The additional installment payment of $10 was made during the third quarter of 2020.

~~The Company’s consolidated~~ financial ~~statements include SIM’s~~position, results of operations, ~~from August 1, 2019, the date of acquisition. Net sales~~ and ~~net income (loss) attributable to Chemours contributed by SIM during this period were not material to the Company’s or its Titanium Technologies segment’s results of operations.~~cash flows.

The following table sets forth a disaggregation of the Company’s net sales by geographic region and segment and product group for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Net sales by geographic region (1)
North America:
Fluoroproducts	$	233	$	260	$	727	$	851
Titanium Technologies									$	250	$	176	$	456	$	369
Thermal & Specialized Solutions										168		117		315		263
Advanced Performance Materials										130		112		240		230
Chemical Solutions		52		87		158		246		50		51		83		106
Titanium Technologies		203		178		571		550
Total North America		488		525		1,456		1,647		598		456		1,094		968
Asia Pacific:
Fluoroproducts		142		173		428		511
Titanium Technologies										269		161		515		354
Thermal & Specialized Solutions										49		32		86		61
Advanced Performance Materials										150		121		290		225
Chemical Solutions		4		16		17		47		6		5		12		13
Titanium Technologies		185		225		539		587
Total Asia Pacific		331		414		984		1,145		474		319		903		653
Europe, the Middle East, and Africa:
Fluoroproducts		117		151		387		515
Titanium Technologies										223		99		398		247
Thermal & Specialized Solutions										89		61		176		160
Advanced Performance Materials										67		50		135		110
Chemical Solutions		6		6		17		15		5		6		9		11
Titanium Technologies		135		122		382		358
Total Europe, the Middle East, and Africa		258		279		786		888		384		216		718		528
Latin America (2):
Fluoroproducts		41		52		115		157
Titanium Technologies										117		52		214		130
Thermal & Specialized Solutions										34		21		66		55
Advanced Performance Materials										15		9		30		19
Chemical Solutions		26		31		71		96		33		20		66		45
Titanium Technologies		89		89		219		240
Total Latin America		156		172		405		493		199		102		376		249
Total net sales	$	1,233	$	1,390	$	3,631	$	4,173	$	1,655	$	1,093	$	3,091	$	2,398

Net sales by segment and product group
Fluoroproducts:
Fluorochemicals	$	293	$	304	$	832	$	1,028
Fluoropolymers		240		332		825		1,006
Titanium Technologies:
Titanium dioxide and other minerals									$	859	$	488	$	1,583	$	1,100
Thermal & Specialized Solutions:
Refrigerants										271		188		512		440
Foam, propellants, and other										69		43		131		99
Advanced Performance Materials:
Fluoropolymers and advanced materials										362		292		695		584
Chemical Solutions:
Mining solutions		53		70		150		200		69		47		122		98
Performance chemicals and intermediates		35		70		113		204		25		35		48		77
Titanium Technologies:
Titanium dioxide and other minerals		612		614		1,711		1,735
Total net sales	$	1,233	$	1,390	$	3,631	$	4,173	$	1,655	$	1,093	$	3,091	$	2,398

Substantially all of the Company’s net sales are derived from goods and services transferred at a point in time.

The Company’s assets and liabilities from contracts with customers constitute accounts receivable - trade, deferred revenue, and customer rebates. An amount for accounts receivable - trade is recorded when the right to consideration under a contract becomes unconditional. An amount for deferred revenue is recorded when consideration is received prior to the conclusion that a contract exists, or when a customer transfers consideration prior to the Company satisfying its performance obligations under a contract. Customer rebates represent an expected refund liability to a customer based on a contract. In contracts with customers where a rebate is offered, it is generally applied retroactively based on the achievement of a certain sales threshold. As revenue is recognized, the Company estimates whether or not the sales threshold will be achieved to determine the amount of variable consideration to include in the transaction price.

The following table sets forth the Company’s contract balances from contracts with customers at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Accounts receivable - trade, net (1)	$	523	$	602	$	730	$	449
Deferred revenue		14		15		8		12
Customer rebates		60		72		53		69

Changes in the Company’s deferred revenue balances resulting from additions for advance payments and deductions for amounts recognized in net sales during the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were not significant. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, the amount of net sales recognized from performance obligations satisfied in prior periods (e.g., due to changes in transaction price) was not significant.

Contract asset balances or capitalized costs associated with obtaining or fulfilling customer contracts were not significant as of ~~September~~June 30, ~~2020~~2021 or December 31, ~~2019.~~2020.

Certain of the Company’s master services agreements or other arrangements contain take-or-pay clauses, whereby customers are required to purchase a fixed minimum quantity of product during a specified period, or pay the Company for such orders, even if not requested by the customer. The Company considers these take-or-pay clauses to be an enforceable contract, and as such, the legally-enforceable minimum amounts under such an arrangement are considered to be outstanding performance obligations on contracts with an original expected duration greater than one year. At ~~September~~June 30, ~~2020,~~2021, Chemours had ~~$47~~$78 of remaining performance obligations.The Company expects to recognize approximately ~~47%~~21% of its remaining performance obligations as revenue in ~~2020,~~2021, approximately an ~~approximate~~ additional ~~28%~~21% as revenue in ~~2021,~~2022, and the balance thereafter. The Company applies the allowable practical expedient and does not include remaining performance obligations that have original expected durations ofone year or less, or amounts for variable consideration allocated to wholly-unsatisfied performance obligations or wholly-unsatisfied distinct goods that form part of a single performance obligation, if any. Amounts for contract renewals that are not yet exercised by ~~September~~June 30, ~~2020~~2021 are also excluded.

The following table sets forth the components of the Company’s restructuring, asset-related, and other charges for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,					Six Months Ended June 30,
	2020		2019		2020		2019		2021			2020		2021			2020
Restructuring and other charges:
Employee separation charges	$	3	$	17	$	18	$	15	$	(1	)	$	6	$	(2	)	$	14
Decommissioning and other charges		1		5		3		22		6			1		2			3
Total restructuring and other charges		4		22		21		37		5			7		0			17
Asset-related charges		5		12		16		12		0			10		0			11
Total restructuring, asset-related, and other charges	$	9	$	34	$	37	$	49	$	5		$	17	$	0		$	28

The following table sets forth the impacts of the Company’s restructuring programs to segment earnings for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,					Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
	2020		2019			2020			2019			2021			2020			2021			2020
Restructuring and other charges:
Restructuring charges:
Plant and product line closures:
Chemical Solutions	$	1	$	0		$	4		$	0		$	4		$	3		$	8		$	4
Corporate and Other		0		5			1			18			0			0			0			1
Total plant and product line closures		1		5			5			18			4			3			8			5
2017 Restructuring Program:
Fluoroproducts		0		1			0			2
Titanium Technologies		0		0			0			1
Corporate and Other		0		0			(1	)		0			0			(1	)		0			(1	)
Total 2017 Restructuring Program		0		1			(1	)		3			0			(1	)		0			(1	)
2018 Restructuring Program:
Corporate and Other		0		(1	)		0			(1	)
Total 2018 Restructuring Program		0		(1	)		0			(1	)
2019 Restructuring Program:
Fluoroproducts		0		7			3			7
Chemical Solutions		0		2			0			2
Titanium Technologies		0		5			0			5
Corporate and Other		0		3			0			3
Thermal & Specialized Solutions													0			1			0			1
Advanced Performance Materials													0			2			0			2
Total 2019 Restructuring Program		0		17			3			17			0			3			0			3
2020 Restructuring Program:
Fluoroproducts		1		0			4			0
Titanium Technologies													0			0			0			2
Thermal & Specialized Solutions													0			0			0			1
Advanced Performance Materials													(1	)		0			(1	)		2
Chemical Solutions		0		0			1			0			0			1			0			1
Titanium Technologies		0		0			3			0
Corporate and Other		2		0			6			0			0			1			0			4
Total 2020 Restructuring Program		3		0			14			0			(1	)		2			(1	)		10
Total restructuring and other charges		4		22			21			37
Total restructuring charges													3			7			7			17
Asset-related charges:
Fluoroproducts		5		0			5			0
Chemical Solutions		0		12			7			12			0			6			0			7
Corporate and Other		0		0			4			0			0			4			0			4
Total asset-related charges		5		12			16			12			0			10			0			11
Other charges:
Chemical Solutions													2			0			(7	)		0
Total other charges													2			0			(7	)		0
Total restructuring, asset-related, and other charges	$	9	$	34		$	37		$	49		$	5		$	17		$	0		$	28

In connection with the construction work at the Mining Solutions facility in Gomez Palacio, Durango, Mexico, the Company had previously entered into an agreement with a third-party services provider. In the fourth quarter of 2020, the Company entered into dispute resolution with the third-party services provider, resulting in a $26 charge related to probable contract termination fees, as well as immediate recognition of $11 of other related prepaid costs, for a total of $37 in Other Charges. During the first quarter of 2021, the Company and the third-party services provider reached an agreement to terminate the contractual relationship resulting in a payment of $26 for the aforementioned contract termination fees and, in exchange, the Company received title to approximately $22 of assets classified as construction-in-process, of which only approximately $9 are expected to be used by the Company when construction resumes. Accordingly, approximately $13 was recognized in impairment charges in the first quarter of 2021, offset by $22 of the liability recorded in the fourth quarter of 2020 being reversed in the first quarter of 2021, resulting in a net $9 gain in Other Charges. Additionally, during the second quarter of 2021, the Company incurred $2 of freight charges associated with transportation of the impaired assets.

In the fourth quarter of 2015, the Company announced its completion of the strategic review of its Reactive Metals Solutions business and the decision to stop production at its Niagara Falls, New York manufacturing plant. The Company recorded additional decommissioning and dismantling-related charges of $1 for the six months ended June 30, 2021, and $1 and $2 for the three and ~~nine~~six months ended ~~September~~June 30, 2020, ~~respectively, and less than $1 and $1 for the three and nine months ended September 30, 2019,~~ respectively. The Company expects to incur and spend approximately $4$2 related to additional restructuring charges for similar activities ~~through 2021,~~by the end of 2022, all of which relate to Chemical Solutions. As of ~~September~~June 30, ~~2020,~~2021, the Company has incurred, in the aggregate, ~~$40~~$41 in restructuring charges related to these activities, excluding asset-related ~~charges.~~charges.

In the first quarter of 2018, the Company began a project to demolish and remove several dormant, unused buildings at its Chambers Works site in Deepwater, New Jersey, which were assigned to Chemours in connection with its Separation from DuPont and never used in Chemours’ operations. The Company recorded additional decommissioning and dismantling-related charges of $1 for the nine months ended September 30, 2020, and $4 and $18 for the three and nine months ended September 30, 2019, respectively. As of September 30, 2020, the Company has incurred, in the aggregate, $28 in restructuring charges related to these activities, all of which relate to Corporate and Other. The Company does not currently expect to incur additional charges related to these activities at its Chambers Works site through the end of 2021, and any remaining future charges and cash outflows associated with these activities are not expected to be material.

In the third quarter of 2019, in an effort to improve the profitability of the Company’s Chemical Solutions segment, the Company announced plans to exit its Methylamines and Methylamides business at its Belle, West Virginia manufacturing plant, which culminated in the completed exit and sale of the business in the fourth quarter of 2019. For the three and nine months ended September 30, 2019, the Company recorded accelerated depreciation of $12. Through the fourth quarter of 2019, the Company incurred, in the aggregate, $34 in restructuring charges related to these activities, all of which relate to Chemical Solutions.

In the second quarter of 2020, the Company completed a business review of its Aniline business. It was determined that the Aniline business iswas not core to the Company’s future strategy, and ~~the decision~~production was ~~made to stop production~~ceased at the Pascagoula, Mississippi manufacturing plant by in the ~~end~~fourth quarter of 2020. As a result, during the ~~nine~~three and six months ended ~~September~~June 30, 2020, the Company recorded asset-related charges of ~~$10, which are primarily comprised of $6~~ ~~for property, plant,~~$10 and ~~equipment and other asset impairments, as well as $4 for environmental remediation liabilities to be paid over a period of approximately 16 years. The Company also recorded~~ employee separation-related liabilities of $2. ~~In conjunction with this decision, approximately 75 employees will separate from~~Furthermore, the Company inrecorded decommissioning and dismantling-related charges of $4 and $8 for the three and six months ended June 30, 2021, respectively. At June 30, 2021 and ~~will be subject to our customary involuntary termination benefits.~~ ~~The associated~~December 31, 2020 $1 and $2 remained as an employee separation-related liability, respectively, and the remaining severance payments ~~will also~~are expected to be made inby the end of 2021. The Company expects to incur approximately $9$5 in additional restructuring charges related to decommissioning, dismantling, and other costs in connection with the exit of its Pascagoula site by the end of 2021, all of which relate to Chemical Solutions. The future net cash outflows associated with these exit costs are not expected to be material.

In the ~~third~~first quarter of ~~2020,~~2018, the Company began a project to demolish and remove several dormant, unused buildings at its Chambers Works site in Deepwater, New Jersey, which were assigned to Chemours in connection with ~~various property, plant,~~its Separation from EID and ~~equipment~~never used in Chemours’ operations. The Company recorded additional decommissioning and ~~other asset impairments,~~dismantling-related charges of $1 for the six months ended June 30, 2020.As of June 30, 2021, the Company ~~recorded asset-related~~has incurred, in the aggregate, $28 in restructuring charges related to these activities. The Company does not currently expect to incur additional charges related to these activities at its Chambers Works site through the end of ~~$5, all of which relate~~2021, and any remaining future charges and cash outflows associated with these activities are not expected to ~~Fluoroproducts.~~

In 2017, the Company announced certain restructuring activities designed to further the cost savings and productivity improvements outlined under management’s transformation plan. These activities include, among other efforts: (i) outsourcing and further centralizing certain business process activities; (ii) consolidating existing, outsourced third-party information technology (“IT”) providers; and, (iii) implementing various upgrades to the Company’s current IT infrastructure. ~~In connection with these corporate function efforts, the Company recorded $1 and $3 in restructuring-related charges for the three and nine months ended September 30, 2019, respectively.~~

In 2017, the Company also announced a voluntary separation program (“VSP”) for certain eligible U.S. employees in an effort to better manage the anticipated future changes to its workforce. Employees who volunteered for and were accepted under the VSP received certain financial incentives above the Company’s customary involuntary termination benefits to end their employment with Chemours after providing a mutually agreed-upon service period. Approximately 300 employees separated from the Company through the end of 2018. An accrual representing the majority of these termination benefits, amounting to $18, was recognized in the fourth quarter of 2017. The remaining $9 of incremental, one-time financial incentives under the VSP were recognized over the period that each participating employee continued to provide service to Chemours.

The ~~Company recorded charges for its 2017 Restructuring Program of $1 and $3 for the three and nine months ended September 30, 2019, respectively. The~~ cumulative amount incurred, in the aggregate, for the Company’s 2017 Restructuring Program amounted to $61 at ~~September~~June 30, ~~2020.~~ ~~The Company has substantially completed all actions related to this program.~~

~~In the fourth quarter of 2018, management initiated a restructuring program of the Company’s corporate functions and recorded the related estimated severance costs of $5.~~2021. The Company has substantially completed all actions related to this program.

In the third quarter of 2019, management initiated a severance program of the Company’s corporate functions and businesses, and the majority of employees separated from the Company during the fourth quarter of 2019. As of ~~September~~June 30, ~~2020,~~2021, the cumulative amount incurred, in the aggregate, for the Company’s 2019 Restructuring Program amounted to $25, the majority of which was incurred in the third and fourth quarters of 2019. The Company believes that it has completed incurring severance costs for this program. At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, $1 and $2 ~~and $14~~ remained as an employee separation-related liability, respectively, and the remaining severance payments are expected to be made by the end of 2021.

In the first quarter of 2020, management initiated the first phase of a severance program that was largely attributable to further aligning the cost structure of the Company’s businesses and corporate functions with its strategic and financial objectives. A second phase of this program was initiated in the third quarter of 2020. As of ~~September~~June 30, ~~2020,~~2021, the cumulative amount incurred, in the aggregate, for the Company’s 2020 Restructuring Program amounted to ~~$14. The~~$12 and the Company has ~~largely~~substantially completed ~~incurring severance costs for~~all actions related to this program. ~~At September 30, 2020, $7 remained as an employee separation-related liability, and the remaining severance payments are expected to be made by the end of 2021.~~

The following table sets forth the change in the Company’s employee separation-related liabilities associated with its restructuring programs for the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021.

	Chemical Solutions Site Closures		2017 Restructuring Program			2019 Restructuring Program			2020 Restructuring Program			Total			Chemical Solutions Site Closures			2019 Restructuring Program			2020 Restructuring Program			Total
Balance at December 31, 2019	$	0	$	1		$	14		$	0		$	15
Balance at December 31, 2020															$	2		$	2		$	3		$	7
Charges (credits) to income		2		(1	)		3			14			18			(1	)		0			(1	)		(2	)
Payments		0		0			(15	)		(7	)		(22	)		0			(1	)		(2	)		(3	)
Balance at September 30, 2020	$	2	$	0		$	2		$	7		$	11
Balance at June 30, 2021															$	1		$	1		$	0		$	2

At ~~September~~June 30, ~~2020,~~2021, there were no significant outstanding liabilities related to the Company’s decommissioning and other restructuring-related charges.

The following table sets forth the components of the Company’s other income (expense), net for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,					Three Months Ended June 30,				Six Months Ended June 30,
	2020			2019			2020			2019		2021		2020		2021			2020
Leasing, contract services, and miscellaneous income ~~(1)~~	$	2		$	6		$	11		$	47	$	10	$	3	$	12		$	9
Royalty income ~~(2)~~(1)		1			6			9			16		4		4		7			8
Gain on sales of assets and businesses ~~(3)~~		0			9			0			11		2		0		2			0
Exchange (losses) gains, net (4)		(9	)		5			(28	)		2
Non-operating pension and other post-retirement employee benefit income (cost) (5)		1			(1	)		2			5
Total other (expense) income, net	$	(5	)	$	25		$	(6	)	$	81
Exchange gains (losses), net (2)													3		6		(5	)		(19	)
Non-operating pension and other post-retirement employee benefit income (3)													2		1		5			1
Total other income (expense), net												$	21	$	14	$	21		$	(1	)

During the first quarter of 2020, the Company recorded a one-time tax benefit of $18, which was related to the United States Internal Revenue Service acceptance of a non-automatic accounting method change that allows for the recovery of tax basis for depreciation, which had been previously disallowed. The balance sheet impact of this adjustment is reflected as a deferred tax asset on the consolidated balance sheet.

During the third quarter of 2020, the Company recorded an income tax benefit of $11, net, which was related to the filing of its 2019 U.S. federal income tax return. The tax return included the favorable impacts of certain elections and accounting method changes, which were not reflected in the Company’s benefit from income taxes for the year ended December 31, 2019 as they were not yet able to be quantified.

In the United States, the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act was passed on March 27, 2020. This legislative relief, as well as other government relief programs, include measures that could impact direct and indirect tax provisions. Management has analyzed the relief in jurisdictions in which the Company operates, and the applicable impacts, which are not material to the Company’s benefit from income taxes for the three and nine months ended September 30, 2020.

During the third quarter of 2020, the U.S. Treasury Department released final and proposed regulations which impact U.S. business interest expense limitations, foreign income inclusion, and foreign tax credits. These regulations will be effective for tax years 2020 or 2021 forward, with the option of applying to tax years 2018 – 2020. The Company has assessed the impact of these regulations, the effect of which is not material to any of its historical or current tax positions.

The following table sets forth the reconciliations of the numerators and denominators for the Company’s basic and diluted earnings per share (“EPS”) calculations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,				Nine Months Ended September 30,				Three Months Ended June 30,				Six Months Ended June 30,
	2020		2019		2020		2019		2021		2020		2021		2020
Numerator:
Net income attributable to Chemours	$	76	$	76	$	200	$	265	$	66	$	24	$	161	$	124
Denominator:
Weighted-average number of common shares outstanding - basic		164,762,621		163,815,483		164,556,139		165,254,084		166,168,550		164,648,103		165,912,089		164,448,226
Dilutive effect of the Company’s employee compensation plans		1,851,050		1,325,380		1,209,143		2,780,874		3,989,453		765,838		3,693,498		888,190
Weighted-average number of common shares outstanding - diluted		166,613,671		165,140,863		165,765,282		168,034,958		170,158,003		165,413,941		169,605,587		165,336,416

Basic earnings per share of common stock	$	0.46	$	0.46	$	1.22	$	1.60	$	0.40	$	0.15	$	0.97	$	0.75
Diluted earnings per share of common stock		0.46		0.46		1.21		1.58		0.39		0.15		0.95		0.75

The following table sets forth the average number of stock options that were anti-dilutive and, therefore, were not included in the Company’s diluted EPS calculations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

The following table sets forth the components of the Company’s accounts and notes receivable, net at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Accounts receivable - trade, net (1,2)	$	523	$	602
Accounts receivable - trade, net (1)					$	730	$	449
VAT, GST, and other taxes ~~(3)~~(2)		43		59		63		49
Other receivables ~~(4)~~(3)		6		13		9		13
Total accounts and notes receivable, net	$	572	$	674	$	802	$	511

Accounts and notes receivable are carried at amounts that approximate fair value. Bad debt expense amounted to ~~$2 for the three and nine months ended September 30, 2020, and less than $1 and~~ $1 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019, respectively~~2021, and less than $1 for the three and six months ended June 30, 2020..

The following table sets forth the components of the Company’s inventories at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020			December 31, 2019			June 30, 2021			December 31, 2020
Finished products	$	625		$	589		$	607		$	579
Semi-finished products		175			189			173			180
Raw materials, stores, and supplies		462			559			510			433
Inventories before LIFO adjustment		1,262			1,337			1,290			1,192
Less: Adjustment of inventories to LIFO basis		(269	)		(258	)		(244	)		(253	)
Total inventories	$	993		$	1,079		$	1,046		$	939

Inventory values, before last-in, first-out (“LIFO”) adjustment are generally determined by the average cost method, which approximates current cost. Inventories are valued under the LIFO method at substantially all of the Company’s U.S. locations, which comprised ~~$639~~$563 and ~~$674~~$585 (or ~~51%~~44% and ~~50%~~49%, respectively) of inventories before the LIFO adjustments at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively. The remainder of the Company’s inventory held in international locations and certain U.S. locations is valued under the average cost method.

The following table sets forth the components of the Company’s property, plant, and equipment, net at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020			December 31, 2019			June 30, 2021			December 31, 2020
Equipment	$	7,678		$	7,600		$	7,889		$	7,816
Buildings		1,155			1,174			1,204			1,198
Construction-in-progress		415			493			428			421
Land		107			110			111			111
Mineral rights		36			36			36			36
Property, plant, and equipment		9,391			9,413			9,668			9,582
Less: Accumulated depreciation		(5,973	)		(5,854	)		(6,220	)		(6,108	)
Total property, plant, and equipment, net	$	3,418		$	3,559		$	3,448		$	3,474

Property, plant, and equipment, net included gross assets under finance leases of ~~$75~~$102 and ~~$68~~$86 at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

Depreciation expense amounted to ~~$77~~$78 and ~~$234~~$158 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and ~~$76~~$80 and ~~$226~~$157 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively.

The Company engages in transactions with its equity method investees in the ordinary course of business. Net sales to the Company’s equity method investees amounted to $2140 and ~~$68~~$74 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and ~~$40~~$25 and ~~$104~~$47 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively. Purchases from the Company’s equity method investees amounted to $3851 and ~~$107~~$86 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and ~~$48~~$34 and ~~$215~~$69 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively. The Company also received less than $1$1 and $4$1 in dividends from its equity method investees for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020, respectively,~~2021, and less than $1 and $4 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively.

The following table sets forth the components of the Company’s other assets at June 30, 2021 and December 31, 2020.

~~The following table sets forth the components of the Company’s other assets at September 30, 2020 and December 31, 2019.~~

The following table sets forth the components of the Company’s other accrued liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Compensation and other employee-related costs	$	71	$	52
Employee separation costs (1)		11		15	$	2	$	7
Accrued litigation (2)		8		10		33		37
Environmental remediation (2)		97		74
Asset retirement obligations (3)		13		7		11		13
Income taxes		98		65		60		64
Customer rebates		60		72		53		69
Deferred revenue		9		7		3		7
Accrued interest		61		21		20		18
Operating lease liabilities		67		66		57		57
Miscellaneous (4)		80		95		82		103
Total other accrued liabilities	$	575	$	484	$	321	$	375

The following table sets forth the components of the Company’s debt at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020			December 31, 2019			June 30, 2021			December 31, 2020
Senior secured term loans:
Tranche B-2 U.S. dollar term loan due April 2025	$	878		$	884		$	851		$	875
Tranche B-2 euro term loan due April 2025 (€341 at September 30, 2020 and €344 at December 31, 2019)		397			383
Tranche B-2 euro term loan due April 2025 (€339 at June 30, 2021 and €340 at December 31, 2020)								404			417
Senior unsecured notes:
6.625% due May 2023		908			908
7.000% due May 2025		750			750			750			750
4.000% due May 2026 (€450 at September 30, 2020 and December 31, 2019)		524			501
4.000% due May 2026 (€450 at June 30, 2021 and December 31, 2020)								537			551
5.375% due May 2027		500			500			500			500
Securitization Facility		—			110
5.750% due November 2028								800			800
Finance lease liabilities		63			59			85			74
Financing obligation (1)		94			95			93			94
Other		13			6
Total debt		4,127			4,196
Total debt principal								4,020			4,061
Less: Unamortized issue discounts		(7	)		(8	)		(6	)		(7	)
Less: Unamortized debt issuance costs		(25	)		(28	)		(25	)		(28	)
Less: Short-term and current maturities of long-term debt		(32	)		(134	)		(25	)		(21	)
Total long-term debt, net	$	4,063		$	4,026		$	3,964		$	4,005

The Company’s credit agreement, as amended and restated on April 3, 2018 (“Credit Agreement”), provides for a seven-year, senior secured term ~~loans~~loan facility and a five-year, $800 senior secured revolving credit facility (“Revolving Credit Facility”) (collectively, the “Senior Secured Credit Facilities”). The Company made term loan payments of $3 and $10 for the three and nine months ended September 30, 2020 and 2019, respectively. On April 8, 2020, as a precautionary measure in light of macroeconomic uncertainties driven by COVID-19, the Company drew $300 from its Revolving Credit Facility. During the third quarter of 2020, based on the Company’s liquidity position, the Company repaid $200 and $100 of the outstanding borrowings on August 28, 2020 and September 17, 2020, respectively. During the third quarter of 2019, the Company repaid $150 of outstanding borrowings under its Revolving Credit Facility, which was drawn during the second quarter of 2019 for general corporate purposes. NaN borrowings were outstanding under the Revolving Credit Facility at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020. The Company made term loan payments of $3 and $7 for the three and six months ended June 30, 2021, respectively, and $3 and $6 for the three and six months ended June 30, 2020, respectively. During the second quarter 2021, the Company repurchased through open market transactions an aggregate principal amount of $20 of its senior secured term loans for $20 in cash. In July 2021, the Company repurchased additional term loan principal amounting to $4. Chemours also had ~~$98~~$111 and ~~$103~~$102 in letters of credit issued and outstanding under the Revolving Credit Facility at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively. At ~~September~~June 30, ~~2020,~~2021, the effective interest rates on the class of term loans denominated in U.S. dollars and the class of term loans denominated in euros were 1.9% and 2.5%, respectively. Also, at ~~September~~June 30, ~~2020,~~2021, commitment fees on the Revolving Credit Facility were assessed at a rate of 0.20% per annum.

~~On March 9, 2020, the~~The Company, through a wholly-owned special purpose entity (“SPE”), ~~entered into~~maintains an amended and restated receivables purchase agreement (the “Amended Purchase Agreement”), dated March 9, 2020, under its accounts receivable securitization facility (“Securitization Facility”). The Amended Purchase Agreement amends and restates, in its entirety, the receivables purchase agreement dated as of July 12, 2019 (the “Original Purchase Agreement”). The Amended Purchase Agreement, among other things, extends the term of the Original Purchase Agreement such that the SPE may sell certain receivables and request investments and letters of credit until the earlier of March 5, 2021 or a termination event, and contains customary representations and warranties, as well as affirmative and negative covenants.

Pursuant to the Original Purchase Agreement, certain of the Company’s subsidiaries sold their accounts receivable to the SPE. In turn, the SPE transferred undivided ownership interests in such receivables to the bank in exchange for cash. However, as the SPE maintained effective control over the accounts receivable under the Original Purchase Agreement, the transfers of the ownership interests to the bank did not meet the criteria to account for the transfers as true sales. As a result, the Company accounted for the transfers as collateralized borrowings.

Pursuant to the Amended Purchase Agreement, the Company no longer maintains effective control over the transferred receivables, and therefore accounts for these transfers as sales of receivables. As a result, ~~on March 9,~~in the first quarter of 2020, the Company repurchased the then-outstanding receivables under the Securitization Facility through repayment of the secured borrowings under the Original Purchase Agreement, resulting in net repayments of $110 for the three months ended March 31, 2020, and sold $125 of its receivables to the bank. These sales were transacted at 100% of the face value of the relevant receivables, resulting in derecognition of the receivables from the Company’s consolidated balance sheets.

On March 5, 2021, the Company, through the SPE, entered into an amendment (the “First Amendment”) to its Amended Purchase Agreement (the “Amended Purchase Agreement”) to, among other things, extend the term of the Amended Purchase Agreement (as amended by the First Amendment), such that the SPE may sell certain receivables and request investments and letters of credit until the earlier of March 6, 2023 or another event that constitutes a “Termination Date” under the Amended Purchase Agreement (as amended by the First Amendment). The First Amendment also increases the facility limit under the arrangement from $125 to $150. As of June 30, 2021, the Securitization Facility is fully utilized.

Cash received from collections of sold receivables is used to fund additional purchases of receivables at 100% of face value on a revolving basis, not to exceed ~~$125,~~the facility limit, which is the aggregate purchase limit. ~~For~~During the three and ~~nine~~six months ended ~~September~~June 30, 2021, the Company received $345 and $616 of cash collections on receivables sold under the Securitization Facility, respectively, following which it sold and derecognized $370 and $641 of incremental accounts receivable, respectively. During the three and six months ended June 30, 2020, the Company received ~~$289~~$298 and ~~$646,~~$358, respectively, of cash collections on receivables sold under the Amended Purchase Agreement, following which it sold and derecognized ~~$292~~$295 and ~~$646,~~$355, respectively, of incremental accounts receivable. The Company maintains continuing involvement as it acts as the servicer for the sold receivables and guarantees payment to the bank. As collateral against the sold receivables, the SPE maintains a certain level of unsold receivables, which amounted to ~~$70~~$123 and $33 at ~~September~~June 30, ~~2020. During the three~~2021 and ~~nine months ended September 30,~~December 31, 2020, ~~the~~respectively. The Company incurred ~~less than~~ $1 ~~and $1, respectively,~~ of servicing and other fees associated with the Securitization ~~Facility.~~Facility during the three and six months ended June 30, 2021, and, less than $1 and $1 during the three and six months ended June 30, 2020, respectively. Costs associated with the sales of receivables are reflected in the Company’s consolidated statements of operations for the periods in which the sales occur.

During the third quarter of 2020, the Company entered into a financing arrangement, by which an external financing company funded certain of the Company’s annual insurance premiums for $15. During the three months ended September 30, 2020, the Company made payments of $2, and the remaining $13 is to be paid within the next twelve months. During the third quarter of 2019, the Company entered into a similar financing arrangement for $11, of which $6 remained outstanding at December 31, 2019. The Company repaid all remaining borrowings under its 2019 financing arrangement by June 30, 2020.

The Company has required quarterly principal payments related to its senior secured term loans equivalent to 1.00% per annum through December 2024, with the balance due at maturity. Also, following the end of each fiscal year commencing on the year ended December 31, 2019, on an annual basis, the Company is required to make additional principal payments depending on leverage levels, as defined in the Credit ~~Agreement.~~Agreement, equivalent to up to 50% of excess cash flows based on certain leverage targets with step-downs to 25% and 0% as actual leverage decreases to below a 3.50 to 1.00 leverage target. The Company is not required to make additional principal payments in ~~2020.~~2021.

The following table sets forth the Company’s ~~contractual senior~~ debt principal maturities for the next five years and thereafter.

Remainder of 2020	$	3
2021		13
Remainder of 2021			$	7
2022		13		13
2023		921		13
2024		13		13
2025				1,959
Thereafter		2,994		1,837
Total principal maturities on debt	$	3,957	$	3,842

~~The Company’s senior secured terms loans due~~ ~~April 2025~~ ~~are subject to a springing maturity in the event that its 6.625% senior unsecured notes due~~ ~~May 2023~~ ~~are not redeemed, repaid, modified, and/or refinanced within the 91-day period prior to their maturity date.~~

The following table sets forth the estimated fair values of the Company’s senior debt issues, which are based on quotes received from third-party brokers, and are classified as Level 2 financial instruments in the fair value hierarchy. ~~The carrying value of borrowings under the Securitization Facility approximate fair value based on the facility’s short-term nature and maturity.~~

	September 30, 2020					December 31, 2019					June 30, 2021					December 31, 2020
	Carrying Value			Fair Value		Carrying Value			Fair Value		Carrying Value			Fair Value		Carrying Value			Fair Value
Senior secured term loans:
Tranche B-2 U.S. dollar term loan due April 2025	$	878		$	850	$	884		$	865	$	851		$	845	$	875		$	862
Tranche B-2 euro term loan due April 2025 (€341 at September 30, 2020 and €344 at December 31, 2019)		397			385		383			378
Tranche B-2 euro term loan due April 2025 (€339 at June 30, 2021 and €340 at December 31, 2020)												404			403		417			413
Senior unsecured notes:
6.625% due May 2023		908			921		908			917
7.000% due May 2025		750			761		750			755		750			775		750			774
4.000% due May 2026 (€450 at September 30, 2020 and December 31, 2019)		524			503		501			455
4.000% due May 2026 (€450 at June 30, 2021 and December 31, 2020)												537			552		551			551
5.375% due May 2027		500			499		500			450		500			543		500			536
Securitization Facility		—			—		110			110
5.750% due November 2028												800			857		800			821
Total senior debt		3,957		$	3,919		4,036		$	3,930		3,842		$	3,975		3,893		$	3,957
Less: Unamortized issue discounts		(7	)				(8	)				(6	)				(7	)
Less: Unamortized debt issuance costs		(25	)				(28	)				(25	)				(28	)
Total senior debt, net	$	3,925				$	4,000				$	3,811				$	3,858

The following table sets forth the components of the Company’s other liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Employee-related costs (1)	$	107	$	113	$	105	$	108
Accrued litigation (2)		51		50		52		51
Environmental remediation (2)		301		332
Asset retirement obligations (3)		59		69		63		63
Deferred revenue		5		8		5		5
Miscellaneous (4)		73		61		71		68
Total other liabilities	$	596	$	633	$	296	$	295

In addition to the matters discussed below, the Company and certain of its subsidiaries, from time to time, are subject to various lawsuits, claims, assessments, and proceedings with respect to product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters that arise in the ordinary course of business. In addition, Chemours, by virtue of its status as a subsidiary of ~~DuPont~~EID prior to the Separation, is subject to or required under the Separation-related agreements executed prior to the Separation to indemnify ~~DuPont~~EID against various pending legal proceedings. It is not possible to predict the outcomes of these various lawsuits, claims, assessments, or proceedings. Except as noted below, while management believes it is reasonably possible that Chemours could incur losses in excess of the amounts accrued, if any, for the aforementioned proceedings, it does not believe any such loss would have a material impact on the Company’s consolidated financial position, results of operations, or cash flows. ~~Additional disputes~~Disputes between Chemours and ~~DuPont~~EID may ~~also~~ arise ~~with respect to~~regarding indemnification matters, including disputes based on matters of law or contract interpretation. ~~If and to the extent these~~Should disputes arise, they could materially adversely affect Chemours.

In January 2021, Chemours, DuPont, Corteva, and EID, a subsidiary of Corteva, entered into a binding Memorandum of Understanding (the “MOU”), reflecting the parties’ agreement to share potential future legacy liabilities relating to per- and polyfluoroalkyl substances (“PFAS”) arising out of pre-July 1, 2015 conduct (i.e., “Indemnifiable Losses”, as defined in the separation agreement, dated as of June 26, 2015, as amended, between EID and Chemours (the “Separation Agreement”)) until the earlier to occur of: (i) December 31, 2040; (ii) the day on which the aggregate amount of Qualified Spend is equal to $4,000; or, (iii) a termination in accordance with the terms of the MOU (e.g., non-performance of the escrow funding requirements pursuant to the MOU by any party). As defined in the MOU, Qualified Spend includes:

The parties have agreed that, during the term of the cost-sharing arrangement, Chemours will bear half of the cost of such future potential legacy PFAS liabilities, and DuPont and Corteva will collectively bear the other half of the cost of such future potential legacy PFAS liabilities. Any recoveries of Qualified Spend from DuPont and/or Corteva under the cost-sharing arrangement will be recognized as an offset to the Company’s cost of goods sold or selling, general, and administrative expense, as applicable, when realizable. Any Qualified Spend incurred by DuPont and/or Corteva under the cost-sharing arrangement will be recognized in the Company’s cost of goods sold or selling, general, and administrative expense, as applicable, when the amounts of such costs are probable and estimable. The three and six months ended June 30, 2021 Qualified Spend is estimated at approximately $30 and $43, respectively, of which half would be subject to recovery from DuPont and Corteva. In July, the Company invoiced DuPont and Corteva for the first quarter Qualified Spend.

After the term of this arrangement, Chemours’ indemnification obligations under the Separation Agreement would continue unchanged, subject in each case to certain exceptions set out in the MOU. Pursuant to the terms of the MOU, the parties have agreed to release certain claims regarding Chemours’ Delaware lawsuit and confidential arbitration (concerning the indemnification of specified liabilities that EID assigned to Chemours in its spin-off), including that Chemours has released any claim set forth in the complaint filed in the Delaware lawsuit, any other similar claims arising out of or resulting from the facts recited by Chemours in the complaint or the process and manner in which EID structured or conducted the spin-off, and any other claims that challenge the spin-off or the assumption of Chemours Liabilities (as defined in the Separation Agreement) by Chemours and the allocation thereof, subject in each case to certain exceptions set out in the MOU. The parties have further agreed not to bring any future, additional claims regarding the Separation Agreement or the MOU outside of arbitration.

In order to support and manage the payments for potential future PFAS liabilities, the parties have also agreed to establish an escrow account. The MOU provides that: (i) no later than each of September 30, 2021 and September 30, 2022, Chemours shall deposit $100 into an escrow account and DuPont and Corteva shall together deposit $100 in the aggregate into an escrow account, and (ii) no later than September 30 of each subsequent year through and including 2028, Chemours shall deposit $50 into an escrow account and DuPont and Corteva shall together deposit $50 in the aggregate into an escrow account. Subject to the terms and conditions set forth in the MOU, each party may be permitted to defer funding in any year (excluding 2021). Additionally, if on December 31, 2028, the balance of the escrow account (including interest) is less than $700, Chemours will make 50% of the deposits and DuPont and Corteva together will make 50% of the deposits necessary to restore the balance of the escrow account to $700. Such payments will be made in a series of consecutive annual equal installments commencing on September 30, 2029 pursuant to the escrow account replenishment terms as set forth in the MOU. Any funds that remain in escrow at termination of the MOU will revert to the party that deposited them. As such, future payments made by the Company into the escrow account will remain an asset of Chemours, and such payments will be reflected as a transfer to restricted cash on its consolidated balance sheets. No withdrawals are permitted from the escrow account before January 2026, except for funding mutually agreed-upon third-party settlements in excess of $125. Starting in January 2026, withdrawals may be made from the escrow account to fund Qualified Spend if the parties’ aggregate Qualified Spend in that particular year is greater than $200. Starting in January 2031, the amounts in the escrow account can be used to fund any Qualified Spend. Future payments from the escrow account for potential future PFAS liabilities will be reflected on the Company’s consolidated statement of cash flows at that point in time.

The parties will cooperate in good faith to enter into additional agreements reflecting the terms set forth in the MOU.

The Company accrues for litigation matters when it is probable that a liability has been incurred, and the amount of the liability can be reasonably estimated. Where the available information is only sufficient to establish a range of probable liability, and no point within the range is more likely than any other, the lower end of the range has been used. When a material loss contingency is reasonably possible, but not probable, we do not record a liability, but instead disclose the nature of the matter and an estimate of the loss or range of loss, to the extent such estimate can be made. Legal costs such as outside counsel fees and expenses are recognized in the period in which the expense was incurred. Management believes the Company’s litigation accruals are appropriate based on the facts and circumstances for each matter, which are discussed in further detail below.

~~The following table sets forth the components of the Company’s accrued litigation at September 30, 2020 and December 31, 2019.~~

The following table sets forth the components of the Company’s accrued litigation at June 30, 2021 and December 31, 2020.

The following table sets forth the current and long-term components of the Company’s accrued litigation and their balance sheet locations at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	Balance Sheet Location	September 30, 2020		December 31, 2019		Balance Sheet Location	June 30, 2021		December 31, 2020
Accrued Litigation:
Current accrued litigation(1)	Other accrued liabilities (Note 14)	$	8	$	10	Other accrued liabilities (Note 12)	$	33	$	37
Long-term accrued litigation	Other liabilities (Note 16)		51		50	Other liabilities (Note 14)		52		51
Total accrued litigation		$	59	$	60		$	85	$	88

For information regarding the Company’s ongoing litigation and environmental remediation matters at its Fayetteville Works site in Fayetteville, North Carolina (“Fayetteville”), refer to “Fayetteville Works, Fayetteville, North Carolina” under the “Environmental Overview” within this “Note 1715 – Commitments and Contingent Liabilities”.

In the Separation, ~~DuPont~~EID assigned its asbestos docket to Chemours. At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, there were approximately 1,000 and 1,100 lawsuits pending against ~~DuPont~~EID alleging personal injury from exposure to ~~asbestos.~~asbestos, respectively. These cases are pending in state and federal court in numerous jurisdictions in the U.S. and are individually set for trial. A small number of cases are pending outside of the U.S. Most of the actions were brought by contractors who worked at sites between the 1950s and the 1990s. A small number of cases involve similar allegations by ~~DuPont~~EID employees or household members of contractors or ~~DuPont~~EID employees. Finally, certain lawsuits allege personal injury as a result of exposure to ~~DuPont~~EID products.

At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, Chemours had an accrual of $34 related to these matters.

In the Separation, ~~DuPont~~EID assigned its benzene docket to Chemours. At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, there were 1821 and 1617 cases pending against ~~DuPont~~EID alleging benzene-related illnesses, respectively. These cases consist of premises matters involving contractors and deceased former employees who claim exposure to benzene while working at ~~DuPont~~EID sites primarily in the 1960s through the 1980s, and product liability claims based on alleged exposure to benzene found in trace amounts in aromatic hydrocarbon solvents used to manufacture ~~DuPont~~EID products such as paints, thinners, and reducers.

Management believes that a loss is reasonably possible as to the docket as a whole; however, given the evaluation of each benzene matter is highly fact-driven and impacted by disease, exposure, and other factors, a range of such losses cannot be reasonably estimated at this time.

In May 2021, the Company and EID filed suit in Delaware state court against multiple insurance companies for breach of their contractual obligations to indemnify Chemours and EID against liabilities, costs and losses relating to benzene litigation which are covered under liability insurance policies purchased by EID during the period 1967 to 1986. EID and Chemours are seeking payment of all costs and settlement amounts for past and future benzene cases falling under those policies. The outcome of this matter is not expected to have a material impact on Chemours’ results of operations or financial position.

Chemours does not, and has never, used “PFOA” (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) as a polymer processing aid and/or sold it as a commercial product. Prior to the Separation, the performance chemicals segment of ~~DuPont~~EID made PFOA at Fayetteville and used PFOA as a processing aid in the manufacture of fluoropolymers and fluoroelastomers at certain sites, including: Washington Works, Parkersburg, West Virginia; Chambers Works, Deepwater, New Jersey; Dordrecht Works, Netherlands; Changshu Works, China; and, Shimizu, Japan. These sites are now owned and/or operated by Chemours.

At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, Chemours maintained accruals of ~~$21~~$22 and ~~$20,~~$21, respectively, related to PFOA matters under the Leach Settlement, ~~DuPont’s~~EID’s obligations under agreements with the U.S. Environmental Protection Agency (“EPA”), and voluntary commitments to the New Jersey Department of Environmental Protection (“NJ DEP”). These obligations and voluntary commitments include surveying, sampling, and testing drinking water in and around certain Company sites, and offering treatment or an alternative supply of drinking water if tests indicate the presence of PFOA in drinking water at or greater than the state or the national health advisory. The Company will continue to work with the EPA and other authorities regarding the extent of work that may be required with respect to these matters.

In 2004, ~~DuPont~~EID settled a class action captioned Leach v. DuPont, filed in West Virginia state court, alleging that approximately 80,000 residents living near the Washington Works facility had suffered, or may suffer, deleterious health effects from exposure to PFOA in drinking water. Among the settlement terms, ~~DuPont~~EID funded a series of health studies by an independent science panel of experts (“C8 Science Panel”) to evaluate available scientific evidence on whether any probable link exists, as defined in the settlement agreement, between exposure to PFOA and disease.

The C8 Science Panel found probable links, as defined in the settlement agreement, between exposure to PFOA and pregnancy-induced hypertension, including preeclampsia, kidney cancer, testicular cancer, thyroid disease, ulcerative colitis, and diagnosed high cholesterol. Under the terms of the settlement, ~~DuPont~~EID is obligated to fund up to $235 for a medical monitoring program for eligible class members and pay the administrative costs associated with the program, including class counsel fees. The court-appointed Director of Medical Monitoring implemented the program, and testing is ongoing with associated payments to service providers disbursed from an escrow account which the Company replenishes pursuant to the settlement agreement. As of ~~September~~June 30, ~~2020,~~2021, approximately $1.7 has been disbursed from escrow related to medical monitoring. While it is reasonably possible that the Company will incur additional costs related to the medical monitoring program, such costs cannot be reasonably estimated due to uncertainties surrounding the level of participation by eligible class members and the scope of testing.

In addition, under the Leach settlement agreement, ~~DuPont~~EID must continue to provide water treatment designed to reduce the level of PFOA in water to 6 area water districts and private well users. At Separation, this obligation was assigned to Chemours, and ~~$21~~$22 and ~~$20~~$21 was accrued for these matters at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, respectively.

Further, under the Leach settlement, class members may pursue personal injury claims against ~~DuPont~~EID only for those diseases for which the C8 Science Panel determined a probable link exists. Approximately 3,500 lawsuits were subsequently filed in various federal and state courts in Ohio and West Virginia and consolidated in multi-district litigation (“MDL”) in Ohio federal court. These were resolved in March 2017 when ~~DuPont~~EID entered into an agreement settling all MDL cases and claims, including all filed and unfiled personal injury cases and claims that were part of the plaintiffs’ counsel’s claims inventory, as well as cases tried to a jury verdict (“First MDL Settlement”) for $670.7 in cash, with half paid by Chemours, and half paid by ~~DuPont.~~EID.

Concurrently with the First MDL Settlement, ~~DuPont~~EID and Chemours agreed to a limited sharing of potential future PFOA costs ~~(indemnifiable losses,~~(i.e. “Indemnifiable Losses”, as defined in the Separation agreement between ~~DuPont~~EID and Chemours) for a period of five years. ~~During that five-year period, Chemours will annually pay future PFOA~~The cost-sharing agreement entered concurrently with the First MDL Settlement has been superseded by the binding MOU addressing certain PFAS matters and costs ~~up to $25~~as detailed in “Note 15 – Commitments and if such amount is exceeded, DuPont will pay any excess amount up to the next $25 (which payment will not be subject to indemnification by Chemours), with Chemours annually bearing any further excess costs under the terms of the Separation agreement. After the five-year period, this limited sharing agreement will expire, and Chemours’ indemnification obligations under the Separation agreement will continue unchanged. Chemours has also agreed that it will not contest its indemnification obligations to DuPont under the Separation agreement for PFOA costs on the basis of defenses generally applicable to the indemnification provisions under the Separation agreement, including defenses relating to punitive damages, fines or penalties, or attorneys’ fees, and waives any such defenses with respect to PFOA costs. Chemours has, however, retained other defenses, including as to whether any particular PFOA claim is within the scope of the indemnification provisions of the Separation agreement.Contingent Liabilities”.

While all MDL lawsuits were dismissed or resolved through the First MDL Settlement, the First MDL Settlement did not resolve PFOA personal injury claims of plaintiffs who did not have cases or claims in the MDL or personal injury claims based on diseases first diagnosed after February 11, 2017. ~~Since~~Approximately 96 plaintiffs filed matters after the ~~resolution~~First MDL Settlement. In January 2021, EID and Chemours entered into settlement agreements with counsel representing these plaintiffs, providing for a settlement of all but one of the ~~MDL, approximately 82 personal injury cases have been~~96 then filed and ~~are~~ pending ~~in West Virginia or Ohio courts alleging status~~cases, as ~~a Leach class member. These~~well as additional pre-suit claims, under which those cases ~~are consolidated before~~and claims of settling plaintiffs were resolved for approximately $83 (the “Second MDL Settlement”). Chemours contributed approximately $29, and DuPont and Corteva each contributed approximately $27 to the Second MDL ~~court. A 6-plaintiff trial involving kidney cancer matters previously set for~~Settlement. During the three and six months ended June 30, 2021, Chemours made payments of $22 and $29 associated with the Second MDL Settlement. At December 31, 2020, ~~has been delayed due to COVID-19.~~Chemours had accrued approximately $29 associated with this matter.

InThe single matter not included in the Second MDL Settlement is a testicular cancer case tried in March 2020 ~~a 2-plaintiff trial before the MDL court resulted in: a mistrial in a kidney cancer case when the jury could not reach~~to a verdict ~~and an award~~ of $40 in compensatory and emotional distress damages and $10 in loss of consortium ~~damages in a testicular cancer case.~~damages. The jury found that ~~DuPont’s~~EID’s conduct did not warrant punitive damages. In March 2021, the trial court issued post trial rulings which reduced the consortium damages to $0.25. The Company ~~will appeal~~has appealed the verdict. Management believes that the probability of a loss regarding the verdict is remote, given numerous meritorious grounds for pending post-trial motions and appeal.

In February 2018, the State of Ohio initiated litigation against ~~DuPont~~EID regarding historical PFOA emissions from the Washington Works site. Chemours is an additional named defendant. Ohio alleges damage to natural resources and fraudulent transfer in the spin-off that created Chemours and seeks damages including remediation and other costs and punitive damages.

~~DuPont~~EID and Chemours have received governmental and regulatory inquiries and have been named in other litigations, including class actions, brought by individuals, municipalities, businesses, and water districts alleging exposure to and/or contamination from ~~perfluorinated and polyfluorinated compounds (“PFAS”),~~PFAS, including PFOA. Many actions include an allegation of fraudulent transfer in the spin-off that created Chemours. Chemours has declined ~~DuPont’s~~EID’s requests for indemnity for fraudulent transfer claims.

Chemours has responded to letters and inquiries from governmental law enforcement entities regarding PFAS, including in January 2020, a letter informing it that the U.S. Department of Justice, Consumer Protection Branch, and the United States Attorney’s Office for the Eastern District of Pennsylvania are considering whether to open a criminal investigation under the Federal Food, Drug, and Cosmetic Act and asking that it retain its documents regarding PFAS and food contact applications. In July 2020, Chemours received a grand jury subpoena for documents. We are presently unable to predict the duration, scope, or result of any potential governmental, criminal, or civil proceeding that may result, the imposition of fines and penalties, and/or other remedies. We are also unable to develop a reasonable estimate of a possible loss or range of losses, if any.

Chemours does not, and has never, manufactured aqueous film forming foam (“AFFF”). ~~DuPont~~Numerous defendants, including EID and Chemours have been named in approximately ~~800~~1,300 matters, involving AFFF, which is used to extinguish hydrocarbon-based (i.e., Class B) fires and subject to U.S. military specifications. Most matters have been transferred to or filed directly into a multi-district litigation (“AFFF MDL”) in South Carolina federal court or identified by a party for transfer. The matters pending in the AFFF MDL allege damages as a result of contamination, in most cases due to migration from military installations or airports, or personal injury from exposure to AFFF. Plaintiffs seek to recover damages for investigating, monitoring, remediating, treating, and otherwise responding to the contamination. Others have claims for personal injury, property diminution, and punitive damages.

There are AFFF lawsuits pending outside the AFFF MDL that have not been designated by a party for inclusion in the MDL. These matters identifying ~~DuPont~~EID and/or Chemours as a defendant are:

Valero Refining (“Valero”) has ~~six~~five pending state court lawsuits filed commencing in June 2019 regarding its Tennessee, Texas, Oklahoma, California, and Louisiana facilities. These lawsuits allege that several defendants that designed, manufactured, marketed, and/or sold AFFF or PFAS incorporated into AFFF have caused Valero to incur damages and costs including remediation, AFFF disposal, and replacement. Valero also alleges fraudulent transfer.

In September 2019, a lawsuit alleging personal injury resulting from exposure to AFFF in Long Island drinking water was filed by 4 individuals in New York state court.Plaintiffs also allege violation of New York Uniform Fraudulent Conveyance Act and seek compensatory and punitive damages, and medical monitoring.

In addition to the State of New Jersey actions (as detailed below) and the State of Ohio action (as detailed above), the states of Vermont, New Hampshire, New York, Michigan, ~~and~~ North Carolina, Mississippi, Alaska, and Pennsylvania have filed lawsuits against defendants, including ~~DuPont~~EID and Chemours, relating to the alleged contamination of state natural resources with PFAS compounds either from AFFF and/or other sources. These lawsuits seek damages including costs to investigate, clean up, restore, treat, monitor, or otherwise respond to contamination to natural resources. The lawsuits include counts for fraudulent transfer.

~~Notes~~has engaged with the State of Delaware regarding potential similar causes of action for PFAS and other contaminants. On July 13, 2021, Chemours, DuPont, Corteva, and EID entered into a settlement agreement with the State of Delaware to settle such potential claims, including for environmental releases or sales of products containing PFAS or other known contaminants. Under the agreement, the companies shall make a payment in the total amount of $50 to the ~~Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars~~State of Delaware, which shall be treated as Qualified Spend under the MOU, of which Chemours shall contribute $25, which shall be utilized to fund a Natural Resources and Sustainability Trust (the “Trust”) to be used for environmental restoration and enhancement of resources, sampling and analysis, community environmental justice and equity grants, and other natural resource needs. If the companies enter into a proportionally similar agreement to settle or resolve claims of another state for PFAS-related natural resource damages, for an amount greater than $50, the companies may be required to make one or more supplemental payment(s) directly to the Trust, with such payment(s) not to exceed $25 in ~~millions, except per share amounts)~~the aggregate. At this time, the Company has concluded the probability of loss as to any supplemental payment(s) under the settlement agreement to be remote.

~~DuPont~~EID has also been named in approximately 5040 lawsuits pending in New York courts, which are not part of the Leach class, brought by individual plaintiffs alleging negligence and other claims in the release of PFAS, including PFOA, into drinking water, and seeking medical monitoring, compensatory, and punitive damages against current and former owners and suppliers of a manufacturing facility in Hoosick Falls, New York. NaN other lawsuits in New York have been filed by a business seeking to recover its losses and by nearby property owners and residents in a putative class action seeking medical monitoring, compensatory and punitive damages, and injunctive relief.

In May 2017, the Water Works and Sewer Board of the Town of Centre, Alabama filed suit against numerous carpet manufacturers located in Dalton, Georgia and suppliers and former suppliers, including ~~DuPont,~~EID, in Alabama state court. The complaint alleges negligence, nuisance, and trespass in the release of PFAS, including PFOA, into a river leading to the town’s water source, and seeks compensatory and punitive damages.

In February 2018, the New Jersey-American Water Company, Inc. (“NJAW”) filed suit against ~~DuPont~~EID and Chemours in New Jersey federal court alleging that discharges in violation of the New Jersey Spill Compensation and Control Act (“Spill Act”) were made into groundwater utilized in the NJAW Penns Grove water system. NJAW alleges that damages include costs associated with remediating, operating, and maintaining its system, and attorney fees. In October 2020, this matter was transferred to the AFFF MDL.

In October 2018, a putative class action was filed in Ohio federal court against 3M, ~~DuPont,~~EID, Chemours, and other defendants seeking class action status for U.S. residents having a detectable level of PFAS in their blood serum. The complaint seeks declaratory and injunctive relief, including the establishment of a “PFAS Science Panel”.

In December 2018, the owners of a dairy farm filed a lawsuit in Maine state court against numerous defendants including ~~DuPont~~EID and Chemours alleging that their dairy farm was contaminated by PFAS, including perfluorooctanesulfonic acid (“PFOS”) and PFOA present in treated municipal sewer sludge used in agricultural spreading applications on their farm. The complaint asserts negligence, trespass, and other tort and state statutory claims and seeks damages. This lawsuit has since been dismissed.

In May 2019, a putative class action was filed in Delaware state court against two electroplating companies, 3M and ~~DuPont,~~EID, alleging responsibility for PFAS contamination, including PFOA and PFOS, in drinking water and the environment in the nearby community. Although initially named in the lawsuit, Chemours was subsequently dismissed. The putative class of residents alleges negligence, nuisance, trespass, and other claims and seeks medical monitoring, personal injury and property damages, and punitive damages. The matter was removed to federal court.

Since August 2019, 812 Long Island water suppliers have filed lawsuits in New York federal court against defendants including ~~DuPont~~EID and Chemours regarding alleged PFAS, PFOA, and PFOS contamination through releases from industrial and manufacturing facilities and business locations where PFAS-contaminated water was used for irrigation andsites where consumer products were disposed.  The complaints allege products liability, negligence, nuisance, trespass, and fraudulent transfer. Plaintiffs seek declaratory and injunctive relief, as well as compensatory andpunitive damages.

Since November 2019, ~~two~~seven lawsuits representing approximately 3550 residents have been filed against ~~DuPont,~~EID, Chemours, and other defendants alleging that they are responsible for PFAS contamination, including PFOA and PFOS, in groundwater and drinking water. Plaintiffs have claims including medical monitoring, property value diminution, trespass, punitive damages, and ~~punitive damages.~~personal injury. The lawsuits are pending in New Jersey federal court.

In November 2019, the City of Rome, Georgia filed suit against numerous carpet manufacturers located in Dalton, Georgia, suppliers, ~~DuPont,~~EID, and Chemours in Georgia state court alleging negligence, nuisance, and trespass in the release of perfluorinated compounds, including PFOA, into a river leading to the town’s water source. City of Rome alleges damages to property and lost profits, and expenses for abatement and remediation and punitive damages.

In December 2019, a putative class action was filed in Georgia state court on behalf of customers of the Rome, Georgia water division and the Floyd County, Georgia water department against numerous carpet manufacturers located in Dalton, Georgia, suppliers, ~~DuPont,~~EID, and Chemours in Georgia state court alleging negligence and nuisance and related to the release of perfluorinated compounds, including PFOA, into a river leading to their water sources. The matter was removed to federal court. Damages sought include compensatory damages for increased water surcharges, as well as punitive damages and injunctive relief for abatement and remediation.

In May 2020, the Weirton Area Water Board and City of Weirton, West Virginia, filed a lawsuit in West Virginia state court against defendants, including ~~DuPont~~EID and Chemours, alleging PFAS, PFOA and PFOS contamination through releases from the manufacture, sale, and use of PFAS and from facilities owned by AccelorMittal. Damages sought include declaratory relief, economic damages, indemnification, expenses, remediation, and punitive damages. The matter has been removed to federal court. In January 2021, this matter was transferred to the AFFF MDL.

InSince July ~~and August~~ 2020, five lawsuits were filed in New Jersey federal court by parents of ~~two~~ adult children alleging that exposure to PFAS and other chemicals, including two suits by parents on behalf of their adult children claiming pre-natal exposure ~~resulted~~resulting in the children’s cognitive delays, neurological, genetic and autoimmune conditions. Plaintiffs ~~claim~~seek compensatory and punitive damages.

In September 2020, the Golden State Water Company filed a lawsuit in California federal court against several defendants, including ~~DuPont~~EID and Chemours, alleging manufacturers of PFOA and PFOS are responsible for contaminating the drinking water supply. The complaint alleges products liability, negligence, nuisance, trespass, and fraudulent transfer. Plaintiff seeks injunctive relief, as well as compensatory and punitive damages. In January 2021, the court dismissed the complaint on defendants’ motion regarding jurisdiction grounds.

In December 2020, Suez Water New Jersey and Suez Water New York filed lawsuits in New Jersey and New York federal courts against defendants, including EID and Chemours, alleging damages from PFAS releases into the environment, including PFOA and PFOS, that impacted water sources that the utilities use to provide water. The complaints allege products liability, negligence, nuisance, and trespass. Plaintiffs seek monetary damages, including present and future compliance costs for the respective state-adopted PFAS maximum contaminant levels for public water systems.

In December 2020, 11 southern California public water systems filed a lawsuit in California state court against several defendants, including EID and Chemours, alleging manufacturers of PFOA and PFOS are responsible for contaminating the drinking water supply. The complaint alleges products liability, negligence, nuisance, trespass, state law claims, and fraudulent transfer. Plaintiffs seek injunctive relief, as well as compensatory and punitive damages. The case has been removed to federal court.

In February 2021, the City of Corona, California and the Corona Utility Authority filed a lawsuit in California state court against several defendants, including Chemours and DuPont, alleging manufacturers of PFOA and PFOS are responsible for contaminating the drinking water supply. The lawsuit alleges product liability, negligence, nuisance, trespass, state law claims and fraudulent transfer. Plaintiff seeks injunctive relief, as well as compensatory and punitive damages.

In April 2021, Chemours, along with DuPont and Corteva entities, received a civil summons filed before the Court of Rotterdam by four municipalities (Dordrecht, Papendrecht, Sliedrecht and Molenlanden) seeking liability declarations relating to the Dordrecht site’s operations and emissions. Chemours is reviewing the summons and preparing a statement of defense. At this time, management believes that a loss related to this matter is remote.

Chemours Washington Works discharges, through outfalls at the site, wastewater and stormwater pursuant to a National Pollutant Discharge Elimination System (“NPDES”) permit issued by the West Virginia Department of Environmental Protection (“WV DEP”). In connection with actions being taken by Chemours to comply with certain NPDES effluent limits, including for PFOA and hexafluoropropylene oxide dimer acid, Chemours submitted a permit modification to WV DEP relating to groundwater abatement for certain process water used at the facility, a temperature reduction project and realigning discharge flows to certain outfalls. In July 2021, the EPA provided a specific objection to the draft modification based on Clean Water Act (“CWA”) regulations and requirements. Chemours is reviewing the objections with WV DEP and will seek to resolve EPA’s objections.

In March 2019, the NJ DEP issued two Directives and filed 4 lawsuits against Chemours and other defendants. The Directives are: (i) a state-wide PFAS Directive issued to ~~DuPont,~~EID, DowDuPont, DuPont Specialty Products USA (“DuPont SP USA”), Solvay S.A., 3M, and Chemours seeking a meeting to discuss future costs for PFAS-related costs incurred by the NJ DEP and establishing a funding source for such costs by the Directive recipients, and information relating to historic and current use of certain PFAS compounds; and, (ii) a Pompton Lakes Natural Resources Damages (“NRD”) Directive to ~~DuPont~~EID and Chemours demanding $0.1 to cover the cost of preparation of a natural resource damage assessment plan and access to related documents.

The lawsuits filed in New Jersey state courts by the NJ DEP are: (i) in Salem County, against ~~DuPont,~~EID, 3M, and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, the Water Pollution Control Act (“WPCA”), the Industrial Site Recovery Act (“ISRA”), and common law regarding past and present operations at Chambers Works, a site assigned to Chemours at Separation; (ii) in Middlesex County, against ~~DuPont,~~EID, DuPont SP USA, 3M, and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, ISRA, WPCA, and common law regarding past and present operations at Parlin, ~~a DuPont~~an EID owned site; (iii) in Gloucester County, against ~~DuPont~~EID and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, WPCA, and common law regarding past operations at Repauno, a non-operating remediation site assigned to Chemours at Separation which has been sold; and, (iv) in Passaic County, against ~~DuPont~~EID and Chemours primarily alleging clean-up and removal costs and damages and natural resource damages under the Spill Act, WPCA, and common law regarding past operations at Pompton Lakes, a non-operating remediation site assigned to Chemours at Separation. The alleged pollutants listed in the Salem County and Middlesex County matters above include PFAS. Each lawsuit also alleges fraudulent transfer.

In August 2020, a Second Amended Complaint was filed in each matter, adding fraudulent transfer and other claims against DuPont SP USA, Corteva, Inc., and ~~DuPont de Nemours, Inc.~~DuPont. For the Salem County matter, ~~NJDEP~~NJ DEP added claims relating to failure to comply with state directives, including the state-wide PFAS Directive.

The matters were removed to federal court and consolidated for case management and pretrial purposes.

~~DuPont~~EID requested that Chemours defend and indemnify it in these matters. Chemours has accepted the indemnity and defense of EID while reserving rights and declining ~~DuPont’s~~EID’s demand as to matters ~~under~~involving other EID entities, as well as ISRA and fraudulent transfer, ~~or involving other DuPont entities.~~subject to the terms of the MOU.

With the exception of the ~~trial verdict in the testicular cancer case~~matters noted otherwise above, management believes that it is reasonably possible that the Company could incur losses related to PFOA (in addition to the Second MDL Settlement) and/or PFAS matters in excess of amounts accrued, but any such losses are not estimable at this time due to various reasons, including, among others, that such matters are in their early stages and have significant factual issues to be resolved.

There are six lawsuits, including a putative class action, pending against ~~DuPont~~EID by area residents concerning the U.S. Smelter and Lead Refinery multi-party Superfund site in East Chicago, Indiana. Several of the lawsuits allege that Chemours is now responsible for ~~DuPont~~EID environmental liabilities. The lawsuits include allegations for personal injury damages, property diminution, and other damages. At Separation, ~~DuPont~~EID assigned Chemours its former plant site, which is located south of the residential portion of the Superfund area, and its responsibility for the environmental remediation at the Superfund site. Management believes a loss is reasonably possible, but not estimable at this time due to various reasons including, among others, that such matters are in their early stages and have significant factual issues to be resolved. In one of the six lawsuits, pursuant to a March 2021 court decision, there are no current pending claims against EID or Chemours.

In October 2019, a putative class action was filed in Delaware federal court against Chemours and certain of its officers. Following appointment of lead plaintiff, the New York State Teachers’ Retirement System, and counsel, the plaintiff filed an amended complaint alleging that the defendants violated the Securities and Exchange Act of 1934 by making materially false and misleading statements and omissions in public disclosures regarding environmental liabilities and litigation matters assigned to Chemours in connection with its spin-off from ~~DuPont.~~EID. The amended complaint seeks a class of purchasers of Chemours stock between February 16, 2017 and August 1, 2019 and demands compensatory damages and fees.

Commencing in July 2020, follow-on derivative lawsuits were filed by individual shareholders in Delaware courts against Chemours, its directors, and certain of its officers. The lawsuits rely on factual allegations similar to those in the securities action discussed above and allege breach of fiduciary duty and other claims.

Management believes that it is not possible at this time to reasonably assess the outcome of these litigations or to estimate the loss or range of loss, if any, as the matters are in the early stages with significant issues to be resolved. The Company believes that it has applicable insurance, and coverage has been accepted by the primary insurance carrier with a reservation of rights for the putative class action matter. If the Company were not to prevail in the litigations and were to fail to secure insurance coverage or ample insurance coverage, the impact could be material to the Company’s results of operations, financial position, and cash flows.

~~In March 2018, a civil association in Mexico filed a complaint against the government authorities involved~~The Company is currently in the ~~permitting~~ process of ~~the Company’s~~constructing a new Mining Solutions facility ~~under construction~~ in Gomez Palacio, Durango, Mexico. ~~The claimant sought and obtained a suspension from~~In connection with the district judge to stop the Company’s construction work. The suspension was subsequently lifted on appeal and affirmed by the Supreme Court of Mexico. A second similar complaint was filed in September 2019, and again, a suspension of construction was granted. Chemours has filed an appeal. In the event that the suspension of construction is ultimately upheld, the Company would incur $26 of contract termination fees with a third-party services provider.facility:

In August 2017, a lawsuit was filed by several residents of Durango, Mexico against the government authority involved in granting the Company’s environmental permit for the aforementioned facility. Construction was not suspended in this matter,At June 30, 2021 and the defendants and the Company have responded to the complaint. In October 2020, an Administrative Federal Tribunal in Mexico City, Mexico nullified the existing environmental permit and requested its amendment, including details regarding the handling, storage, and offloading of ammonia at the Company’s facility. The Company will file an appeal and follow an administrative procedure to resolve this matter.

~~At September 30,~~December 31, 2020, the Company had ~~$145~~$157 and $146 of long-lived assets under construction at the ~~facility, $10 of other related prepaid costs,~~facility. The Company ultimately believes that it will be successful in obtaining its permits and ~~$51~~will continue with its planned development of the ~~Company’s goodwill assigned to~~site. While the ~~Mining Solutions reporting unit. Management~~Company currently believes these amounts are recoverable, asfurther significant delays in confirming the validity of ~~September 30, 2020.~~necessary permits to resume construction or other factors could lead to a fixed asset impairment assessment that potentially impairs all or a portion of the facility, resulting in a non-cash charge in the Company’s results of operations at that time.

In July 2020, Iluka Resources Limited, one of the Company’s suppliers of ore feedstock, commenced breach of contract proceedings against the Company in New York state court. Management ~~believes~~believed that the lawsuit ~~lacks~~lacked merit, and that the Company’s actions ~~have been~~were consistent with its rights under the provisions of the contract. ~~The outcome of this matter is~~In June 2021, Iluka Resources Limited and Chemours reached a settlement that does not ~~expected to~~ have a material impact on the Company’s results of operations or financial position, and management does not anticipate any impact on the Company’s supply of ore feedstock.

Chemours, due to the terms of the Separation-related agreements with ~~DuPont,~~EID, is subject to contingencies pursuant to environmental laws and regulations that in the future may require further action to correct the effects on the environment of prior disposal practices or releases of chemical substances, which are attributable to ~~DuPont’s~~EID’s activities before it spun-off Chemours. Much of this liability results from the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”, often referred to as “Superfund”), the Resource Conservation and Recovery Act (“RCRA”), and similar federal, state, local, and foreign laws. These laws require Chemours to undertake certain investigative, remediation, and restoration activities at sites where ownership was transferred to Chemours ~~conducts or once conducted operations~~under the Separation-related agreements or at sites where ~~Chemours-generated~~EID-generated waste was ~~disposed.~~disposed before the 2015 separation. The accrual also includes estimated costs related to a number of sites identified for which it is probable that environmental remediation will be required, but which are not currently the subject of enforcement activities.

Chemours accrues for remediation activities when it is probable that a liability has been incurred and a reasonable estimate of the liability can be made. Where the available information is sufficient to estimate the amount of liability, that estimate has been used. Where the available information is only sufficient to establish a range of probable liability, and no point within the range is more likely than any other, the lower end of the range has been used. Estimated liabilities are determined based on existing remediation laws and technologies and the Company’s planned remedial responses, which are derived from environmental studies, sampling, testing, and analyses. Inherent uncertainties exist in such evaluations, primarily due to unknown environmental conditions, changing governmental regulations regarding liability, and emerging remediation technologies. These accruals are adjusted periodically as remediation efforts progress and as additional technological, regulatory, and legal information becomes available. Environmental liabilities and expenditures include claims for matters that are liabilities of ~~DuPont~~EID and its subsidiaries, which Chemours may be required to indemnify pursuant to the Separation-related agreements. These accrued liabilities are undiscounted and do not include claims against third parties. Costs related to environmental remediation are charged to expense in the period that the associated liability is accrued.

The following table sets forth the components of the Company’s environmental remediation liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019~~2020 for the five sites that are deemed the most significant by management, including Fayetteville as further discussed below.

	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Chambers Works, Deepwater, New Jersey(1)	$	19	$	20	$	27	$	20
East Chicago, Indiana		14		17		11		11
Fayetteville Works, Fayetteville, North Carolina(2)		199		201		355		194
Pompton Lakes, New Jersey		42		43		41		42
USS Lead, East Chicago, Indiana		13		13		15		12
All other sites		111		112		107		111
Total environmental remediation	$	398	$	406	$	556	$	390

The following table sets forth the current and long-term components of the Company’s environmental remediation liabilities and their balance sheet locations at September 30, 2020 and December 31, 2019.

The ~~time-frame~~following table sets forth the current and long-term components of the Company’s environmental remediation liabilities at June 30, 2021 and December 31, 2020.

Typically, the timeframe for a site to go through all phases of remediation (investigation and active clean-up) may take about 15 to 20 years, followed by several years of operation, maintenance, and monitoring (“OM&M”) activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, and diverse regulatory requirements, as well as the presence or absence of other potentially responsible parties. In addition, for claims that Chemours may be required to indemnify ~~DuPont~~EID pursuant to the Separation-related agreements, Chemours, through ~~DuPont,~~EID, has limited available information for certain sites or is in the early stages of discussions with regulators. For these sites in particular, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately ~~$560~~$680 above the amount accrued at ~~September~~June 30, ~~2020.~~2021.

Chemours incurred environmental remediation expenses of ~~$14~~$187 and ~~$53~~$212 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and ~~$10~~$24 and ~~$60~~$39 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively.

Fayetteville has been in operation since the 1970s and is located next to the Cape Fear River southeast of the City of Fayetteville, North Carolina. Hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid”, sometimes referred to as “GenX” or “C3 Dimer Acid”) is manufactured at Fayetteville. The Company has operated the site since its ~~separation~~Separation from ~~DuPont~~EID in 2015.

The Company believes that discharges from Fayetteville to the Cape Fear River, site surface water, groundwater, and air emissions have not impacted the safety of drinking water in North Carolina. The Company is cooperating with a variety of ongoing inquiries and investigations from federal, state, and local authorities, regulators, and other governmental entities.

Consent Order with North Carolina Department of Environmental Quality (“NC DEQ”)

In September 2017, the NC DEQ issued a 60-day notice of intent to suspend the ~~National Pollutant Discharge Elimination System (“NPDES”)~~NPDES permit for Fayetteville, and the State of North Carolina filed an action in North Carolina state court regarding site discharges, seeking a temporary restraining order and preliminary injunction, as well as other relief, including abatement and site correction. The state court entered a partial consent order resolving NC DEQ’s motion for a temporary restraining order.

In November 2017, NC DEQ informed the Company that it was suspending the NPDES permit for Fayetteville. The Company thereafter commenced the capture and separate disposal of all process wastewater from Fayetteville related to the Company’s own operations.

In June 2018, the North Carolina Legislature enacted legislation (i) granting the governor the authority, in certain circumstances, to require a facility with unauthorized PFAS discharges to cease operations, and (ii) granting the governor the authority, in certain circumstances, to direct the NC DEQ secretary to order a PFAS discharger to establish permanent replacement water supplies for parties whose water was contaminated by the discharge.

In July 2018, Cape Fear River Watch (“CFRW”), a non-profit organization, sued NC DEQ in North Carolina state court, seeking to require NC DEQ to take additional actions at Fayetteville. OnIn August ~~29,~~ 2018, CFRW sued the Company in North Carolina federal court for alleged violations of the ~~Clean Water Act (“CWA”)~~CWA and the Toxic Substances Control Act (“TSCA”), seeking declaratory and injunctive relief and penalties.

In February 2019, the North Carolina Superior Court for Bladen County approved a Consent Order (“CO”) between NC DEQ, CFRW and the Company, resolving the State’s and CFRW’s lawsuits and other matters (including Notices of Violation (“NOVs”) issued by the State). Under the terms of the CO, Chemours paid $13 in March 2019 to cover a civil penalty and investigative costs and agreed to certain compliance measures (with stipulated penalties for failures to do so), including the following:

In August 2020, NC DEQ, CFRW, and the Company reached agreement on the terms of an addendum to the CO (the “Addendum”), which includes procedures for implementing specified remedial measures ~~and defined timelines~~ for reducing PFAS loadings from Fayetteville to the Cape Fear River. The Addendum also includes stipulated financial penalties, inclusive of daily and weekly fines for untimeliness in meeting deadlines for construction, installation and other requirements, as well as intermittent performance-based fines for noncompliance in meeting PFAS loading reduction requirements and removal efficiency targets. After a period of public comment, the Addendum was approved by the North Carolina Superior Court for Bladen County on October 12, 2020. A Motion to Intervene filed by Cape Fear Public Utility Authority was denied.

The following table sets forth the on-site and off-site components of the Company’s accrued environmental remediation liabilities related to PFAS at Fayetteville at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
On-site remediation	$	142	$	155	$	301	$	140
Off-site groundwater remediation		57		46		54		54
Total accrued liabilities	$	199	$	201
Total Fayetteville environmental remediation					$	355	$	194

The following table sets forth the current and long-term components of the Company’s accrued environmental remediation liabilities related to PFAS at Fayetteville ~~and their balance sheet locations~~ at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

Fayetteville operates multiple permitted air discharge stacks, blowers, and vents as part of its manufacturing activities. A thermal oxidizer (“TO”) became fully operational at the site on December 27, 2019, and Chemours switched to the permitted operating scenario for the TO on December 31, 2019 as set forth in the CO. The TO is designed to reduce aerial PFAS emissions from Fayetteville, and, on March 30, 2020, Chemours announced that testing results conducted in the first 90 days of operation show that the TO is controlling PFAS emissions at an average efficiency exceeding 99.999%. On March 31, 2021, Chemours reported to NC DEQ the results of testing that occurred in January 2021 which continued to show the 99.999% efficiency. Testing was conducted by Chemours and monitored by the North Carolina Division of Air Quality (“NC DAQ”). Environmental costs are capitalized and subsequently depreciated if the costs extend the useful life of the property, increase the property’s capacity, and/or reduce or prevent contamination from future operations.

The CO requires the Company to provide permanent replacement drinking water supplies, including via connection to public water supply, whole building filtration units and/or RO units, to qualifying surrounding residents, businesses, schools, and public buildings with private drinking water wells. Qualifying surrounding properties with private drinking water wells that have tested above the state provisional health goal of 140 parts per trillion (ppt) for GenX may be eligible for public water or a whole building filtration system. Qualifying surrounding properties with private drinking water wells that have tested above 10 ppt for GenX or other perfluorinated compounds (“Table 3 Compounds”) are eligible for three under-sink RO units. The Company provides bottled drinking water to a qualifying property when it becomes eligible for a replacement drinking water supply, and continues to provide delivery of bottled drinking water to the property until the eligible supply is established or installed. Under the terms of the CO, Chemours must make the offer to install a water treatment system to property owners in writing multiple times, and property owners have approximately one year to accept the Company’s offer before it expires.

The Company’s estimated liability for off-site replacement drinking water supplies is based on management’s assessment of the current facts and circumstances for this matter, which are subject to various assumptions that include, but are not limited to, the number of affected surrounding properties, response rates to the Company’s offer, the timing of expiration of offers made to the property owners, the type of water treatment systems selected (i.e., whole building filtration or RO units), the cost of the selected water treatment systems, and any related OM&M requirements, fines and penalties, and other charges contemplated by the CO. For off-site drinking water supplies, OM&M is accrued for 20 years on an undiscounted basis based on the Company’s current plans under the CO.

For the three and ~~nine~~six months ended ~~September~~June 30, 2021, the Company accrued $5 and $10, respectively, and for the three and six months ended June 30, 2020, the Company accrued $9$13 and ~~$27,~~$18, respectively, for off-site groundwater testing and water treatment system installations at additional qualifying third-party properties in the vicinity surrounding Fayetteville. The amounts accrued during the three and nine months ended September 30, 2020 are net of $3 and $7, respectively, of changes in estimates related to the cost of installing, maintaining, and monitoring certain water treatment systems. During most of the second quarter of 2020, testing of drinking water wells and water treatment system installations were temporarily suspended in connection with health and safety precautions taken during the COVID-19 pandemic. Chemours resumed residential sampling and installation of water treatment systems in June 2020. Off-site installation, maintenance, and monitoring may be impacted by additional changes in estimates as actual experience may differ from management’s estimates. It is currently estimated that ~~$57~~$54 of disbursements related to off-site replacement drinking water supplies and toxicity studies will be made over approximately 20 years,. as well as toxicity studies over the next three years.

Abatement and remediation measures already taken by Chemours, including the capture and ~~separate~~ disposal of its operations’ process wastewater and other interim actions, have addressed and abated nearly all PFAS discharges from the Company’s continuing operations at Fayetteville. However, the Company continues to have active dialogue with NC DEQ and other stakeholders regarding the potential remedies that are both economically and technologically feasible to achieve the CO and Addendum objectives related to the impact of site surface water and ~~groundwater.~~groundwater from historical operations.

In the fourth quarter of 2019, the Company completed and submitted its Cape Fear River PFAS Loading Reduction Plan - Supplemental Information Report and its Corrective Action Plan (“CAP”) to NC DEQ. The Supplemental Information Report provided information to support the evaluation of potential interim remedial options to reduce PFAS loadings to surface waters. The CAP described potential long-term remediation activities to address PFAS in on-site groundwater and surface waters at the site, in accordance with the requirements of the CO and the North Carolina groundwater standards, and built upon the previous submissions to NC DEQ. The NC DEQ ~~made~~received comments on the CAP ~~available for~~during a public ~~review and~~ comment ~~until April 6, 2020,~~period, and the Company is awaiting formal response to the CAP from NC ~~DEQ following the conclusion of the public comment period.~~DEQ. With respect to the CO, the Addendum was approved by the North Carolina Superior Court for Bladen County on October 12, 2020 and ~~represents our agreement with~~establishes the ~~NC DEQ and CFRW regarding~~procedure to implement specified remedial measures ~~and defined timelines to reduce~~for reducing PFAS loadings from Fayetteville to the Cape Fear River, including construction of a barrier wall with a groundwater extraction system to be completed by March 15, 2023. ~~Detailed engineering and design work has commenced with~~

Following issuance of an NPDES permit by NC DEQ ~~approval~~on September 18, 2020, the Company began operation of a capture and treatment system from the site’s old outfall channel on September 30, 2020. During the first quarter of 2021, the operation of the old outfall treatment system was interrupted on two occasions, and notice was provided to NC DEQ of the low treatment flow conditions through the system. On January 26, 2021, the Company received an NOV from NC DEQ, alleging violations of the CO and the NPDES water permit ~~applications anticipated~~arising from the design and operation of the treatment system related to the old outfall. The Company and its third-party service provider have taken, and continue to take, interim actions intended to improve the operation of the old outfall treatment system and address challenges posed by substantial rain events, sediment loading into the system, and variability in ~~August~~water influent conditions. In addition, the Company and its third-party service provider are actively working on long-term enhancements to the treatment system based on learnings from the recent challenges. These enhancements will, or may include, the construction of a holding pond, installation of new ultra-filtration units, a sediment trap to manage sediment flow in the stream channel, alternate equipment to remove solids created during water pretreatment, and enhancement of the carbon absorption system. An incremental $60 was accrued in the three months ended June 30, 2021, ~~as well as two stages~~representing approximately $3 per year for 20 years of ~~design approval anticipated~~estimated operation of the system, primarily related to the probable enhancements and the long-term operation of the water treatment system in ~~August 2021 and March 2022.~~accordance with the requirements of the CO.

The Company’s estimated liability for the remediation activities that are probable and estimable is based on the CO, the Addendum, the CAP, and management’s assessment of the current facts and circumstances, which are subject to various assumptions including the transport pathways (being pathways by which PFAS reaches the Cape Fear River) which will require remedial actions, the types of interim and permanent site surface water and on-site remedies and treatment systems selected and implemented, the estimated cost of such potential remedies and treatment systems, any related OM&M requirements, and other charges contemplated by the CO and the Addendum.

In the second quarter of 2021, work commenced on the detailed engineering design of the barrier wall and refinement of models for the planned groundwater extraction system. Engineering designs for our major construction projects are typically reviewed at 30, 60 and 90% complete. Per the Addendum, a 60% design is required to be submitted to NC DEQ by August 15, 2021 for their review and approval. Additionally, applications for the necessary permits for the groundwater extraction system are expected to be submitted by that date.A 90% complete design is required to be submitted to NC DEQ by March 31, 2022 for their review and approval. In June 2021, the Company reviewed the 30% complete design and associated preliminary vendor estimates for the construction and operation of a barrier wall and groundwater treatment system at Fayetteville.

The current planned construction site of the future barrier wall, that will address both on-site groundwater and long-term seep remediation, is expected to be located at an approximately 30 feet higher elevation above the Cape Fear River as compared to the initial, conceptual design that was prepared in support of the CAP submission to NC DEQ on December 31, 2019, which addressed groundwater only. The CAP submission unit cost estimate was the principal basis of unit costs for our liability estimates through March 31, 2021. It was determined in the quarter ended June 30, 2021, based upon the 30% design information completed during the quarter, that there was significantly increased construction complexity and related vendor and other design costs to be incurred.For example, the steep slope of the revised construction site results in the depth of the wall increasing from the original estimates of approximately 65 feet to approximately 85 feet below ground along most of its length. Construction of approximately 64 pumping wells, a more than 50% increase from the conceptual design, are expected to be required to extract groundwater for treatment based on studies of groundwater flows that were completed in May 2021. The wells will also need to be drilled deeper into the ground based on the revised location. A 2-mile access road, with retaining walls above and below the road to reduce slope erosion and landslides, will now be required for large, heavy construction equipment to access the barrier wall location safely. The estimated cost for construction as a result of these changes is based on third-party contractor estimates provided in late May 2021. Together, all these modifications to the design resulted in an additional $49 accrued for construction of the barrier wall in the quarter ended June 30, 2021.

The volume of groundwater, seep water, and stormwater (up to a 0.5 inch rain event in any 24 hours period per the Addendum) intercepted for treatment is estimated to be up to a maximum of 1,500 gallons per minute (“gpm”) based on groundwater flow modeling completed in the second quarter of 2021. Until the pre-design investigation and groundwater modeling was complete, the volume of water captured for treatment was estimated to be approximately 1,200 gpm, and the pretreatment requirements to remove dissolved solids had not been determined. Hence, the Company determined in the second quarter of 2021 that construction of a larger treatment plant than previously considered in the conceptual design and previous cost estimates was required. Consistent with prior periods, the Company accrued 20 years of ongoing monitoring and maintenance for Fayetteville environmental remediation systems based on the CO and Addendum. The revised estimate to process higher volumes of groundwater than originally contemplated resulted in a change in estimate of $60 being recorded in the quarter ended June 30, 2021 related to estimated higher power consumption, ongoing monitoring, pretreatment, filtering supplies, principally carbon and regular maintenance of the system over a 20-year period of estimated operation starting in 2023.

Accordingly, as discussed above, in the three months ended June 30, 2021, the Company revised in accordance with ASC 250 – Accounting Changes and Error Corrections, its estimated liability to comply with the CO and Addendum, and an incremental $49 was accrued related to the construction of the barrier wall and an additional $60 related to the future operation of the groundwater extraction and treatment system. In accordance with ASC 410 – Asset Retirement and Environmental Obligations, these amounts were recorded as a component of cost of ~~a permanent~~goods sold as the Company only capitalizes environmental costs if the costs extend the useful life of the property, increase the property’s capacity, and/or reduce or prevent contamination from future operations.

Pre-construction site preparation activities are in progress and construction of the water treatment facility is expected to commence before the end of 2021. Construction of the barrier wall is expected to commence in 2022 with completion planned in the first quarter of 2023. At June 30, 2021, several significant uncertainties remain, principally related to an extension of the barrier wall along Willis Creek at the northern end of the site, additional wetlands mitigation fees, finalization of the volume of water to be treated, contract negotiations with key construction and water treatment vendors and the estimated future time period of OM&M. The Company believes that extension of the barrier wall along the Willis Creek is technically impracticable and not necessary to comply with the terms of the CO and Addendum. Accordingly, the Company has increased the upper range of its cost estimates for the barrier wall and groundwater OM&M from $111 at December 31, 2020 to $303 at June 30, 2021, of which $173 is already accrued. The Company has not accrued for the incremental costs in the upper range, including the extension of the barrier wall. Estimated costs for the barrier wall extension included in the upper range of the cost estimates is approximately $30.

The final cost of the on-site groundwater treatment system primarily depends on receiving timely NC DEQ design and permit approvals and thus the ~~determination~~timely finalization of certain significant design details, notably the actual barrier wall ~~installation method (i.e., slurry wall vs. steel sheets),~~location, depth, and length, number and configuration of extraction wells, water extraction rates and ~~extraction rates.~~

~~Accordingly, during~~estimated carbon usage. The engineering design is expected to be approximately 60% complete in the third quarter of ~~2020,~~2021, which will form the basis of a submission for the first approval by NC DEQ which is required to be submitted by the Company no later than August 15, 2021. Per the Addendum, the NC DEQ shall use best efforts to complete its review and notify the Company whether the design is approved within 30 days after submittal. If not approved within 30 days, subsequent deadlines shall be extended by the time required for NC DEQ approval in excess of 30 days. Unanticipated schedule delays or other factors beyond the Company’s control could lead to further increases in the cost of the barrier wall and groundwater treatment system, which could be material. Changes in estimates are recorded in results of operations in the period that the events and circumstances giving rise to such changes occur. If the Company does not achieve project completion of the barrier wall and groundwater treatment system by March 15, 2023, the Addendum specifies penalties of $0.15 plus an additional $0.02 per week until installation is completed.

Accordingly, based on the CO, the Addendum, the CAP, and management’s plans, which are based on current regulations and technology, ~~there were no changes to~~ the ~~estimated on-site remediation liability. The~~ Company has accrued ~~$142~~$301 and $140 at June 30, 2021 and December 31, 2020, respectively, related to the estimated cost of on-site remediation, which is within the existing estimated range of potential outcomes, based on current potential remedial options, and projected to be paid over a period of approximately 20 years. The final costs of any selected remediation will depend primarily on the final approved design and actual labor and material costs. ~~With respect to the Addendum, at this time, the Company believes that payment of any of the stipulated financial penalties for untimeliness or noncompliance is remote.~~

It is possible that issues relating to site discharges in various transport pathways, the selection of remediation alternatives to achieve PFAS loading reductions, or the operating effectiveness of the TO could result in further litigation and/or regulatory demands with regards to Fayetteville, including potential permit modifications or penalties under the CO and the Addendum. It is also possible that, as additional data is collected on the transport pathways and dialogue continues with NC DEQ and other stakeholders, the type or extent of remediation actions required to achieve the objectives committed to in the CO may change (increase or decrease) or remediation activities could be delayed. If such issues arise, or if the CO is further amended, an additional loss is reasonably possible, but not estimable at this time.

~~Notes~~ With respect to the ~~Interim Consolidated Financial Statements (Unaudited)~~

~~(Dollars in millions, except per share amounts)~~Addendum, at this time, the Company believes that payment of any of the stipulated financial penalties for untimeliness or noncompliance is remote.

AnIn February 2019, the Company received an NOV ~~was received~~ from the EPA, ~~in February 2019,~~ alleging certain TSCA violations at Fayetteville. Matters raised in the NOV could have the potential to affect operations at Fayetteville. For this NOV, the Company responded to the EPA in March 2019, asserting that the Company has not violated environmental laws. The Company also received an NOV in April 2020 from NC DEQ, alleging an air permit violation under the North Carolina Administrative Code. As of ~~September~~June 30, ~~2020,~~2021, management does not believe that a loss is probable.

In June 2020, the Company received an NOV from the NC DEQ, alleging violations of the North Carolina Solid Waste Generator Requirements in connection with clearing land and yard waste materials to a landfill during construction of the water treatment plant required for remediation under the CO. The Company responded that it did not commit a violation and had addressed any concerns prior to issuance of the NOV. ~~Management does not believe that~~In March 2021, the Company received a ~~loss~~compliance order associated with the June 2020 NOV. The NOV has been resolved and the matter is ~~probable.~~now closed.

In 2019, civil actions were filed against ~~DuPont~~EID and Chemours in North Carolina federal court relating to discharges from Fayetteville. These actions include a consolidated action brought by public water suppliers seeking damages and injunctive relief, a consolidated purported class action seeking medical monitoring, and property damage and/or other monetary and injunctive relief on behalf of the putative classes of property owners and residents in areas near or that draw drinking water from the Cape Fear River, and two actions encompassing ~~several hundred~~approximately 1,000 private well owners seeking compensatory and punitive damages. Ruling on the Company’s motions in April 2019, the court dismissed the medical monitoring, injunctive demand, and many other alleged causes of actions in these lawsuits. It is possible that additional litigation may be filed against the Company and/or ~~DuPont~~EID concerning the discharges.

In addition to natural resource damages matter filed by the State of North Carolina (as discussed within the “PFAS” section of this “Note 1715 – Commitments and Contingent Liabilities”), in September 2020, 3 additional lawsuits were filed in North Carolina state court against Chemours and ~~DuPont,~~EID, as well as other defendants. One of the lawsuits is a putative class action on behalf of residents who are served by the Cape Fear Public Water utility, alleges negligence, nuisance, and other claims related to the release of perfluorinated compounds from Fayetteville, and seeks compensatory and punitive damages and medical monitoring. The other two lawsuits were filed on behalf of individuals residing near Fayetteville and allege negligence, nuisance, and other claims related to the release of perfluorinated compounds. The individuals seek compensatory property damages, punitive damages, and, in some cases, medical monitoring. All three lawsuits allege fraudulent transfer against ~~DuPont~~EID and other ~~DuPont~~EID entities, but not against Chemours. In October 2020, the cases were removed to federal court.

It is not possible at this point to predict the timing, course, or outcome of all governmental and regulatory inquiries and notices and litigation, and it is reasonably possible that these matters could ~~materially affect~~have a material adverse effect on the Company’s financial position, results of operations, and cash flows. In addition, local communities, organizations, and federal and state regulatory agencies have raised questions concerning HFPO Dimer Acid and other perfluorinated and polyfluorinated compounds at certain other manufacturing sites operated by the Company. It is possible that additional developments similar to those described above and centering on Fayetteville could arise in other locations.

On August 1, 2018, the Company’s board of directors approved a share repurchase program authorizing the purchase of shares of Chemours’ issued and outstanding common stock in an aggregate amount not to exceed $750, plus any associated fees or costs in connection with the Company’s share repurchases activity (the “2018 Share Repurchase Program”). On February 13, 2019, the Company’s board of directors increased the authorization amount of the 2018 Share Repurchase Program from $750 to $1,000. Under the 2018 Share Repurchase Program, shares of Chemours’ common stock can be purchased on the open market from time to time, subject to management’s discretion, as well as general business and market conditions. The Company’s 2018 Share Repurchase Program became effective on August 1, 2018, was announced to the public on August 2, 2018, and was originally scheduled to continue through the earlier of its expiration on December 31, 2020 or the completion of repurchases up to the approved amount. On December 8, 2020, the Company’s board of directors approved the extension of the 2018 Share Repurchase Program through December 31, 2022. The program may be suspended or discontinued at any time. All common shares purchased under the 2018 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

Under the 2018 Share Repurchase Program, the Company purchased an additional 423,273 shares of Chemours’ issued and outstanding common stock during the second quarter of 2021, which amounted to $15 at an average share price of $35.08 per share. The aggregate amount of Chemours’ common stock that remained available for purchase under the 2018 Share Repurchase Program at June 30, 2021 was $413.

The Company’s total stock-based compensation expense amounted to $3$8 and ~~$12~~$20 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and $4$1 and ~~$18~~$9 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively.

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, Chemours granted approximately ~~2,780,000~~1,120,000 non-qualified stock options to certain of its employees, all of which ~~2,750,000 non-qualified stock options~~ were granted in the first quarter of ~~2020.~~2021. These awards will vest over a three-year period and expire 10 years from the date of grant. The fair value of the Company’s stock options is based on the Black-Scholes valuation model.

The following table sets forth the weighted-average assumptions used at the respective grant dates to determine the fair value of the Company’s stock option awards that were granted during the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021.

	Nine Months Ended September 30, 2020			Six Months Ended June 30, 2021
Risk-free interest rate		0.94	%		0.91	%
Expected term (years)		6.00			6.00
Volatility		53.18	%		63.85	%
Dividend yield		6.93	%		4.16	%
Fair value per stock option	$	3.74		$	9.78

The Company recorded $1$2 and $8$7 in stock-based compensation expense specific to its stock options for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and $2 and $8$7 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively. At ~~September~~June 30, ~~2020,~~2021, approximately ~~7,870,000~~7,650,000 stock options remained outstanding.

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, Chemours granted approximately ~~530,000~~380,000 restricted stock units (“RSUs”) to certain of its ~~employees.~~employees, of which approximately 340,000 were granted in the first quarter of 2021. These awards will vest over a three-year period and, upon vesting, convert 1-for-one to Chemours’ common stock. The fair value of the RSUs is based on the market price of the underlying common stock at the grant date.

The Company recorded $1$3 and $5$7 in stock-based compensation expense specific to its RSUs for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and $1$2 and $5$4 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively. At ~~September~~June 30, ~~2020,~~2021, approximately ~~1,110,000~~1,440,000 RSUs remained non-vested.

During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, Chemours granted approximately ~~540,000~~290,000 performance share units (“PSUs”) to key senior management ~~employees.~~employees, all of which were granted in the first quarter of 2021. Upon vesting, these awards convert 1-for-one to Chemours’ common stock if specified performance goals, including certain market-based conditions, are met over the three-year performance period specified in the grant, subject to exceptions through the respective vesting period of three years. Each grantee is granted a target award of PSUs, and may earn between 0% and 250% of the target amount depending on the Company’s performance against stated performance goals.

A portion of the fair value of PSUs was estimated at the grant date based on the probability of satisfying the market-based conditions associated with the PSUs using the Monte Carlo valuation method, which assesses probabilities of various outcomes of market conditions. The other portion of the fair value of the PSUs is based on the fair market value of the Company’s stock at the grant date, regardless of whether the market-based conditions are satisfied.

The Company recorded $3 and $6 in stock-based compensation expense ~~of $1 and reductions of stock-based compensation of $1~~ specific to its PSUs for the three and ~~nine~~six months ended ~~September~~June 30, 2021, respectively, and reductions of $3 and $2 for the three and six months ended June 30, 2020, respectively, based on its assessment of Company performance relative to award-based financial objectives. ~~The Company recorded less than $1 and $5 in stock-based compensation expense specific to its PSUs for the three and nine months ended September~~At June 30, ~~2019, respectively. At September 30, 2020,~~2021, approximately ~~850,000~~1,010,000 PSUs at 100% of the target amount remained non-vested.

Since 2017, the Company has provided employees the opportunity to participate in The Chemours Company Employee Stock Purchase Plan (“ESPP”). Under the ESPP, a total of 7,000,000 shares of Chemours’ common stock is reserved and authorized for issuance to participating employees, as defined by the ESPP, which excludes executive officers of the Company. The ESPP provides for consecutive 12-month offering periods, each with 2 purchase periods in March and September within those offering periods. The initial offering period under the ESPP began on October 2, 2017. Participating employees are eligible to purchase the Company’s common stock at a discounted rate equal to 95% of its fair value on the last trading day of each purchase period. ~~During~~In the first ~~and third quarters~~quarter of ~~2020,~~2021, the Company executed an open market ~~transactions~~transaction to purchase ~~its~~the Company’s common stock on behalf of ESPP ~~participants. Total purchases~~participants, which amounted to ~~less than $1~~approximately 22,000 shares at $1.

The following table sets forth the changes and ~~$1 for~~after-tax balances of the ~~three and nine months ended September 30, 2020, respectively, which approximated 105,000 shares of Chemours’ common stock purchased during~~Company’s components comprising accumulated other comprehensive loss.

Notes to the ~~nine months ended September 30, 2020.~~Interim Consolidated Financial Statements (Unaudited)

In the ordinary course of business, Chemours enters into contractual arrangements to reduce its exposure to foreign currency risks. The Company has established a financial risk management program, which currently includes four distinct risk management instruments: (i) foreign currency forward contracts, which are used to minimize the volatility in the Company’s earnings related to foreign exchange gains and losses resulting from remeasuring its monetary assets and liabilities that are denominated in non-functional currencies; (ii) foreign currency forward contracts, which are used to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of the Company’s international subsidiaries that use the euro as their functional currency; (iii) interest rate swaps, which are used to mitigate the volatility in the Company’s cash payments for interest due to fluctuations in LIBOR, as is applicable to the portion of the Company’s senior secured term loan facility denominated in U.S. dollars; and, (iv) euro-denominated debt, which is used to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar for certain of its international subsidiaries that use the euro as their functional currency. The Company’s financial risk management program reflects varying levels of exposure coverage and time horizons based on an assessment of risk. The program operates within Chemours’ financial risk management policies and guidelines, and the Company does not enter into derivative financial instruments for trading or speculative purposes.

Net Monetary Assets and Liabilities Hedge – Foreign Currency Forward Contracts

At ~~September~~June 30, ~~2020,~~2021, the Company had 2014 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of ~~$528,~~$350, and an average maturity of one month. At December 31, ~~2019,~~2020, the Company had 1625 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of ~~$530,~~$688, and an average maturity of one month. Chemours recognized a net gain of $9 and a net loss of $11 for the three and six months ended June 30, 2021, respectively, and net gains of $10 and ~~$14~~$4 for the three and ~~nine~~six months ended ~~September~~June 30, 2020, ~~respectively, and net gains of $1 and less than $1 for the three and nine months ended September 30, 2019,~~ respectively, in other income (expense), net.

At ~~September~~June 30, ~~2020,~~2021, the Company had ~~117~~156 foreign currency forward contracts outstanding under its cash flow hedge program with an aggregate notional U.S. dollar equivalent of ~~$86,~~$119, and an average maturity of ~~five~~four months. At December 31, ~~2019,~~2020, the Company had ~~150~~144 foreign currency forward contracts outstanding under its cash flow hedge program with an aggregate notional U.S. dollar equivalent of ~~$124,~~$101, and an average maturity of ~~five~~four months. Chemours recognized a pre-tax ~~losses~~loss of $2$1 and a pre-tax gain of $3 for the three and six months ended June 30, 2021, respectively, and a pre-tax loss of $1 and a pre-tax gain of $1 for the three and ~~nine~~six months ended ~~September~~June 30, 2020, ~~respectively, and pre-tax gains of $5 and $7 for the three and nine months ended September 30, 2019,~~ respectively, within accumulated other comprehensive loss. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, $1 and $5$3 of ~~gain~~loss was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, $2 and $8$3 of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively.

The Company expects to reclassify ~~an approximate $3~~less than $1 of net ~~loss~~gain from accumulated other comprehensive loss to the cost of goods sold over the next 12 months, based on current foreign currency exchange rates.

~~Beginning in the second quarter of 2020, the Company elected to expand its cash flow hedge program and enter into interest rate swaps. The objective of entering interest rate swaps is to~~ mitigate the volatility in the Company’s cash payments for interest related to the portion of the Company’s senior secured term loan facility denominated in U.S. dollars, which bears a variable interest rate equal to, at the election of the Company, adjusted LIBOR plus 1.75% or adjusted base rate plus 0.75%, subject to an adjusted LIBOR or an adjusted base rate floor of 0.00% or 1.00%, respectively. All gains and losses resulting from the revaluation of the derivative instruments are recognized as a component of accumulated other comprehensive loss on the consolidated balance sheets during the period in which they occur, and are reclassified to interest expense, net in the consolidated statements of operations during the period in which the underlying transaction affects earnings.

At ~~September~~June 30, 2021 and December 31, 2020, the Company had 3 interest rate swaps outstanding under its cash flow hedge program with an aggregate notional U.S. dollar equivalent of $400; each of the interest rate swaps mature on March 31, 2023. Chemours recognized a pre-tax ~~losses~~loss of less than $1 and a pre-tax gain of less than $1 for the three and six months ended June 30, 2021, and pre-tax losses of $3 for the three and ~~nine~~six months ended ~~September~~June 30, 2020, ~~respectively,~~ within accumulated other comprehensive loss. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2020, less than~~2021, $1 of loss was reclassified to interest expense, net from accumulated other comprehensive ~~loss.~~loss, respectively.

The Company expects to reclassify an approximate $1$1 of net loss from accumulated other comprehensive loss to interest expense, net over the next 12 months.

The Company recognized a pre-tax ~~losses~~loss of ~~$32~~$13 and ~~$40~~a pre-tax gain of $24 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and pre-tax ~~gains~~losses of ~~$33~~$18 and ~~$36~~$8 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively, on its net investment hedge within accumulated other comprehensive loss. NaN amounts were reclassified from accumulated other comprehensive loss for the Company’s net investment hedges during the three and ~~nine~~six months ended ~~September~~ June 30, ~~2020~~2021 and ~~2019.~~2020.

The following table sets forth the fair value of the Company’s derivative assets and liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

		Fair Value Using Level 2 Inputs					Fair Value Using Level 2 Inputs
	Balance Sheet Location	September 30, 2020		December 31, 2019		Balance Sheet Location	June 30, 2021		December 31, 2020
Asset derivatives:
Foreign currency forward contracts not designated as a hedging instrument	Accounts and notes receivable, net (Note 9)	$	—	$	1	Accounts and notes receivable, net (Note 7)	$	—	$	4
Foreign currency forward contracts designated as a cash flow hedge	Accounts and notes receivable, net (Note 9)		—		1	Accounts and notes receivable, net (Note 7)		1		—
Total asset derivatives		$	—	$	2		$	1	$	4

Liability derivatives:
Foreign currency forward contracts not designated as a hedging instrument	Other accrued liabilities (Note 14)	$	—	$	1	Other accrued liabilities (Note 12)	$	1	$	1
Foreign currency forward contracts designated as a cash flow hedge	Other accrued liabilities (Note 14)		2		—	Other accrued liabilities (Note 12)		—		4
Interest rate swaps designated as a cash flow hedge	Other accrued liabilities (Note 14)		3		—	Other accrued liabilities (Note 12)		2		3
Total liability derivatives		$	5	$	1		$	3	$	8

The Company’s foreign currency forward contracts and interest rate swaps are classified as Level 2 financial instruments within the fair value hierarchy as the valuation inputs are based on quoted prices and market observable data of similar instruments. For derivative assets and liabilities, standard industry models are used to calculate the fair value of the various financial instruments based on significant observable market inputs, such as foreign exchange rates and implied volatilities obtained from various market sources. Market inputs are obtained from well-established and recognized vendors of market data, and are subjected to tolerance and/or quality checks.

The following table sets forth the pre-tax changes in fair value of the Company’s financial instruments for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Gain (Loss) Recognized In									Gain (Loss) Recognized In
							Accumulated Other												Accumulated
	Cost of		Interest		Other Income		Comprehensive												Other
Three Months Ended September 30,	Goods Sold		Expense, Net		(Expense), Net		Loss
										Cost of			Interest			Other Income			Comprehensive
Three Months Ended June 30,										Goods Sold			Expense, Net			(Expense), Net			Loss
2021
Foreign currency forward contracts not designated as a hedging instrument										$	—		$	—		$	9		$	—
Foreign currency forward contracts designated as a cash flow hedge											(1	)		—			—			(1	)
Interest rate swaps designated as a cash flow hedge											—			(1	)		—			—
Euro-denominated debt designated as a net investment hedge											—			—			—			(13	)

2020
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	—	$	10	$	—		$	—		$	—		$	10		$	—
Foreign currency forward contracts designated as a cash flow hedge		1		—		—		(2	)		2			—			—			(1	)
Interest rate swaps designated as a cash flow hedge		—		—		—		—			—			—			—			(3	)
Euro-denominated debt designated as a net investment hedge		—		—		—		(32	)		—			—			—			(18	)

2019
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	—	$	1	$	—
Foreign currency forward contracts designated as a cash flow hedge		2		—		—		5
Euro-denominated debt designated as a net investment hedge		—		—		—		33
										Gain (Loss) Recognized In
	Gain (Loss) Recognized In																		Accumulated
							Accumulated Other												Other
	Cost of		Interest		Other Income		Comprehensive			Cost of			Interest			Other Income			Comprehensive
Nine Months Ended September 30,	Goods Sold		Expense, Net		(Expense), Net		Loss
Six Months Ended June 30,										Goods Sold			Expense, Net			(Expense), Net			Loss
2021
Foreign currency forward contracts not designated as a hedging instrument										$	—		$	—		$	(11	)	$	—
Foreign currency forward contracts designated as a cash flow hedge											(3	)		—			—			3
Interest rate swaps designated as a cash flow hedge											—			(1	)		—			—
Euro-denominated debt designated as a net investment hedge											—			—			—			24

2020
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	—	$	14	$	—		$	—		$	—		$	4		$	—
Foreign currency forward contracts designated as a cash flow hedge		5		—		—		(1	)		3			—			—			1
Interest rate swaps designated as a cash flow hedge		—		—		—		(3	)		—			—			—			(3	)
Euro-denominated debt designated as a net investment hedge		—		—		—		(40	)		—			—			—			(8	)

2019
Foreign currency forward contracts not designated as a hedging instrument	$	—	$	—	$	—	$	—
Foreign currency forward contracts designated as a cash flow hedge		8		—		—		7
Euro-denominated debt designated as a net investment hedge		—		—		—		36

Chemours sponsors defined benefit pension plans for certain of its employees in various jurisdictions outside of the U.S. The Company’s net periodic pension (cost) income is based on estimated values and the use of assumptions about the discount rate, expected return on plan assets, and the rate of future compensation increases received by its employees.

The following table sets forth the Company’s net periodic pension (cost) income and amounts recognized in other comprehensive income for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019			2021			2020			2021			2020
Service cost	$	(4	)	$	(3	)	$	(11	)	$	(9	)	$	(4	)	$	(4	)	$	(8	)	$	(7	)
Interest cost		(2	)		(4	)		(6	)		(13	)		(2	)		(2	)		(3	)		(4	)
Expected return on plan assets		4			12			12			38			5			4			10			8
Amortization of actuarial loss		(2	)		(6	)		(6	)		(18	)		(2	)		(2	)		(4	)		(4	)
Amortization of prior service gain		1			1			2			2			1			1			2			1
Settlement loss		(1	)		(3	)		(1	)		(4	)
Curtailment gain		1			—			1			—
Total net periodic pension cost	$	(3	)	$	(3	)	$	(9	)	$	(4	)	$	(2	)	$	(3	)	$	(3	)	$	(6	)

Net gain (loss)	$	1		$	—		$	1		$	(3	)
Prior service (cost) benefit		(1	)		—			(1	)		5
Amortization of actuarial loss		2			6			6			18			2			2			4			4
Amortization of prior service gain		(1	)		(1	)		(2	)		(2	)		(1	)		(1	)		(2	)		(1	)
Settlement loss		1			3			1			4
Curtailment gain		4			—			4			—
Effect of foreign exchange rates		(3	)		9			(4	)		10			(2	)		(2	)		2			(1	)
Benefit recognized in other comprehensive income		3			17			5			32
(Cost) benefit recognized in other comprehensive income														(1	)		(1	)		4			2
Total changes in plan assets and benefit obligations recognized in other comprehensive income	$	—		$	14		$	(4	)	$	28		$	(3	)	$	(4	)	$	1		$	(4	)

The Company made cash contributions of $3 and ~~$17~~$8 to its defined benefit pension plans during the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and $2$6 and ~~$15~~$14 for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively, and expects to make additional cash contributions of $2$8 to its defined benefit pension plans during the remainder of ~~2020.~~2021. The Company’s future contributions to its defined benefit pension plans are dependent on market-based discount rates, and, as stated in “Note 1 – Background, Description of the Business, and Basis of Presentation” to these interim consolidated financial statements, may differ due to the impacts of the COVID-19 pandemic on the macroeconomic environment.

Chemours’ operations consist of 4 reportable segments ~~are Fluoroproducts,~~based on similar economic characteristics, the nature of products and production processes, end-use markets, channels of distribution, and regulatory environments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical ~~Solutions, and Titanium Technologies.~~Solutions. Corporate costs and certain legal and environmental expenses, stock-based compensation expenses, and foreign exchange gains and losses arising from the remeasurement of balances in currencies other than the functional currency of the Company’s legal entities are reflected in Corporate and Other.

During the fourth quarter of 2020, the Company changed the level of detail at which its CODM regularly reviews and manages certain of its businesses, resulting in the bifurcation of its former Fluoroproducts segment into two standalone reportable segments: Thermal & Specialized Solutions (formerly Fluorochemicals) and Advanced Performance Materials (formerly Fluoropolymers). This change allows Chemours to enhance its customer focus and better align its business models, resources, and cost structure to the specific current and future secular growth drivers of each business, while providing increased transparency to the Company’s shareholders. The historical segment information has been recast to conform to the current segment structure.

Segment net sales include transfers to another reportable segment. Certain products are transferred between segments on a basis intended to reflect, as nearly as practicable, the market value of the products. These product transfers were limited and were not significant for each of the periods presented. Depreciation and amortization includes depreciation on research and development facilities and the amortization of other intangible assets, excluding any write-downs of assets.

Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is the primary measure of segment profitability used by the ~~Company’s Chief Operating Decision Maker~~CODM and is defined as income (loss) before income taxes, excluding the following:

~~The following table sets forth certain summary financial information for the Company’s reportable segments for the three and nine months ended September 30, 2020 and 2019.~~

~~Corporate~~ and Other depreciation and amortization expense amounted to $6 and $23 for the three and nine months ended September 30, 2020, respectively, and $8 and $24 for the three and nine months ended September 30, 2019, respectively.

The following table sets forth certain summary financial information for the Company’s reportable segments for the three and six months ended June 30, 2021 and 2020.

Corporate and Other depreciation and amortization expense amounted to $7 and $15 for the three and six months ended June 30, 2021, respectively, and $8 and $16 for the three and six months ended June 30, 2020, respectively. Corporate and Other total assets amounted to $1,903 and $1,860 at June 30, 2021 and December 31, 2020, respectively.

The following table sets forth a reconciliation of segment Adjusted EBITDA to the Company’s consolidated net income (loss) before income taxes for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019			2021			2020			2021			2020
Segment Adjusted EBITDA	$	253		$	282		$	756		$	906		$	429		$	210		$	752		$	503
Corporate and Other Adjusted EBITDA		(43	)		(34	)		(123	)		(113	)
Corporate and Other expenses (excluding items below)														(63	)		(44	)		(118	)		(80	)
Interest expense, net		(53	)		(53	)		(160	)		(156	)		(47	)		(53	)		(97	)		(107	)
Depreciation and amortization		(79	)		(78	)		(240	)		(232	)		(79	)		(82	)		(163	)		(160	)
Non-operating pension and other post-retirement employee benefit income (cost)		1			(1	)		2			5
Exchange (losses) gains, net		(9	)		5			(28	)		2
Non-operating pension and other post-retirement employee benefit income														2			1			5			1
Exchange gains (losses), net														3			6			(5	)		(19	)
Restructuring, asset-related, and other charges (1)		(9	)		(34	)		(37	)		(49	)		(5	)		(17	)		—			(28	)
Gain on sales of assets and businesses ~~(2)~~		—			9			—			11			2			—			2			—
Transaction costs		—			—			(2	)		(1	)
Legal and environmental charges (3)		(1	)		(5	)		(12	)		(43	)
Natural disasters and catastrophic events (2)														(3	)		—			(19	)		—
Transaction costs (3)														—			—			(5	)		(2	)
Legal and environmental charges (4,5)														(195	)		(1	)		(208	)		(12	)
Income before income taxes	$	60		$	91		$	156		$	330		$	44		$	20		$	144		$	96

On July 26, 2021, the Company entered into a definitive agreement with Manchester Acquisition Sub LLC, a Delaware limited liability company and a subsidiary of Draslovka Holding a.s., to sell the Mining Solutions business of its Chemical Solutions segment for cash consideration of approximately $520 (the “Mining Solutions Transaction”). We are currently evaluating the financial statement impacts of the Mining Solutions Transaction and we currently expect to record a pre-tax gain of approximately $80 to $130 on the Mining Solutions Transaction in the fourth quarter of 2021, as a component of Other Income. We will classify the related assets and liabilities as held for sale on our consolidated balance sheet at September 30, 2021. The Mining Solutions Transaction is expected to close in the fourth quarter of 2021, subject to customary closing conditions, including regulatory approvals. We do not expect the Mining Solutions Transaction to qualify as discontinued operations.

Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) supplements the unaudited Interim Consolidated Financial Statements and the related notes thereto included elsewhere herein to help provide an understanding of our financial condition, changes in our financial condition, and the results of our operations for the periods presented.Unless the context otherwise requires, references herein to “The Chemours Company”, “Chemours”, “the Company”, “our Company”, “we”, “us”, and “our” refer to The Chemours Company and its consolidated subsidiaries. References herein to ~~“DuPont”~~“EID” refer to E. I. du Pont de Nemours and Company, which is now a subsidiary of Corteva, Inc. (“Corteva”), a Delaware corporation, unless the context otherwise requires.

This MD&A should be read in conjunction with the unaudited Interim Consolidated Financial Statements and the related notes thereto included in Item 1 of this Quarterly Report on Form 10-Q, as well as our audited Consolidated Financial Statements and the related notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020.

This section and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements, within the meaning of the federal securities laws, that involve risks and uncertainties. Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact.The words “believe”, “expect”, “anticipate”, “plan”, “estimate”, “target”, “project”, and similar expressions, among others, generally identify “forward-looking statements”, which speak only as of the date the statements were made. The matters discussed in these forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those set forth in the forward-looking statements.

Our forward-looking statements are based on certain assumptions and expectations of future events that may not be accurate or realized. These statements, as well as our historical performance, are not guarantees of future performance. Forward-looking statements also involve risks and uncertainties that are beyond our control. Additionally, there may be other risks and uncertainties that we are unable to identify at this time or that we do not currently expect to have a material impact on our business. Factors that could cause or contribute to these differences include, but are not limited to, the risks, uncertainties, and other factors discussed in the Forward-looking Statements and the Risk Factors sections in our Annual Report on Form 10-K for the year ended December 31, ~~2019,~~2020, and as otherwise discussed in this report, particularly as it pertains to the current novel coronavirus disease (“COVID-19”). We assume no obligation to revise or update any forward-looking statement for any reason, except as required by law.

We are a leading, global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries. We deliver customized solutions with a wide range of industrial and specialty chemicals products for markets, including coatings, plastics, ~~and coatings,~~ refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, ~~electronics,~~ mining, and oil ~~refining.~~and gas. Our principal products include titanium dioxide (“TiO₂“) pigment, refrigerants, industrial fluoropolymer resins, sodium cyanide, and performance chemicals and ~~intermediates, and titanium dioxide (“TiO~~₂~~”) pigment.~~intermediates. We manage and report our operating results through ~~three~~four reportable segments: ~~Fluoroproducts,~~Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions, and Titanium Technologies. Our Fluoroproducts segment is a leading, global provider of fluoroproducts, including refrigerants and industrial fluoropolymer resins. Our Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications.Solutions. Our Titanium Technologies segment is a leading, global provider of TiO₂ pigment, a premium white pigment used to deliver whiteness, brightness, opacity, and protection in a variety of applications. Our Thermal & Specialized Solutions segment is a leading, global provider of refrigerants, propellants, blowing agents, and specialty solvents. Our Advanced Performance Materials segment is a leading, global provider of high-end polymers and advanced materials that deliver unique attributes, including low friction coefficients, extreme temperature resistance, weather resistance, ultraviolet and chemical resistance, and electrical insulation. Our Chemical Solutions segment is a leading, North American provider of industrial chemicals used in gold production, industrial, and consumer applications.

We are a different kind of chemistry company, driven by our purpose to create a more colorful, capable, and cleaner world through the power of chemistry. Our world-class product portfolio brings everyday convenience to virtually everything people touch in their daily lives, making our products and the solutions they enable both vital and essential. We are committed to creating value for our customers and stakeholders around the world through the reliable delivery of our high-quality products and ~~services around~~services. Our global workforce, renowned for their deep and unmatched expertise, bring our chemistry to life, guided by five values that form the ~~world. To achieve this goal,~~bedrock foundation for how we ~~have a global team dedicated to upholding our five core values:~~operate: (i) ~~customer centricity~~Customer Centricity – driving customer growth, and our own, by understanding our customers’ needs and building long-lasting relationships with them; (ii) ~~refreshing simplicity~~Refreshing Simplicity – cutting complexity by investing in what matters, and getting results faster; (iii) ~~collective entrepreneurship~~Collective Entrepreneurship – empowering our employees to act like they own our business, while embracing the power of inclusion and teamwork; (iv) ~~safety obsession~~Safety Obsession – living our steadfast belief that a safe workplace is a profitable workplace; and, (v) ~~unshakable integrity~~Unshakable Integrity – doing what’s right for our customers, colleagues, and communities – always.

Additionally, our Corporate Responsibility Commitment focuses on three key principles – inspired people, a shared planet, and an evolved portfolio – in an effort to achieve, among other goals, increased diversity and inclusion in our global workforce, increased sustainability of our products, and becoming carbon positive. We call this responsible chemistry – it is rooted in who we are, and we expect that our Corporate Responsibility Commitment will drive sustainable, long-term earnings growth.

The COVID-19 pandemic has, to date, resulted in ~~nearly 50~~more than 195 million confirmed infections, over ~~one~~four million deaths, and continues to spread throughout the world. More contagious COVID-19 variants continue to emerge driving up infection rates globally, particularly in jurisdictions where vaccination rates have lagged. As a global provider of performance chemicals that are key inputs in end-products and processes in a variety of industries, a pandemic presents obstacles that can adversely impact customer demand for our products, our manufacturing operations, our supply chain effectiveness and efficiencies, ~~our manufacturing operations, customer demand for our products,~~ and ultimately, our financial results. Throughout the outbreak and subsequent stages of the COVID-19 pandemic that have occurred thus far, above all, we have remained steadfast in our commitment to the health, safety, and well-being of our employees and their families, while serving our customers, and conserving cash to ensure the continuity of our business operations into the future.

Although COVID-19 infections have continued to spread throughout the ~~United States,~~Americas, Europe, and parts of Asia Pacific, we continue to experience minimal disruption in our operations and business-related processes. ~~We have taken~~Where necessary, based on COVID-19 infection rates and local regulations, we continue to take a number of measures to promote the safety and security of our employees, including requiring remote working arrangements for employees where practicable, the imposition of travel restrictions, limiting non-essential visits to plant sites, performing health checks before every shift, and providing personal protective equipment for our “essential” operations employees at our sites and labs. ~~Due to reduced consumer demand for certain of our customers’ end-products, however, we have experienced the negative impact of~~ COVID-19 ~~in our results of operations, and while certain markets and regions have started to exhibit early stages of market recovery, we anticipate that weakened consumer demand will~~vaccines continue to ~~have a negative impact on our financial results.~~be distributed and administered in the United States and globally. Refer to the “Segment Reviews” and ~~“2020~~“2021 Outlook” sections within this MD&A for further considerations regarding the quickly evolving market dynamics that are impacting our businesses and our associated response. We cannot predict with certainty the potential future impact of the COVID-19 pandemic on our customers’ ability to manufacture their products, as well as any potential future disruptions in our supply chain due to restrictions on travel and transport, regional quarantines, and other social distancing measures. The risks and uncertainties posed by this significant, widespread event are ~~enumerable~~innumerable and far-reaching, including but not limited to those described in Item 1A – Risk Factors in ~~this Quarterly~~in our Annual Report on Form ~~10-Q.~~10-K for the year ended December 31, 2020.

Despite the health and safety, business continuity, and macroeconomic challenges associated with conducting business in the current environment, we remain committed to anticipating and meeting the demands of our customers, as they, like us, continue to navigate uncharted territory. ~~As a precautionary measure in light of macroeconomic uncertainties driven by COVID-19,~~In 2020, we ~~drew $300 million from our revolving credit facility on April 8, 2020, which we subsequently repaid during the third quarter of 2020 based on the Company’s liquidity position. We also~~ elected to accept tax relief provided by various taxing jurisdictions, resulting in the deferral of approximately $80 million in tax ~~payments.~~payments, of which approximately $35 million was paid in the fourth quarter of 2020, the remainder of which will be paid in 2021 and 2022. We continue to anticipate that our cash generated from operations, available cash, ~~cash from operations,~~receivables securitization, and existing debt financing arrangements will provide us with sufficient liquidity through at least ~~November 2021. Additionally, we continue to engage in scenario planning, and, as further discussed in the “2020 Outlook” and “Liquidity and Capital Resources” sections of this~~ ~~MD&A~~, we have implemented a range of actions aimed at temporarily reducing costs and preserving liquidity, including exercising careful discretion in our near-term operating and capital spending decisions. We will evaluate additional cost actions, as necessary, as the operational and financial impacts to our Company continue to evolve.July 2022.

In March 2021, we announced the initiation of a strategic review to assess the potential sale of the Mining Solutions business. The process continued throughout the second quarter and is intended to drive shareholder value and portfolio focus. On July 26, 2021, we entered into a definitive agreement with Manchester Acquisition Sub LLC, a Delaware limited liability company and a subsidiary of Draslovka Holding a.s., (“Draslovka”) to sell the Mining Solutions business of our Chemical Solutions segment for cash consideration of $520 million. We expect the transaction to close in the fourth quarter of 2021, subject to customary closing conditions, including regulatory approvals.

In June of 2021, we announced the retirement of Mark P. Vergnano, President and Chief Executive Officer of our Company effective July 1, 2021. Mark E. Newman, who served as the Chief Operating Officer of our Company since 2019, succeeded Mr. Vergnano as the Company’s President and Chief Executive Officer and joined the Board of Directors of our Company effective July 1, 2021.

The following table sets forth our results of operations for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions, except per share amounts)	2020			2019			2020			2019			2021			2020			2021			2020
Net sales	$	1,233		$	1,390		$	3,631		$	4,173		$	1,655		$	1,093		$	3,091		$	2,398
Cost of goods sold		976			1,096			2,877			3,260			1,391			894			2,530			1,901
Gross profit		257			294			754			913			264			199			561			497
Selling, general, and administrative expense		112			130			347			423			172			110			310			235
Research and development expense		22			20			67			61			27			20			51			44
Restructuring, asset-related, and other charges		9			34			37			49			5			17			—			28
Total other operating expenses		143			184			451			533			204			147			361			307
Equity in earnings of affiliates		4			9			19			25			10			7			20			14
Interest expense, net		(53	)		(53	)		(160	)		(156	)		(47	)		(53	)		(97	)		(107	)
Other (expense) income, net		(5	)		25			(6	)		81
Other income (expense), net														21			14			21			(1	)
Income before income taxes		60			91			156			330			44			20			144			96
(Benefit from) provision for income taxes		(16	)		15			(44	)		65
Benefit from income taxes														(22	)		(4	)		(17	)		(28	)
Net income		76			76			200			265			66			24			161			124
Net income attributable to Chemours	$	76		$	76		$	200		$	265		$	66		$	24		$	161		$	124
Per share data
Basic earnings per share of common stock	$	0.46		$	0.46		$	1.22		$	1.60		$	0.40		$	0.15		$	0.97		$	0.75
Diluted earnings per share of common stock		0.46			0.46			1.21			1.58			0.39			0.15			0.95			0.75

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our net sales for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared with the same periods in ~~2019.~~2020.

Change in net sales from prior period	Three Months Ended September 30, 2020			Nine Months Ended September 30, 2020			Three Months Ended June 30, 2021			Six Months Ended June 30, 2021
Price		(5	)%		(5	)%		2	%		—	%
Volume		(4	)%		(6	)%		46	%		27	%
Currency		—	%		—	%		4	%		3	%
Portfolio		(2	)%		(2	)%		(1	)%		(1	)%
Total change in net sales		(11	)%		(13	)%		51	%		29	%

Our net sales ~~decreased~~increased by ~~$157~~$562 million (or ~~11%~~51%) to ~~$1.2~~$1.7 billion for the three months ended ~~September~~June 30, ~~2020,~~2021, compared with net sales of ~~$1.4~~$1.1 billion for the same period in ~~2019.~~2020. The components of the ~~decrease~~increase in our net sales by segment for the three months ended ~~September~~June 30, ~~2020~~2021 were as follows:in our ~~Fluoroproducts~~Titanium Technologies segment, volume was up 66%, price was up 5%; in our Thermal & Specialized Solutions segment, volume was up 48% and price declined ~~5% and~~3%; in our Advanced Performance Materials segment, volume was ~~down 11%~~up 19% and price was up 1%; and, in our Chemical Solutions segment, ~~price declined 5%,~~ volume was ~~down 13%~~up 26%, price was up 6%, and portfolio change led to a ~~19% decrease; and, in our Titanium Technologies segment, price declined 5% and volume was up 4%.~~17% decrease. Favorable currency movements also added a 1% tailwind to our net sales of 5% in our Titanium Technologies segment, 2% in our Thermal & Specialized Solutions segment, and 4% in our Advanced Performance Materials segment.

Our net sales ~~decreased~~increased by ~~$542~~$693 million (or ~~13%~~29%) to ~~$3.6~~$3.1 billion for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared with net sales of ~~$4.2~~$2.4 billion for the same period in ~~2019.~~2020. The components of the ~~decrease~~increase in our net sales by segment for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were as follows:in our ~~Fluoroproducts~~Titanium Technologies segment, volume was up 38%, price was up 2%; in our Thermal & Specialized Solutions segment, volume was up 22% and price declined ~~4% and~~5%; in our Advanced Performance Materials segment, volume was ~~down 14%~~up 16% and price declined 1%; and, in our Chemical Solutions segment, ~~price declined 4%,~~ volume was ~~down~~up 12%, price was up 3%, and portfolio change led to a ~~19% decrease; and,~~18% decrease. Favorable currency movements also added a tailwind to our net sales of 4% in our Titanium Technologies segment, ~~price declined 6% and volume was up 5%. Unfavorable currency movements also added a 1% headwind to net sales~~2% in our ~~Fluoroproducts~~Thermal & Specialized Solutions segment, and 4% in our Advanced Performance Materials segment.

The drivers of these changes for each of our segments are discussed further under the “Segment Reviews” section within this MD&A.

Our cost of goods sold (“COGS”) ~~decreased~~increased by ~~$120~~$497 million (or ~~11%~~56%) and ~~$383~~$629 million (or ~~12%~~33%) to ~~$1.0~~$1.4 billion and ~~$2.9~~$2.5 billion for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared with COGS of ~~$1.1~~$0.9 billion and ~~$3.3~~$1.9 billion for the same periods in ~~2019.~~2020. The ~~decreases~~increases in our COGS for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily attributable to ~~lower~~higher net sales, ~~as well as lower~~higher distribution, freight, and logistics ~~expenses. In comparison~~expenses, increased on-site environmental remediation costs at our Fayetteville Works site in Fayetteville, North Carolina (“Fayetteville”), as well as plant fixed costs expensed in conjunction with ~~the prior year, we also did not incur costs during the nine months ended September 30, 2020 in connection with unplanned outages~~plant downtime at certain of our ~~operating~~ facilities orand under absorption of fixed costs ~~associated with the start-up of our Opteon~~^TM ~~refrigerants facility in Corpus Christi, Texas. Our previous exit of the Methylamines~~due to operational issues and ~~Methylamides business at our Belle, West Virginia production facility also contributed~~supply chain disruptions related to ~~the reduction in COGS. These comparative reductions in COGS were partially offset by costs incurred in conjunction with the temporary idling of certain of our production lines~~inclement weather from Winter Storm Uri during the ~~second and third quarters~~first quarter of ~~2020 due to reduced customer demand.~~2021.

Our selling, general, and administrative (“SG&A”) expense ~~decreased~~increased by ~~$18~~$62 million (or ~~14%~~56%) and ~~$76~~$75 million (or ~~18%~~32%) to ~~$112~~$172 million and ~~$347~~$310 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared with SG&A expense of ~~$130~~$110 million and ~~$423~~$235 million for the same periods in ~~2019.~~2020. The ~~decreases~~increases in our SG&A expense for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily attributable to ~~our cost reductions and our~~ ~~cost savings initiatives in response to the COVID-19 pandemic as further discussed~~higher performance-related compensation expenses in the ~~“2020 Outlook” section~~current year, $25 million incurred in connection with our portion of ~~this~~ the settlement agreement with the State of Delaware in the second quarter of 2021, and cost deferral activities in the prior year related to COVID-19.

Our research and development expense increased by $2$7 million (or ~~10%~~35%) and $6$7 million (or ~~10%~~16%) to ~~$22~~$27 million and ~~$67~~$51 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared with research and development expense of $20 million and ~~$61~~$44 million for the same periods in ~~2019.~~2020. The increases in our research and development expense for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily attributable to ~~real estate costs associated with our research and development facility on~~project activity returning to normal from reduced levels in the ~~Science, Technology, and Advanced Research campus of the University of Delaware in Newark, Delaware.~~prior year due to cost deferral activities related to COVID-19.

Our restructuring, asset-related, and other charges decreased by ~~$25 million (or 74%) and~~ $12 million (or ~~24%~~71%) and $28 million (or over 100%) to $9$5 million and ~~$37~~less than $1 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared with restructuring, asset-related, and other charges of ~~$34~~$17 million and ~~$49~~$28 million for the same periods in ~~2019.~~2020. Our restructuring, asset-related, and other charges for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily attributable to $3$4 million and ~~$16 million, respectively, of net charges incurred in connection with employee-related separation liabilities under our recent restructuring programs. We also incurred $5~~$8 million of ~~asset-related~~decommissioning and dismantling related charges during the three and nine months ended September 30, 2020 in connection with various property, plant, and equipment and other asset impairments in our Fluoroproducts segment, as well as $12 million of charges during the nine months ended September 30, 2020 in connection with our decision ~~announced in the second quarter of 2020~~ to exit the Aniline business and stop production at our Pascagoula, Mississippi manufacturing ~~plant~~plants. For the six months ended June 30, 2021 the decrease was offset by ~~the end of 2020.~~ a net $7 million gain in Other Charges in connection with our contract termination with a third-party services provider at our Mining Solutions facility currently under construction in Gomez Palacio, Durango, Mexico.

Our restructuring, asset-related, and other charges for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019~~2020 were primarily attributable to $12 million of charges incurred in connection with our decision to exit the ~~Methylamines~~Aniline business and ~~Methylamides business~~stop production at our ~~Belle, West Virginia~~Pascagoula, Mississippi manufacturing ~~plant, as well as $17~~plant. We also incurred net charges of $4 million ~~incurred~~and $12 million, respectively, in connection with employee-related separation liabilities under our 2019 Restructuring Program. We also incurred $4 million and $18 million, respectively, of decommissioning and dismantling-related charges associated with the demolition and removal of certain unused buildings at our Chambers Works site in Deepwater, New Jersey.recent restructuring programs.

Our equity in earnings of affiliates ~~decreased~~increased by $5$3 million (or ~~56%~~43%) and $6 million (or ~~24%~~43%) to $4$10 million and ~~$19~~$20 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared with equity in earnings of affiliates of $9$7 million and ~~$25~~$14 million for the same periods in ~~2019.~~2020. The ~~decreases~~increase in our equity in earnings of affiliates for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily attributable to ~~our reduced~~increased demand for our investees’ ~~products and the negative impacts of COVID-19 on end-market demand.~~products.

Our interest expense, net ~~was largely unchanged at $53~~decreased by $6 million (or 11%) and $10 million (or 9%) to $47 million and ~~$160~~$97 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, compared with interest expense, net of $53 million and ~~$156~~$107 million for the same periods in ~~2019.~~2020. The decrease in our interest expense, net for the three and six months ended June 30, 2021 was primarily attributable to a reduction in our outstanding debt obligations and associated rates following the refinancing of our 2023 Dollar Notes in the fourth quarter of 2020, as well as lower variable interest rates on our senior secured term loans.

Our other income (expense), net ~~decreased~~increased by ~~$30~~$7 million (or 50%) and ~~$87~~increased by $22 million (or over 100%) to other ~~expense,~~income, net of ~~$5 million and $6~~$21 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020, respectively,~~2021, compared with other income, net of ~~$25~~$14 million and ~~$81~~other expense, net of $1 million for the same periods in ~~2019. The decreases~~2020. During the three months ended June 30, 2021, the comparative increase in our other income (expense), net ~~were~~was primarily attributable to ~~unfavorable~~a comparative increase in our non-qualified pension plan gains from the prior year, higher European Union (“EU”) fluorinated greenhouse gas (“F-Gas”) authorization sales, and $3 million of income received from customer take-or-pay agreement penalties. During the six months ended June 30, 2021, the comparative increase in our other income (expense), net was primarily attributable to favorable changes in net exchange gains and losses of $14 million and $30 million during the three and nine months ended September 30, 2020, respectively, driven by unfavorable movements in several foreign currencies, primarily the strengthening of the euro against the U.S. dollar, partially offset by our foreign currency forward contracts. Decreases in our leasing, contract services, and miscellaneous income further contributed to the decrease in our other income, net, driven by $1 million and $35 million lower European Union (“EU”) fluorinated greenhouse gas (“F-Gas”) quota authorization sales during the three and nine months ended September 30, 2020, respectively. We also recognized a non-cash gain of $9 million in the third quarter of 2019 in connection with the sale of our Repauno, New Jersey site.million.

Our ~~provision for (benefit from)~~benefit from income taxes amounted to a benefit from income taxes of ~~$16~~$22 million and ~~a provision for income taxes of $15~~$4 million for the three months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively, which represented effective tax rates of negative ~~27%~~50% and ~~16%~~negative 20%, respectively. The ~~$31~~$18 million decrease in our provision for income taxes for the three months ended September 30, 2020 was primarily attributable to decreased profitability and changes to our geographic mix of earnings, as well as an income tax benefit of $11 million, net, related to the favorable impacts of certain elections and accounting method changes in connection with the filing of our 2019 U.S. federal income tax return. Such elections and accounting method changes were not reflectedincrease in our benefit from income taxes for the ~~year~~three months ended ~~December 31, 2019, as they were not yet able~~June 30, 2021 was primarily attributable to ~~be quantified.~~a $41 million tax benefit associated with non-recurring accrued environmental remediation liabilities and an $11 million income tax benefit associated with a 2012 income tax refund received in a foreign subsidiary. This was partially offset by increased profitability and changes to our geographical mix of earnings.

Our ~~provision for (benefit from)~~benefit from income taxes amounted to a benefit from income taxes of ~~$44~~$17 million and ~~a provision for income taxes of $65~~$28 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively, which represented effective tax rates of negative ~~28%~~12% and ~~20%~~negative 29%, respectively. The ~~$109~~$11 million decrease in our ~~provision for~~benefit from income taxes for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 was primarily attributable to ~~decreased~~increased profitability, changes to our ~~geographic~~geographical mix of earnings, and $8 million of additional income tax expense recorded in the second quarter of 2019 associated with the recognition of a valuation allowance on the deferred tax assets of a certain foreign subsidiary. We also recorded an income tax benefit of $18 million recorded in the first quarter of 2020, which was related to the United States Internal Revenue Service acceptance of a non-automatic ~~accounting~~ method change that allows for the recovery of tax basis for depreciation, which had been previously disallowed. We also recorded an income tax benefit of $11 million, net, in the third quarter of 2020, related to the aforementioned favorable impacts of certain elections and accounting method changes in connection with the filing of our 2019 U.S. federal income tax return. Our benefit from income taxesThis was partially offset by $8a $41 million ~~of lower~~ income tax ~~benefits related to share-based payments.~~benefit associated with non-recurring accrued environmental remediation liabilities and an $11 million income tax benefit associated with a 2012 income tax refund received in a foreign subsidiary.

During the fourth quarter of 2020, we changed the level of detail at which our Chief Operating Decision Maker (“CODM”) regularly reviews and manages certain of our businesses, resulting in the bifurcation of our former Fluoroproducts segment into two standalone reportable segments: Thermal & Specialized Solutions (formerly Fluorochemicals) and Advanced Performance Materials (formerly Fluoropolymers). This change allows us to enhance our customer focus and better align our business models, resources, and cost structure to the specific current and future secular growth drivers of each business, while providing increased transparency to our shareholders. Our historical segment information has been recast to conform to the current segment structure.

Adjusted earnings before interest, taxes, depreciation, and amortization (“Adjusted EBITDA”) is the primary measure of segment profitability used by our ~~Chief Operating Decision Maker (“CODM”)~~CODM and is defined as income (loss) before income taxes, excluding the following:

A reconciliation of ~~Adjusted EBITDA to~~ net income (loss) attributable to Chemours to Adjusted EBITDA for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019~~2020 is included in the “Non-GAAP Financial Measures” section of this MD&A.

The following table sets forth our Adjusted EBITDA by segment for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions)	2020			2019			2020			2019			2021			2020			2021			2020
Fluoroproducts	$	112		$	122		$	350		$	461
Titanium Technologies													$	219		$	94		$	388		$	232
Thermal & Specialized Solutions														117			55			210			144
Advanced Performance Materials														74			42			125			94
Chemical Solutions		12			23			45			55			19			19			29			33
Titanium Technologies		129			137			361			390
Corporate and Other		(43	)		(34	)		(123	)		(113	)		(63	)		(44	)		(118	)		(80	)
Total Adjusted EBITDA	$	210		$	248		$	633		$	793		$	366		$	166		$	634		$	423

The following table sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our ~~Fluoroproducts~~Titanium Technologies segment for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions)	2020			2019			2020			2019			2021			2020			2021			2020
Segment net sales	$	533		$	636		$	1,657		$	2,034		$	859		$	488		$	1,583		$	1,100
Adjusted EBITDA		112			122			350			461			219			94			388			232
Adjusted EBITDA margin		21	%		19	%		21	%		23	%		25	%		19	%		25	%		21	%

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our ~~Fluoroproducts~~Titanium Technologies segment’s net sales for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared with the same periods in ~~2019.~~2020.

Change in segment net sales from prior period	Three Months Ended September 30, 2020			Nine Months Ended September 30, 2020			Three Months Ended June 30, 2021			Six Months Ended June 30, 2021
Price		(5	)%		(4	)%		5	%		2	%
Volume		(11	)%		(14	)%		66	%		38	%
Currency		—	%		(1	)%		5	%		4	%
Portfolio		—	%		—	%		—	%		—	%
Total change in segment net sales		(16	)%		(19	)%		76	%		44	%

Our ~~Fluoroproducts~~Titanium Technologies segment’s net sales ~~decreased~~increased by ~~$103~~$371 million (or ~~16%~~76%) to ~~$533~~$859 million for the three months ended ~~September~~June 30, ~~2020,~~2021, compared with segment net sales of ~~$636~~$488 million for the same period in ~~2019.~~2020. The ~~decrease~~increase in segment net sales for the three months ended ~~September~~June 30, ~~2020~~2021 was primarily attributable to ~~decreases~~a 66% increase in volume and an increase in price of ~~11%~~5%. Volume increases were driven by steady demand recovery for our products across all end-markets and ~~5%, respectively. Volumes declined~~regions throughout the quarter. Price increases were due to ~~the lagged~~ ~~negative impacts of COVID-19 on~~ ~~demand for fluoropolymers products, as~~ lower end-market demand experienced by our customers in the second quarter of 2020 drove a reduction in our customers’ demand for fluoropolymers products in the third quarter of 2020. The negative impact of demand weakness for fluoropolymers products was partially offset as the ~~early stages of market recovery led to increased~~ ~~customer demand for our refrigerants, particularly in the automotive sector as~~ original equipment manufacturers (“OEM”) continued to improve their operating rates following their shutdowns in the first and second quarters of 2020. Prices declined during the three months ended September 30, 2020, driven by our composition of product and customerchannel mix, as well as contractual price ~~adjustments for refrigerants and market weakness in certain geographies.~~

Our Fluoroproducts segment’s net sales decreased by $377 million (or 19%) to $1.7 billion for the nine months ended September 30, 2020, compared with segment net sales of $2.0 billion for the same period in 2019. The decrease in segment net sales for the nine months ended September 30, 2020 was primarily attributable to decreases in volume and price of 14% and 4%, respectively. Volumes declined due to lower global customer demand for our refrigerants and fluoropolymers, ~~as initial softness in the automotive and other global end-markets was compounded by the negative impact of COVID-19 on end-market demand from our customers across several market sectors.~~ Prices declined during the nine months ended September 30, 2020, driven by our composition of product and customer mix, as well as contractual price adjustments for refrigerants and market weakness in certain geographies. Unfavorableincreases. Favorable currency movements added a ~~1% headwind~~5% tailwind to the segment’s net sales during the ~~nine~~three months ended ~~September~~June 30, 2021.

Our Titanium Technologies segment’s net sales increased by $483 million (or 44%) to $1.6 billion for the six months ended June 30, 2021, compared with segment net sales of $1.1 billion for the same period in 2020. The increase in segment net sales for the six months ended June 30, 2021 was primarily attributable to a 38% increase in volume and an increase in price of 2%. Volume increases were driven by steady demand recovery for our products across all end-markets and regions throughout the first half of the year. Price increases were due to customer, regional, and channel mix, as well as contractual price increases. Favorable currency movements added a 4% tailwind to the segment’s net sales during the six months ended June 30, 2021.

For the three months ended ~~September~~June 30, ~~2020,~~2021, segment Adjusted EBITDA ~~decreased~~increased by ~~$10~~$125 million (or 8%over 100%) to ~~$112~~$219 million and Adjusted EBITDA margin increased by approximately 600 basis points to 25%, compared with segment Adjusted EBITDA of $94 million and Adjusted EBITDA margin of 19% for the same period in 2020. For the six months ended June 30, 2021, segment Adjusted EBITDA increased by $156 million (or 67%) to $388 million and Adjusted EBITDA margin increased by approximately 400 basis points to 25%, compared with segment Adjusted EBITDA of $232 million and Adjusted EBITDA margin of 21% for the same period in 2020. The increase in Adjusted EBITDA during the three and six months ended June 30, 2021 was primarily attributable to the aforementioned increase in volume of the segment’s net sales and favorable currency movements, partially offset by higher variable costs due to ore mix and fixed cost headwinds to support the increase in demand.

The following table sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Thermal & Specialized Solutions segment for the three and six months ended June 30, 2021 and 2020.

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our Thermal & Specialized Solutions segment’s net sales for the three and six months ended June 30, 2021, compared with the same periods in 2020.

Our Thermal & Specialized Solutions segment’s net sales increased by $109 million (or 47%) to $340 million for the three months ended June 30, 2021, compared with segment net sales of $231 million for the same period in 2020. The increase in segment net sales for three months ended June 30, 2021 was primarily attributable to an increase in volume of 48%, which was partially offset by a decrease in price of 3%. Volumes increased due to higher global customer demand for our refrigerants as COVID-19 market recovery has increased end-market demand from our customers across all market sectors. Prices declined due to contractual price adjustments for refrigerants, as well as product and customer mix. Favorable currency movements added a 2% tailwind to the segment’s net sales during the three months ended June 30, 2021.

Our Thermal & Specialized Solutions segment’s net sales increased by $104 million (or 19%) to $643 million for the six months ended June 30, 2021, compared with segment net sales of $539 million for the same period in 2020. The increase in segment net sales for six months ended June 30, 2021 was primarily attributable to an increase in volume of 22%, which was partially offset by a decrease in price of 5%. Volumes increased due to higher global customer demand for our refrigerants as COVID-19 market recovery has increased end-market demand from our customers across several market sectors. Prices declined due to our composition of product and customer mix, as well as contractual price reductions for certain refrigerants. Favorable currency movements added a 2% tailwind to the segment’s net sales during the six months ended June 30, 2021.

For the three months ended June 30, 2021, segment Adjusted EBITDA increased by $62 million (or over 100%) to $117 million and Adjusted EBITDA margin increased by approximately 1,000 basis points to 34%, compared with segment Adjusted EBITDA of $55 million and Adjusted EBITDA margin of 24% for the same period in 2020. For the six months ended June 30, 2021, segment Adjusted EBITDA increased by $66 million (or 46%) to $210 million and Adjusted EBITDA margin increased by approximately 600 basis points to 33%, compared with segment Adjusted EBITDA of $144 million and Adjusted EBITDA margin of 27% for the same period in 2020. The increase in segment Adjusted EBITDA for the three and six months ended June 30, 2021 was primarily attributable to the aforementioned increase in the volume of the segment’s net sales, partially offset by a decrease in price of segment’s net sales, and first quarter 2021 plant fixed costs incurred in conjunction with the temporary idling of certain of our facilities due to inclement weather from Winter Storm Uri.

The following table sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Advanced Performance Materials segment for the three and six months ended June 30, 2021 and 2020.

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our Advanced Performance Materials segment’s net sales for the three and six months ended June 30, 2021, compared with the same periods in 2020.

Our Advanced Performance Materials segment’s net sales increased by $70 million (or 24%) to $362 million for the three months ended June 30, 2021, compared with segment net sales of $292 million for the same period in 2020. The increase in segment net sales for the three months ended June 30, 2021 was primarily attributable to a 19% increase in volume and an increase in price of 1%. Volumes increased due to higher global customer demand across nearly all regions and markets. Global average selling price increased slightly due to customer level pricing actions partially offset by our composition of product and customer mix. Favorable currency movements added a 4% tailwind to the segment’s net sales during the three months ended June 30, 2021.

Our Advanced Performance Materials segment’s net sales increased by $111 million (or 19%) to $695 million for the six months ended June 30, 2021, compared with segment net sales of $584 million for the same period in 2020. The increase in segment net sales for the six months ended June 30, 2021 was primarily attributable to a 16% increase in volume, which was partially offset by a 1% decrease in price. Volumes increased due to higher global customer demand across nearly all regions and markets. Global average selling price decreased slightly due to our composition of product and customer mix partially offset by customer level pricing actions. Favorable currency movements added a 4% tailwind to the segment’s net sales during the six months ended June 30, 2021.

For the three months ended June 30, 2021, segment Adjusted EBITDA increased by $32 million (or 76%) to $74 million and Adjusted EBITDA margin increased by approximately 600 basis points to 20%, compared with segment Adjusted EBITDA of $42 million and Adjusted EBITDA margin of 14% for the same period in 2020.For the six months ended June 30, 2021, segment Adjusted EBITDA increased by $31 million (or 33%) to $125 million and Adjusted EBITDA margin increased by approximately 200 basis points to ~~21%~~18%, compared with segment Adjusted EBITDA of ~~$122~~$94 million and Adjusted EBITDA margin of ~~19%~~16% for the same period in ~~2019. For the nine months ended September 30, 2020,~~2020. The increases in segment Adjusted EBITDA ~~decreased by $111 million (or 24%) to $350 million~~ and segment Adjusted EBITDA margin ~~decreased by approximately 200 basis points to 21%, compared with segment Adjusted EBITDA of $461 million and Adjusted EBITDA margin of 23%~~ for the ~~same period in 2019. These changes in earnings~~three and six months ended June 30, 2021 were primarily attributable to the aforementioned ~~decreases~~increase in volumes, partially offset by fixed cost under absorption due to supply chain disruptions in the ~~volume~~first half of 2021 and ~~price and unfavorable currency movements in the segment’s net sales. We also incurred~~by higher fixed costs ~~associated with the temporary idling of certain of our production lines during the second and third quarters of 2020 due~~related to reduced customer demand. Additionally, for the nine months ended September 30, 2020, our EU F-gas quota authorization sales decreased by $35 million when compared with the nine months ended September 30, 2019. The aforementioned decreases to segment Adjusted EBITDA and Adjusted EBITDA margin during the three and nine months ended September 30, 2020 were partially offset, and, in the instance of Adjusted EBITDA margin for the three months ended September 30, 2020, more than offset, by enhanced operational performance at certain of our operating facilities, cost savings associated with the ramp-up of production at our Opteonperformance-based compensation.^TM ~~refrigerants facility in Corpus Christi, Texas, and structural cost reductions.~~

The following table sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Chemical Solutions segment for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions)	2020			2019			2020			2019			2021			2020			2021			2020
Segment net sales	$	88		$	140		$	263		$	404		$	94		$	82		$	170		$	175
Adjusted EBITDA		12			23			45			55			19			19			29			33
Adjusted EBITDA margin		14	%		16	%		17	%		14	%		20	%		23	%		17	%		19	%

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our Chemical Solutions segment’s net sales for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared with the same periods in ~~2019.~~2020.

Change in segment net sales from prior period	Three Months Ended September 30, 2020			Nine Months Ended September 30, 2020			Three Months Ended June 30, 2021			Six Months Ended June 30, 2021
Price		(5	)%		(4	)%		6	%		3	%
Volume		(13	)%		(12	)%		26	%		12	%
Currency		—	%		—	%		—	%		—	%
Portfolio		(19	)%		(19	)%		(17	)%		(18	)%
Total change in segment net sales		(37	)%		(35	)%		15	%		(3	)%

Our Chemical Solutions segment’s net sales ~~decreased~~increased by ~~$52~~$12 million (or ~~37%~~15%) to ~~$88~~$94 million for the three months ended ~~September~~June 30, ~~2020,~~2021, compared with segment net sales of ~~$140~~$82 million for the same period in ~~2019.~~2020. The ~~decrease~~increase in segment net sales for the three months ended ~~September~~June 30, ~~2020~~2021 was primarily attributable to an increase in volume of 26% and an increase in price of 6%. Volumes increased primarily due to increased customer demand in our Mining Solutions business. This was partially offset by portfolio change, which drove a ~~19%~~17% decline in net sales following our exit of the ~~Methylamines and Methylamides~~Aniline business at our ~~Belle, West Virginia~~Pascagoula, Mississippi production facility. Segment net sales volumes decreased 13%, driven by the continued adverse impacts of the COVID-19 pandemic on the operations of several mining customers and overall end-market demand. Average prices decreased 5%, driven by market dynamics compared with the prior year quarter.

Our Chemical Solutions segment’s net sales decreased by ~~$141~~$5 million (or ~~35%~~3%) to ~~$263~~$170 million for the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared with segment net sales of ~~$404~~$175 million for the same period in ~~2019.~~2020. The decrease in segment net sales for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 was primarily attributable to portfolio change, which drove ~~a 19%~~an 18% decline in net sales following our exit of the ~~Methylamines and Methylamides~~Aniline business at our ~~Belle, West Virginia~~Pascagoula, Mississippi production facility. ~~Segment net sales volumes decreased~~This was largely offset by an increase in volume of 12%~~, driven by the adverse impacts~~ and an increase in price of the COVID-19 pandemic on the operations of several mining customers and overall end-market demand. Average prices decreased 4%, driven by market dynamics compared with the nine months ended September 30, 2019.3%. Volumes increased due to increased customer demand in our Mining Solutions business.

For the three months ended ~~September~~June 30, ~~2020,~~2021, segment Adjusted EBITDA increased by less than $1 million (or less than 1%) to $19 million and Adjusted EBITDA margin decreased by approximately 300 basis points to 20%, compared with segment Adjusted EBITDA of $19 million and Adjusted EBITDA margin of 23% for the same period in 2020. For the six months ended June 30, 2021, segment Adjusted EBITDA decreased by ~~$11~~$4 million (or ~~48%~~12%) to ~~$12~~$29 million and Adjusted EBITDA margin decreased by approximately 200 basis points to 14%, compared with segment Adjusted EBITDA of $23 million and Adjusted EBITDA margin of 16% for the same period in 2019. For the nine months ended September 30, 2020, segment Adjusted EBITDA decreased by $10 million (or 18%) to $45 million and Adjusted EBITDA margin increased by approximately 300 basis points to 17%, compared with segment Adjusted EBITDA of ~~$55~~$33 million and Adjusted EBITDA margin of ~~14%~~19% for the same period in ~~2019. These changes~~2020. The slight increase in ~~earnings were primarily attributable~~segment Adjusted EBITDA was due to the aforementioned ~~decreases~~volume increase, while the decrease in ~~segment net sales, as well as licensing income recognized~~Adjusted EBITDA margin was due higher raw material and plant fixed costs. The decrease in ~~the third quarter of 2019 that did not recur in the third quarter of 2020. The aforementioned decreases to~~ segment Adjusted EBITDA and ~~Adjusted EBITDA margin were partially offset, and, in the instance of~~segment Adjusted EBITDA margin for the ~~nine~~six months ended ~~September~~June 30, ~~2020, more than offset, by~~2021 were primarily attributable to plant fixed costs incurred in conjunction with the ~~cost savings associated with~~temporary idling of certain of our ~~exit of~~facilities due to inclement weather from Winter Storm Uri during the ~~Methylamines~~first quarter as well as higher raw material and ~~Methylamides business at our Belle, West Virginia production facility.~~plant fixed costs.

~~The following table sets forth the net sales, Adjusted EBITDA, and Adjusted EBITDA margin amounts for our Titanium Technologies segment for the three and nine months ended September 30, 2020 and 2019.~~

The following table sets forth the impacts of price, volume, currency, and portfolio changes on our Titanium Technologies segment’s net sales for the three and nine months ended September 30, 2020, compared with the same periods in 2019.

Our Titanium Technologies segment’s net sales decreased by $2 million (or less than 1%) to $612 million for the three months ended September 30, 2020, compared with segment net sales of $614 million for the same period in 2019. The decrease in segment net sales for the three months ended September 30, 2020 was primarily attributable to a decrease in price of 5%, which was largely offset by an increase in volume of 4%. Price declined for the three months ended September 30, 2020 due to customer, channel, and product mix, as well as targeted price reductions which occurred prior to the third quarter of 2020. Volume increases were driven by an uptick in global customer demand for our Ti-Pure^TM ~~TiO~~₂~~, as we started to see the early stages of market recovery in~~ ~~several markets and regions.~~ ~~Favorable currency movements added a 1% tailwind to the segment’s net sales during the three months ended September 30, 2020.~~

Our Titanium Technologies segment’s net sales decreased by $24 million (or 1%) to $1.7 billion for the nine months ended September 30, 2020, compared with segment net sales of $1.7 billion for the same period in 2019. The decrease in segment net sales for the nine months ended September 30, 2020 was primarily attributable to a decrease in price of 6%, which was largely offset by an increase in volume of 5%. Price declined for the nine months ended September 30, 2020 due to customer, channel, and product mix, as well as targeted price reductions which primarily occurred prior to the first quarter of 2020. Volume increases were driven by share regain in the first quarter of 2020, as well as the early stages of market recovery in several markets and regions in the third quarter of 2020. These volume increases were partially offset by lower global customer demand for our Ti-Pure^TM ~~TiO~~₂ ~~in the second quarter of 2020,~~ ~~as COVID-19 negatively impacted end-market demand from our customers across several markets and regions.~~

For the three months ended September 30, 2020, segment Adjusted EBITDA decreased by $8 million (or 6%) to $129 million and Adjusted EBITDA margin decreased by approximately 100 basis points to 21%, compared with segment Adjusted EBITDA of $137 million and Adjusted EBITDA margin of 22% for the same period in 2019. For the nine months ended September 30, 2020, segment Adjusted EBITDA decreased by $29 million (or 7%) to $361 million and Adjusted EBITDA margin decreased by approximately 100 basis points to 21%, compared with segment Adjusted EBITDA of $390 million and Adjusted EBITDA margin of 22% for the same period in 2019. These decreases in earnings during the three and nine months ended September 30, 2020 were primarily attributable to the aforementioned decreases in price in the segment’s net sales and lower fixed cost absorption due to reduced operating rates, partially offset by increased volumes in the segment’s net sales.

Corporate and Other costs increased by $9$19 million (or ~~26%~~43%) and ~~$10~~$38 million (or 9%48%) to ~~$43~~$63 million and ~~$123~~$118 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, compared with Corporate and Other costs of ~~$34~~$44 million and ~~$113~~$80 million for the same periods in ~~2019.~~2020. These increases in Corporate and Other costs for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily attributable to higher costs associated with legacy environmental remediation matters,. ~~This increase was partially offset by lower external spend, which is consistent with our~~ primarily related to Fayetteville, legacy legal costs, higher performance-related compensation expenses, and cost ~~savings initiatives in response to the COVID-19 pandemic as further discussed~~reduction activities in the prior year related to COVID-19~~“2020 Outlook” section of this~~ ~~MD&A.~~.

While the COVID-19 pandemic has introduced a tremendous amount of uncertainty into global markets and local economies, we continue to believe that we are well-positioned to respond to the rapidly evolving market dynamics that are impacting our businesses. However, in anticipation of declines in customer demand driven by COVID-19, we implemented a range of actions aimed at reducing costs by reducing all discretionary spend, freezing non-critical hiring, and delaying external spend wherever possible. We also reduced structural plant fixed costs to improve the efficiency of our production units, an initiative that was already in flight at the end of 2019. In addition, where legally permissible, we made temporary base pay reductions for salaried employees globally, until we saw an improvement in demand across the Company. This included our Chief Executive Officer who took a temporary base salary reduction of 40% and the executive team who took a temporary base salary reduction of 30%. These temporary base salary reductions were discontinued in September 2020. Overall, these actions are expected to reduce our costs for the year ending December 31, 2020 by approximately $160 million. We are also reducing our capital spending by $125 million for the year ending December 31, 2020, only proceeding with capital projects considered critical in the near-term. If the macroeconomic situation deteriorates or the duration of the pandemic is extended, we will evaluate additional cost actions, as necessary, as the operational and financial impacts to our Company continue to evolve.

In our Fluoroproducts segment, we anticipate experiencing an uneven recovery in global customer demand, following a third quarter reflective of the early stages of demand recovery for our refrigerants and a lagged reduction in demand for our fluoropolymers products. Customer demand for our refrigerants products may also be somewhat impacted by normal seasonality trends within the business as we enter the fourth quarter of 2020. We remain in frequent communication with our customers to fully understand their evolving product needs and to optimize our production volumes, as necessary. As customer demand for our products continues to recover from the negative impacts of COVID-19 on end-market demand, we expect to continue to recognize the benefits of enhanced operational performance and structural cost reductions within the segment. ~~We are also continuing our investment to prevent the illegal import of legacy HFC refrigerants into the EU, in violation of the EU’s F-gas regulations.~~

~~In our Chemical Solutions segment, trends in our future net sales volumes~~Our 2021 results will be driven by ~~our customers’ mining operations, as they work towards returning to normalized production volumes~~the following temporary operating restrictions imposed during COVID-19. At that time, we anticipate that demand for our products will begin to normalize. Our future net sales will also be dependent upon the average pricesexpectations in each of our ~~products, which~~reportable segments:

Our outlook for 2021 reflects our current visibility and expectations based on market factors, such as currency movements, macro-economic factors, and end-market demand. In particular, end-market demand may be impacted by factors beyond our control, including the ongoing COVID-19 pandemic. Our ability to meet our expectations are ~~driven by~~subject to numerous risks, including, but not limited to, those described in Item 1A – Risk Factors within our Annual Report on Form 10-K for the ~~impacts of market dynamics. We continue to focus on operations productivity, inventory management,~~year ended December 31, 2020 and ~~cash generation~~otherwise as discussed in this ~~segment.~~report.

In our Titanium Technologies segment, we expect that we will continue to experience the early stages of an uneven market recovery in the markets and regions in which we participate, while certain countries within these regions have not yet started to emerge from the negative economic impacts of COVID-19. We continue to collaborate with and remain connected to our customers in meeting their future demands, while simultaneously managing our own inventories balances to optimize net working capital. Given our strong position in ore feedstock and our ability to secure supply, we are appropriately positioned to maintain our commitment to our Ti-Pure^TM ~~Value Stabilization (“TVS”) strategy, allowing us to continue to offer our customers a predictable and reliable supply of high-quality~~ ~~TiO~~₂~~. Through execution of this strategy, our Assured Value Agreements (“AVA”) promote net working capital stability, allowing our customers to purchase~~ ~~TiO~~₂ ~~with supply assurance and price predictability as the market recovery begins. Alternatively, our Ti-Pure~~^TMFlex online portal provides our customers with the opportunity to secure their respective product needs and pricing for up to six months. Our third-party agents and distributors also continue to serve markets that we may not reach directly.

In responding to the COVID-19 pandemic and its subsequent impacts on global markets and local economies, we remain focused on matters that are within our control. Through the underlying strengths of our business operations, financial results and condition, and cash flows, we are fully engaged to protect the health and well-being of our employees and serve our customers.

However, in considering the unpredictability of the duration and magnitude of the impact of the COVID-19 pandemic, particularly as it relates to our operations and end-market demand, we are not currently providing full-year 2020 financial guidance. Our previous guidance, as issued on February 13, 2020, was withdrawn on May 5, 2020.

Our primary sources of liquidity are cash generated from operations and available cash, along with our receivables securitization and borrowings under our debt financing arrangements, both of which are described in further detail in “Note 1513 – Debt” to the Interim Consolidated Financial Statements and “Note 20 – Debt” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020. Our operating cash flow generation is driven by, among other things, the general global economic conditions at any point in time and their resulting impacts on demand for our products, raw materials and energy prices, and industry-specific issues, such as production capacity and utilization. We have generated strong operating cash flows through various past industry and economic cycles, evidencing the underlying operating strength of our businesses. ~~As noted in the “2020 Outlook” section within this~~

~~MD&A, however, significant uncertainty~~Uncertainty continues to exist concerning both the magnitude and the duration of the impacts to our financial results and condition as caused by the ongoing COVID-19 global pandemic. Regardless of size and duration, these rapidly evolving challenges have had and ~~will continue to~~could again in the future have an adverse impact on our operating cash flows. ~~However, based on our responses to the COVID-19 pandemic, including the business-related initiatives discussed in our “2020 Outlook”, we~~We anticipate that our cash generated from operations, available cash, ~~cash from operations,~~receivables securitization, and existing debt financing arrangements will provide us with sufficient liquidity through at least ~~November 2021.~~July 2022. If the macroeconomic situation deteriorates or the duration of the pandemic is further extended, we will evaluate additional cost actions, as necessary, as the operational and financial impacts to our Company continue to evolve.

At ~~September~~June 30, ~~2020,~~2021, we had total cash and cash equivalents of ~~$956 million,~~$1.1 billion, of which ~~$650~~$834 million was held by our foreign subsidiaries. All cash and cash equivalents held by our foreign subsidiaries is readily convertible into currencies used in our operations, including the U.S. dollar. During the ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, we received approximately ~~$280~~$180 million of net cash in the U.S. through intercompany loans and dividends. Traditionally, the cash and earnings of our foreign subsidiaries have generally been used to finance their operations and capital expenditures, and it is our intention to indefinitely reinvest the historical pre-2018 earnings of our foreign subsidiaries. However, beginning in 2018, management asserts that only certain foreign subsidiaries are indefinitely reinvested. For further information related to our income tax positions, see “Note 9 – Income Taxes” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020. Management believes that sufficient liquidity is available in the U.S. through at least ~~November 2021,~~July 2022, which includes borrowing capacity under our revolving credit facility.

~~During~~Over the ~~nine months ended September 30, 2020, we decided to take certain precautionary measures in light~~course of ~~macroeconomic uncertainties driven by COVID-19. On April 8, 2020, we drew $300 million from our revolving credit facility, which we subsequently repaid during~~ the third quarter of 2020 based on the Company’s liquidity position. As of September 30, 2020, no borrowings remain outstanding under the revolving credit facility, although outstanding letters of credit of $98 million offset our borrowing availability from the maximum capacity of $800 million. The availability under our revolving credit facility is subject to a maintenance covenant based on senior secured net debt and the lastnext 12 months ~~of consolidated EBITDA, as defined in our amended~~ and ~~restated credit agreement. Based on our forecasts and plans,~~beyond, we anticipate that we will be in compliance with our credit facility covenants through at least November 2021. For further details regarding our debt covenants pursuant to the amended and restated credit agreement of our senior secured credit facilities, see “Note 20 – Debt” to the ~~Consolidated Financial Statements~~ in our Annual Report on Form 10-K for the year ended December 31, 2019. In addition to the borrowings under our revolving credit facility, we also elected to accept tax relief provided by various taxing jurisdictions. The accepted relief primarily applies to foreign taxing jurisdictions and resulted in the deferral of approximately $80 million in tax payments, which are largely expected to be made in the first quarter of 2021.

We anticipate making significant cash payments for ~~interest, critical capital expenditures, environmental remediation costs and investments, dividends,~~known contractual and other ~~actions over the next 12 months,~~obligations, which we expect to fund through cash generated from operations, available cash, receivables securitization, and ~~borrowings.~~ our existing debt financing arrangements. Such obligations include:

We continue to believe our sources of liquidity are sufficient to fund our planned operations and to meet our interest, dividend, and contractual obligations through at least ~~November 2021.~~July 2022. Our financial policy seeks to: (i) selectively invest in organic and inorganic growth to enhance our portfolio, including certain strategic capital investments; (ii) maintain appropriate leverage by using free cash flows to repay outstanding borrowings; and, (iii) return cash to shareholders through dividends and share repurchases. Specific to our objective to return cash to shareholders, in recent quarters, we have previously announced dividends of $0.25 per share, amounting to approximately $160 million per year, and, on ~~October~~July 28, ~~2020,~~2021, we announced our quarterly cash dividend of $0.25 per share for the ~~fourth~~third quarter of ~~2020.~~2021. Under our 2018 Share Repurchase Program, as further discussed in Item 2 ~~– Unregistered~~–Unregistered Sales of Equity Securities and Use of Proceeds in this Quarterly Report on Form 10-Q, we also have remaining authority to repurchase ~~$428~~$413 million of our outstanding common stock. ~~In light of~~On July 26, 2021, we entered into a definitive agreement with Draslovka to sell the ~~COVID-19 pandemic, we do not currently plan to repurchase additional shares~~Mining Solutions business of our ~~outstanding common stock~~Chemical Solutions segment for a cash consideration of $520 million. We expect the transaction to close in the ~~near future.~~ fourth quarter of 2021, subject to customary closing conditions, including regulatory approvals. We expect to use the proceeds from the sale as permitted by our Credit Agreement and the indenture governing our 2025 Notes which includes, for example, acquisitions of other businesses, properties, assets or intellectual property, capital expenditures, and/or reduction of indebtedness. Subject to approval by our board of directors, we may raise additional capital or borrowings from time to time, or seek to refinance our existing debt. There can be no assurances that future capital or borrowings will be available to us, and the cost and availability of new capital or borrowings could be materially impacted by market conditions. Further, the decision to refinance our existing debt is based on a number of factors, including general market conditions and our ability to refinance on attractive terms at any given point in time. Any attempts to raise additional capital or borrowings or refinance our existing debt could cause us to incur significant charges. Such charges could have a material impact on our financial position, results of operations, or cash flows.

The following table sets forth a summary of the net cash provided by (used for) our operating, investing, and financing activities for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Nine Months Ended September 30,						Six Months Ended June 30,
(Dollars in millions)	2020			2019			2021			2020
Cash provided by operating activities	$	454		$	250		$	295		$	155
Cash used for investing activities		(210	)		(387	)		(134	)		(163	)
Cash used for financing activities		(252	)		(360	)
Cash (used for) provided by financing activities								(118	)		92

We generated ~~$454~~$295 million and ~~$250~~$155 million in cash flows from our operating activities during the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively. The increase in our operating cash inflows ~~for the nine months ended September 30, 2020~~ was primarily attributable to ~~lower~~higher earnings from operations and an increase in our accounts payable, which was driven by higher raw ~~materials inventories~~material inventory purchases in connection with higher sales volumes and the timing of payments to our vendors. This was offset substantially by an increase in our accounts receivable balance, which was driven by higher net sales and the timing of payments from our customers, as well as ~~the~~ $125 million of accounts receivables sold to the bank during the six months ended June 30, 2020. The $125 million of receivables were pursuant to the ~~amended and restated receivables purchase agreement (the “Amended~~Amended Purchase ~~Agreement”)~~Agreement, dated March 9, 2020, under our ~~accounts receivable securitization facility (“~~Securitization ~~Facility”). The increase in our comparative operating cash inflows was also attributable~~Facility. For further information refer to ~~a reduction in tax payments made in 2020, a decrease in certain employee-related costs, and our cost savings initiatives in response~~“Note 13 – Debt” to the ~~COVID-19 pandemic~~Interim Consolidated Financial Statements. These comparative increases in our operating cash flows for the nine months ended September 30, 2020 were partially offset by a decrease in our net income, as well as a comparative increase in our remaining accounts receivable.

We used ~~$210~~$134 million and ~~$387~~$163 million in cash flows for our investing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019,~~2020, respectively. Our investing cash outflows for the ~~nine~~six months ended ~~September~~June 30, ~~2020 and 2019 were~~2021 was primarily attributable to purchases of property, plant, and equipment amounting to ~~$214~~$127 million, ~~and $385~~inclusive of the $22 million ~~respectively. The comparative reduction~~of assets acquired in exchange for the termination of our contract with the third-party service provider at our under-construction Mining Solutions facility in Gomez Palacio, Durango, Mexico. Our investing cash outflows for the six months ended June 30, 2020 was primarily attributable to purchases of property, plant, and equipment ~~during the nine months ended September 30, 2020 was primarily attributable~~amounting to temporary cash preservation initiatives, which were implemented in anticipation of declining customer demand as driven by COVID-19. For further information related to our temporary cash preservation initiatives and the anticipated impact on our capital spending for the year ending December 31, 2020, refer to the ~~“2020 Outlook” section within this~~ ~~MD&A. The comparative reduction in our purchases of property, plant, and equipment was also attributable to our prior year capital expenditures associated with the construction of~~ ~~our research and development facility on the Science, Technology, and Advanced Research campus of the University of Delaware in Newark, Delaware~~ ~~and our investment in a thermal oxidizer to reduce aerial PFAS emissions from our Fayetteville Works site in Fayetteville, North Carolina.~~$167 million.

Our investing cash outflows for the nine months ended September 30, 2020 were also attributable to a $10 million installment payment associated with our acquisition of Southern Ionics Minerals, LLC (“SIM”) in the third quarter of 2019. We also made $10 million of upfront cash consideration payments in connection with this acquisition during the third quarter of 2019. For further information related to our 2019 acquisition of SIM, see “Note 3 – Acquisitions and Divestitures” to the ~~Interim Consolidated Financial Statements~~ ~~and “Note 4 – Acquisitions and Divestitures” to the~~ ~~Consolidated Financial Statements~~ ~~in our Annual Report on Form 10-K for the year ended December 31, 2019.~~

We used ~~$252~~ $118million in cash flows for our financing activities during the ~~nine~~six months ended ~~September~~June 30, ~~2020.~~2021. Our financing cash outflows for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 were primarily attributable to $27 million in debt repayments, $13 million purchases of our ~~capital allocation activities, resulting in $123~~issued and outstanding common stock under our 2018 Share Repurchase Program, and $82 million returned to our shareholders in the form of cash dividends paid. Our financing cash ~~outflows~~inflows for the six months ended June 30, 2020 were ~~also~~primarily attributable to $300 million in proceeds received from drawing on our revolving credit facility, which was executed as a precautionary measure in light of macroeconomic uncertainties driven by COVID-19. Our financing cash inflows were partially offset by the amendment and restatement of our receivables purchase agreement dated as of July 12, 2019 (the “Original Purchase Agreement”) under our Securitization Facility, resulting in net repayments of $110 million to settle the associated collateralized borrowings. Aside from these payments associated with our Securitization Facility, we also made $18 million in debt repayments. Our financing cash outflows for the nine months ended September 30, 2020 are also inclusive of our repayment of $300 million in proceeds received from drawing on our revolving credit facility, which was executed on April 8, 2020 ~~as a precautionary measure in light of macroeconomic uncertainties driven by COVID-19.~~For further information

We used $360 million in cash flows for our financing activities during the nine months ended September 30, 2019. Our financing cash outflows for the nine months ended September 30, 2019 were primarily attributablerefer to our capital allocation activities, resulting in $446 million of cash returned to shareholders through our 2018 Share Repurchase Program and through cash dividends paid. We also made $30 million in payments for withholding taxes on certain of our vested stock-based compensation awards, as well as $15 million in debt repayments. Our financing cash outflows are also inclusive of our repayment of $150 million in proceeds received from drawing on our revolving credit facility, which was executed for general corporate purposes. The repayment was made during the third quarter of 2019, primarily using the $125 million of proceeds received from the Securitization Facility, as well as available cash. The Securitization Facility is further described in “Note 15“Note 13 – Debt” to the Interim Consolidated Financial Statements. We also returned $82 million to our shareholders in the form of cash dividends paid and made $12 million in debt repayments.

The following table sets forth the components of our current assets at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

(Dollars in millions)	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Cash and cash equivalents	$	956	$	943	$	1,139	$	1,105
Accounts and notes receivable, net		572		674		802		511
Inventories		993		1,079		1,046		939
Prepaid expenses and other		84		81		60		78
Total current assets	$	2,605	$	2,777	$	3,047	$	2,633

Our accounts and notes receivable, net ~~decreased~~increased by ~~$102~~$291 million (or ~~15%~~57%) to ~~$572~~$802 million at ~~September~~June 30, ~~2020,~~2021, compared with accounts and notes receivable, net of ~~$674~~$511 million at December 31, ~~2019. The decrease~~2020. These increase in our accounts and notes receivable, net at ~~September~~June 30, ~~2020~~2021 was primarily attributable to ~~$125 million of accounts receivables sold to the bank in accordance with the Amended Purchase Agreement under our Securitization Facility, as well as lower~~higher net sales inand the ~~third quarter~~timing of ~~2020 versus the fourth quarter of 2019. These decreases~~payments from our customers. The increase in our accounts and notes receivable, net ~~at September 30, 2020 were~~was partially offset by the ~~timing~~additional used capacity of ~~payments from~~ our ~~customers at the previous year-end.~~Securitization Facility.

Our inventories ~~decreased~~increased by ~~$86~~$107 million (or 8%11%) to $1.0 billion at ~~September~~June 30, ~~2020,~~2021, compared with inventories of ~~$1.1 billion~~$939 million at December 31, ~~2019.~~2020. The ~~decrease~~increase in our inventories at ~~September~~June 30, ~~2020~~2021 was primarily attributable to ~~lower~~an increase in our finished product and raw materials inventories, ~~purchases in connection with lower sales volumes,~~ which was ~~partially offset by the seasonal build-up of our finished products inventories~~due to ramp-up in ~~the first quarter of 2020.~~production and higher raw material costs.

Our prepaid expenses and other assets ~~were largely unchanged at $84~~decreased by $18 million ~~and $81~~(or 23%) to $60 million at ~~September~~June 30, ~~2020~~2021, compared with prepaid expenses and other assets of $78 million at December 31, ~~2019, respectively.~~

2020. The decrease in our prepaid expenses and other assets at June 30, 2021 was primarily attributable to decreases in our prepaid insurance premiums and income tax receivable balances.

The following table sets forth the components of our current liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020.

(Dollars in millions)	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Accounts payable	$	701	$	923	$	1,061	$	844
Compensation and other employee-related costs						113		107
Short-term and current maturities of long-term debt		32		134		25		21
Current environmental remediation						154		95
Other accrued liabilities		575		484		321		375
Total current liabilities	$	1,308	$	1,541	$	1,674	$	1,442

Our accounts payable ~~decreased~~increased by ~~$222~~$217 million (or ~~24%~~26%) to ~~$701 million~~$1.1 billion at ~~September~~June 30, ~~2020,~~2021, compared with accounts payable of ~~$923~~$844 million at December 31, ~~2019.~~2020. The ~~decrease~~increase in our accounts payable at ~~September~~June 30, ~~2020~~2021 was primarily attributable to ~~lower~~higher raw materials inventories purchases in connection with ~~lower~~higher sales volumes ~~our cost savings initiatives in response to the COVID-19 pandemic,~~ and the timing of payments to our vendors.

Our compensation and other employee-related costs increased by $6 million (or 6%) to $113 million at June 30, 2021, compared with compensation and other employee-related costs of $107 million at December 31, 2020. The increase in our compensation and other employee-related costs at June 30, 2021 was primarily attributable to increased accruals for payroll and performance-based employee compensation.

Our short-term and current maturities of long-term debt ~~decreased~~increased by ~~$102~~$4 million (or ~~76%~~19%) to ~~$32~~$25 million at ~~September~~June 30, ~~2020,~~2021, compared with short-term and current maturities of long-term debt of ~~$134~~$21 million at December 31, ~~2019.~~2020. The ~~decrease~~increase in our short-term and current maturities of long-term debt at ~~September~~June 30, ~~2020~~2021 was primarily attributable to ~~the amendment and restatement~~an increase in our finance lease liabilities.

Our current environmental remediation increased by $59 million (or 62%) to $154 million at June 30, 2021, compared with current environmental remediation of $95 million at December 31, 2020. The increase in our current environmental remediation at June 30, 2021 was primarily attributable to increased liabilities related to construction of the ~~Original Purchase Agreement under our Securitization Facility, resulting in~~barrier wall and operation of the ~~settlement of $110 million in collateralized borrowings outstanding as of December 31, 2019.~~groundwater extraction and treatment system at Fayetteville.

Our other accrued liabilities ~~increased~~decreased by ~~$91~~$54 million (or ~~19%~~14%) to ~~$575~~$321 million at ~~September~~June 30, ~~2020,~~2021, compared with other accrued liabilities of ~~$484~~$375 million at December 31, ~~2019.~~2020. The ~~increase~~decrease in our other accrued liabilities at ~~September~~June 30, ~~2020~~2021 was primarily attributable to a $40 million increase in interest accrued as driven by our senior unsecured notes, a $33 million increase in deferrals of certain income tax payments, a $23 million increase for environmental remediation at certain of our sites, and an increase for certain employee-related costs. These increases in our other accrued liabilities at September 30, 2020 were partially offset by recognitionthe payment of customer rebates, primarily during the first quarter of ~~2020, as well as~~ ~~a $10 million installment~~2021, and the payment ~~in the third quarter~~ of ~~2020~~contract termination fees in connection with construction work at our ~~acquisition of SIM~~Mining Solutions facility in ~~the third quarter of 2019~~.Gomez Palacio, Durango, Mexico.

See “Note 1513 – Debt” to the Interim Consolidated Financial Statements and “Note 20 – Debt” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020 for a discussion of our credit facilities and notes.

The following disclosures set forth summarized financial information and alternative disclosures in accordance with Rule 13-01 of Regulation S-X (“Rule 13-01”). These disclosures have been made in connection with certain subsidiaries' guarantees of the ~~6.625% senior unsecured notes due May 2023, the~~ 7.000% senior unsecured notes due May 2025, the 4.000% senior unsecured notes due May 2026, which are denominated in euros, ~~and~~ the 5.375% senior unsecured notes due May 2027, and the 5.750% senior unsecured notes due November 2028 (collectively, the “Notes”). Each series of the Notes was issued by The Chemours Company (the “Parent Issuer”), and was fully and unconditionally guaranteed, jointly and severally, on a senior unsecured basis by the same group of subsidiaries of the Parent Issuer (together, the “Guarantor Subsidiaries”), subject to certain exceptions as set forth in “Note 20 – Debt” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, ~~2019~~2020. The assets, liabilities, and operations of the Guarantor Subsidiaries primarily consist of those attributable to The Chemours Company FC, LLC, our primary operating subsidiary in the United States, as well as the other U.S.-based operating subsidiaries as set forth in Exhibit 22 to this Quarterly Report on Form 10-Q. Each of the Guarantor Subsidiaries is 100% owned by the Company. None of our other subsidiaries, either direct or indirect, guarantee the Notes (together, the “Non-Guarantor Subsidiaries”). Pursuant to the indentures governing the Notes, the Guarantor Subsidiaries will be automatically released from those guarantees upon the occurrence of certain customary release provisions.

Our summarized financial information is presented on a combined basis, consisting of the Parent Issuer and Guarantor Subsidiaries (collectively, the “Obligor Group”), in accordance with the requirements under Rule 13-01, and is presented after the elimination of: (i) intercompany transactions and balances among the Parent Issuer and Guarantor Subsidiaries, and (ii) equity in earnings from and investments in the Non-Guarantor Subsidiaries.

(Dollars in millions)	Nine Months Ended September 30, 2020			Six Months Ended June 30, 2021
Net sales	$	2,399		$	1,980
Gross profit		318			139
Loss before income taxes		(4	)		(122	)
Net income		32
Net income attributable to Chemours		32
Net loss					(78	)
Net loss attributable to Chemours					(78	)

(Dollars in millions)	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Assets
Current assets (1,2,3)	$	1,223	$	1,063	$	1,331	$	1,057
Long-term assets (4)		4,219		4,339		3,891		4,288

Liabilities
Current liabilities (2)	$	1,220	$	1,045	$	1,230	$	1,298
Long-term liabilities		4,784		4,871		4,771		4,703

There are no significant restrictions that may affect the ability of the Guarantor Subsidiaries in guaranteeing the Parent Issuer’s obligations under our debt financing arrangements. While the Non-Guarantor Subsidiaries do not guarantee the Parent Issuer’s obligations under our debt financing arrangements, we may, from time to time, repatriate post-2017 earnings from certain of these subsidiaries to meet our financing obligations, as well.

We maintain supply chain finance programs with several financial institutions. The programs allow our suppliers to sell their receivables to one of the participating financial institutions at the discretion of both parties on terms that are negotiated between the supplier and the respective financial institution. Our obligations to our suppliers, including the amounts due and scheduled payment dates, are not impacted by our suppliers’ decisions to sell their receivables under this program. At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, the total amounts outstanding under these programs were ~~$109~~$218 million and ~~$106~~$160 million, respectively. Pursuant to their agreement with one of the financial institutions, certain suppliers may elect to be paid early at their discretion. The available capacity under these programs can vary based on the number of investors and/or financial institutions participating in these programs at any point in time.

Our contractual obligations at September 30, 2020 did not significantly change from the contractual obligations previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2019.

In March 2020, through a wholly-owned special purpose entity, we entered into the Amended Purchase Agreement, which amends and restates, in its entirety, the Original Purchase Agreement under our Securitization Facility. In March of 2021, through a wholly-owned special purpose entity we entered into the First Amendment, which among other things, extends the term of the Amended Purchase Agreement and increases the facility limit to $150 million.

See “Note 1513 – Debt” to the Interim Consolidated Financial Statements for further details regarding this off-balance sheet arrangement.

Historically, we have not made significant payments to satisfy guarantee obligations; however, we believe we have the financial resources to satisfy these guarantees in the event required.

Our significant accounting policies are described in our MD&A and “Note 3 – Summary of Significant Accounting Policies” to the Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020. There have been no material changes to these critical accounting policies and estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2019,~~2020, except as described in “Note 2 – Recent Accounting Pronouncements” to the Interim Consolidated Financial Statements.

See “Note 2 – Recent Accounting Pronouncements” to the Interim Consolidated Financial Statements for a discussion about recent accounting pronouncements.

Consistent with our values and our Environment, Health, Safety, and Corporate Responsibility policy, we are committed to preventing releases to the environment at our manufacturing sites to keep our people and communities safe, and to be good stewards of the environment. We are also subject to environmental laws and regulations relating to the protection of the environment. We believe that, as a general matter, our policies, standards, and procedures are properly designed to prevent unreasonable risk of harm to people and the environment, and that our handling, manufacture, use, and disposal of hazardous substances are in accordance with applicable environmental laws and regulations.

In large part, because of past operations, operations of predecessor companies, or past disposal practices, we, like many other similar companies, have clean-up responsibilities and associated remediation costs, and are subject to claims by other parties, including claims for matters that are liabilities of ~~DuPont~~EID and its subsidiaries that we may be required to indemnify pursuant to the Separation-related agreements executed prior to our separation from ~~DuPont~~EID on July 1, 2015 (the “Separation”).

Our environmental liabilities include estimated costs, including certain accruable costs associated with on-site capital projects, related to a number of sites for which it is probable that environmental remediation will be required, whether or not subject to enforcement activities, as well as those obligations that result from environmental laws such as the Comprehensive Environmental Response, Compensation, and Liability Act (“CERCLA”, often referred to as “Superfund”), the Resource Conservation and Recovery Act (“RCRA”), and similar federal, state, local, and foreign laws. These laws require certain investigative, remediation, and restoration activities at sites where we conduct or once conducted operations or at sites where our generated waste was disposed. At ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, our consolidated balance sheets include environmental remediation liabilities of ~~$398~~$556 million and ~~$406~~$390 million, respectively, relating to these matters, which, as discussed in further detail below, include ~~$199~~$355 million and ~~$201~~$194 million, respectively, for ~~our~~ Fayetteville ~~Works site in Fayetteville, North Carolina (“Fayetteville”)~~.

As remediation efforts progress, sites move from the investigation phase (“Investigation”) to the active clean-up phase (“Active Remediation”), and as construction is completed at Active Remediation sites, those sites move to the operation, maintenance, and monitoring (“OM&M”), or closure phase. As final clean-up activities for some significant sites are completed over the next several years, we expect our annual expenses related to these active sites to decline over time. The time frame for a site to go through all phases of remediation (Investigation and Active Remediation) may take about 15 to 20 years, followed by several years of OM&M activities. Remediation activities, including OM&M activities, vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, and diverse regulatory requirements, as well as the presence or absence of other Potentially Responsible Parties (“PRPs”). In addition, for claims that we may be required to indemnify ~~DuPont~~EID pursuant to the Separation-related agreements, we and ~~DuPont~~EID may have limited available information for certain sites or are in the early stages of discussions with regulators. For these sites, there may be considerable variability between the clean-up activities that are currently being undertaken or planned and the ultimate actions that could be required. Therefore, considerable uncertainty exists with respect to environmental remediation costs, and, under adverse changes in circumstances, although deemed remote, the potential liability may range up to approximately ~~$560~~$680 million above the amount accrued at ~~September~~June 30, ~~2020.~~2021. In general, uncertainty is greatest and the range of potential liability is widest in the Investigation phase, narrowing over time as regulatory agencies approve site remedial plans. As a result, uncertainty is reduced, and sites ultimately move into OM&M, as needed. As more sites advance from Investigation to Active Remediation to OM&M or closure, the upper end of the range of potential liability is expected to decrease over time.

Some remediation sites will achieve site closure and will require no further action to protect people and the environment and comply with laws and regulations. At certain sites, we expect that there will continue to be some level of remediation activity due to ongoing OM&M of remedial systems. In addition, portfolio changes, such as an acquisition or divestiture, or notification as a PRP for a multi-party Superfund site, could result in additional remediation activity and potentially additional accrual.

Management does not believe that any loss, in excess of amounts accrued, related to remediation activities at any individual site will have a material impact on our financial position or cash flows for any given year, as such obligation can be satisfied or settled over many years.

While there are many remediation sites that contribute to our total accrued environmental remediation liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019,~~2020, the following table sets forth the sites that are the most significant.

(Dollars in millions)	September 30, 2020		December 31, 2019		June 30, 2021		December 31, 2020
Chambers Works, Deepwater, New Jersey	$	19	$	20	$	27	$	20
East Chicago, Indiana		14		17		11		11
Fayetteville Works, Fayetteville, North Carolina		199		201		355		194
Pompton Lakes, New Jersey		42		43		41		42
USS Lead, East Chicago, Indiana		13		13		15		12
All other sites		111		112		107		111
Total environmental remediation	$	398	$	406	$	556	$	390

The five sites listed above represent 81% and 72% of our total accrued environmental remediation liabilities at ~~September~~June 30, ~~2020~~2021 and December 31, ~~2019.~~2020, respectively. For these five sites, we expect to spend, in the aggregate, ~~$138~~$211 million over the next three years. For all other sites, we expect to spend ~~$67~~$64 million over the next three years.

The Chambers Works complex is located on the eastern shore of the Delaware River in Deepwater, Salem County, New Jersey. The site comprises the former Carneys Point Works in the northern area and the Chambers Works manufacturing area in the southern area. Site operations began in 1892 when the former Carneys Point smokeless gunpowder plant was constructed at the northern end of Carneys Point. Site operations began in the manufacturing area around 1914 and included the manufacture of dyes, aromatics, elastomers, chlorofluorocarbons, and tetraethyl lead. We continue to manufacture a variety of ~~fluorochemicals~~fluoropolymers and finished products at Chambers Works. In addition, ~~three~~two tenants operate processes at Chambers ~~Works including steam/electricity generation, industrial gas production, and the manufacture of intermediate chemicals.~~Works. As a result of over 100 years of continuous industrial activity, site soils and groundwater have been impacted by chemical releases.

In response to identified groundwater contamination, a groundwater interceptor well system (“IWS”) was installed in 1970, which was designed to contain contaminated groundwater and restrict off-site migration. Additional remediation is being completed under a federal RCRA Corrective Action permit. The site has been studied extensively over the years, and more than 25 remedial actions have been completed to date and engineering and institutional controls put in place to ensure protection of people and the environment. In the fourth quarter of 2017, a site perimeter sheet pile barrier intended to more efficiently contain groundwater was completed.

Remaining work beyond continued operation of the IWS and groundwater monitoring includes completion of various targeted studies on site and in adjacent water bodies to close investigation data gaps, as well as selection and implementation of final remedies under RCRA Corrective Action for various solid waste management units and areas of concern not yet addressed through interim measures. In the first quarter of 2021, in connection with ongoing discussions with EPA and NJ DEP relating to such remaining work as well as the scope of remedial programs and investigation relating to the Chambers Works site, we recorded adjustments of $7 million related to the remediation estimate associated with certain areas of the site relating to historic industrial activity as well as ongoing remedial programs.

East Chicago is a former manufacturing facility that we previously owned in East Chicago, Lake County, Indiana. The approximate 440-acre site is bounded to the south by the east branch of the Grand Calumet River, to the east and north by residential and commercial areas, and to the west by industrial areas, including a former lead processing facility. The inorganic chemicals unit on site produced various chloride, ammonia, and zinc products and inorganic agricultural chemicals beginning in 1892 until 1986. Organic chemical manufacturing began in 1944, consisting primarily of chlorofluorocarbons production. The remaining business was sold to W.R. Grace Company (“Grace”) in early 2000. Approximately 172 acres of the site were never developed and are managed by The Nature Conservancy for habitat preservation.

A comprehensive evaluation of soil and groundwater conditions at the site was performed as part of the RCRA Corrective Action process. Studies of historical site impacts began in 1983 in response to preliminary CERCLA actions undertaken by the U.S. Environmental Protection Agency (“EPA”). The EPA eventually issued an Administrative Order on Consent for the site in 1997. The order specified that remediation work be performed under RCRA Corrective Action authority. Work has proceeded under the RCRA Corrective Action process since that time.

Subsequent investigations included the preparation of initial environmental site assessments and multiple phases of investigation. In 2002, as an interim remedial measure, two 2,000-foot long permeable reactive barrier treatment walls were installed along the northern property boundary to address migration of chemicals in groundwater. Since that time, the investigation process has been completed and approved by the EPA, and the final remedy for the site was issued by the EPA in July 2018.

On June 29, 2018, we sold the East Chicago, Indiana site to a third party for $1 million. In connection with the sale, the buyer agreed to assume all costs associated with environmental remediation activities at the site in excess of $21 million, which will remain our responsibility. At the time of the sale, we had accrued the full $21 million, of which ~~$14~~$11 million remained as of ~~September~~June 30, ~~2020.~~2021. We will reimburse the buyer through a series of progress payments to be made at defined intervals as certain tasks are completed.

Fayetteville is located southeast of the City of Fayetteville in Cumberland and Bladen counties, North Carolina. The facility encompasses approximately 2,200 acres, which were purchased by ~~DuPont~~EID in 1970, and are bounded to the east by the Cape Fear River and to the west by North Carolina Highway 87. Currently, the ~~site~~Company manufactures ~~plastic sheeting, fluorochemicals,~~fluorinated monomers, fluorinated vinyl ethers, Nafion^TM membranes and ~~intermediates for plastics manufacturing.~~dispersions, and fluoropolymer processing aids at the site. A former manufacturing area, which was sold in 1992, produced nylon strapping and elastomeric tape. ~~DuPont~~EID sold its Butacite® and SentryGlas® manufacturing units to Kuraray America, Inc. in September 2014. In July 2015, upon our Separation from ~~DuPont,~~EID, we became the owner of the Fayetteville land assets along with fluoromonomers, ~~Nafion®~~Nafion^TM membranes, and the related polymer processing aid manufacturing units. A polyvinyl fluoride resin manufacturing unit remained with ~~DuPont.~~EID.

Beginning in 1996, several stages of site investigation were conducted under oversight by the North Carolina Department of Environmental Quality (“NC DEQ”), as required by the facility's hazardous waste permit. In addition, the site has voluntarily agreed to agency requests for additional investigations of the potential release of “PFAS” (perfluoroalkyl and polyfluoroalkyl substances) beginning with “PFOA” (collectively, perfluorooctanoic acids and its salts, including the ammonium salt) in 2006. As a result of detection of the polymerization processing aid hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid”, sometimes referred to as “GenX” or “C3 Dimer Acid”) in on-site groundwater wells during our investigations in 2017, the NC DEQ issued a Notice of Violation (“NOV”) on September 6, 2017 alleging violations of North Carolina water quality statutes and requiring further response. Since that time, and in response to three additional NOVs issued by NC DEQ and pursuant to the Consent Order (as discussed below), we have worked cooperatively with the agency to investigate and address releases of PFAS to on-site and off-site groundwater and surface water.

As discussed in “Note 1715 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements, we, along with NC DEQ and Cape Fear River Watch (“CFRW”), a non-profit organization, have filed a final Consent Order (“CO”) that comprehensively addressed various issues, NOVs, and court filings made by the NC DEQ regarding Fayetteville and resolved litigations filed by the NC DEQ and CFRW. In connection with the CO, a thermal oxidizer became fully operational at the site in December 2019 to reduce aerial PFAS emissions from Fayetteville.

~~In the fourth quarter of 2019, we completed and submitted our Cape Fear River PFAS Loading Reduction Plan - Supplemental Information Report and our~~ ~~Corrective Action Plan (“CAP”)~~ ~~to NC DEQ.~~ 69

The Supplemental Information Report provided information to support the evaluation of potential interim remedial options to reduce PFAS loadings to surface waters. The CAP described potential long-term remediation activities to address PFAS in on-site groundwater and surface waters at the site, in accordance with the requirements of the CO and the North Carolina groundwater standards, and built on the previous submissions to NC DEQ. ~~The NC DEQ made the CAP available for public review and comment until April 6, 2020, and we are awaiting formal response to the CAP from NC DEQ following the conclusion of the public comment period.~~Chemours Company

In August 2020, we, along with NC DEQ and CFRW, reached agreement on the terms of an addendum to the CO (the “Addendum”). The Addendum ~~represents~~establishes the ~~parties’ collective agreement regarding~~procedure to implement specified remedial measures ~~and defined timelines~~ for reducing PFAS loadings from Fayetteville to the Cape Fear River, including construction of a barrier wall with groundwater extraction system to be completed by March 15, 2023. Detailed engineering and design work has commenced with NC DEQ approval of permit applications anticipated in August 2021, as well as two stages of design approval anticipated in August 2021 and March 2022. After a period of public comment, the Addendum was approved by the North Carolina Superior Court for Bladen County on October 12, ~~2020.~~2020 and establishes the procedure to implement specified remedial measures for reducing PFAS loadings from Fayetteville to the Cape Fear River, including construction of a barrier wall with a groundwater extraction system to be completed by March 15, 2023.

Following issuance of a National Pollutant Discharge Elimination System (“NPDES”) permit by NC DEQ on September 18, 2020, we began operation of a capture and treatment system from the site’s old outfall channel on September 30, 2020. During the first quarter of 2021, the operation of the old outfall treatment system was interrupted on two occasions, and notice was provided to NC DEQ of the low treatment flow conditions through the system. On January 26, 2021, we received an NOV from NC DEQ, alleging violations of the CO and the NPDES water permit arising from the design and operation of the treatment system related to the old outfall. Along with our third-party service provider, we have taken, and continue to take, interim actions intended to improve the operation of the old outfall treatment system and address challenges posed by substantial rain events, sediment loading into the system, and variability in water influent conditions. In addition, along with our third-party service provider, we are actively working on long-term enhancements to the treatment system based on learnings from the recent challenges. These enhancements will, or may include, the construction of a holding pond, installation of new ultra-filtration units, a sediment trap to manage sediment flow in the stream channel, alternate equipment to remove solids created during water pretreatment, and enhancement of the carbon absorption system. An incremental $60 million was accrued in the three months ended June 30, 2021, representing approximately $3 million per year for 20 years of estimated operation of the system, primarily related to the probable enhancements and the long-term operation of the water treatment system in accordance with the requirements of the CO.

Our estimated liability for the remediation activities that are probable and estimable is based on the CO, the Addendum, the CAP, and management’s assessment of the current facts and circumstances, which are subject to various assumptions including the transport pathways (being pathways by which PFAS reaches the Cape Fear River) which will require remedial actions, the types of interim and permanent site surface water and on-site remedies and treatment systems selected and implemented, the estimated cost of such potential remedies and treatment systems, any related OM&M requirements, and other charges contemplated by the CO and the Addendum.

In the second quarter of 2021, work commenced on the detailed engineering design of the barrier wall and refinement of models for the planned groundwater extraction system. Engineering designs for our major construction projects are typically reviewed at 30, 60 and 90% complete. Per the Addendum, a 60% design is required to be submitted to NC DEQ by August 15, 2021 for their review and approval. Additionally, applications for the necessary permits for the groundwater extraction system are expected to be submitted by that date.A 90% complete design is required to be submitted to NC DEQ by March 31, 2022 for their review and approval. In June 2021, we reviewed the 30% complete design and associated preliminary vendor estimates for the construction and operation of a barrier wall and groundwater treatment system at Fayetteville.

The current planned construction site of the future barrier wall, that will address both on-site groundwater and long-term seep remediation, is expected to be located at an approximately 30 feet higher elevation, above the Cape Fear River as compared to the initial, conceptual design that was prepared in support of the CAP submission to NC DEQ on December 31, 2019, which addressed groundwater only. The CAP submission unit cost estimate was the principal basis of unit costs for our liability estimates through March 31, 2021. It was determined in the quarter ended June 30, 2021, based upon the 30% design information completed during the quarter, that there was significantly increased construction complexity and related vendor and other design costs to be incurred.For example, the steep slope of the revised construction site results in the depth of the wall increasing from the original estimates of approximately 65 feet to approximately 85 feet below ground along most of its length. Construction of approximately 64 pumping wells, a more than 50% increase from the conceptual design, are expected to be required to extract groundwater for treatment based on studies of groundwater flows that were completed in May 2021. The wells will also need to be drilled deeper into the ground based on the revised location. A 2-mile access road, with retaining walls above and below the road to reduce slope erosion and landslides, will now be required for large, heavy construction equipment to access the barrier wall location safely. The estimated cost for construction as a result of these changes is based on contractor estimates provided in late May 2021. Together, all these modifications to the design resulted in an additional $49 million accrued for construction of the barrier wall in the quarter ended June 30, 2021.

The volume of groundwater, seep water, and stormwater (up to a 0.5 inch rain event in any 24 hours period per the Addendum) intercepted for treatment is estimated to be up to a maximum of 1,500 gallons per minute (“gpm”) based on groundwater flow modeling completed in the second quarter of 2021. Until the pre-design investigation and groundwater modeling was complete, the volume of water captured for treatment was estimated to be approximately 1,200 gpm, and the pretreatment requirements to remove dissolved solids had not been determined. Hence, we determined in the second quarter of 2021 that construction of a larger treatment plant than previously considered in the conceptual design and previous cost estimates was required. Consistent with prior periods, we accrued 20 years of ongoing monitoring and maintenance for Fayetteville environmental remediation systems based on the CO and Addendum. The revised estimate to process higher volumes of groundwater than originally contemplated resulted in a change in estimate of $60 million being recorded in the quarter ended June 30, 2021 related to estimated higher power consumption, ongoing monitoring, pretreatment, filtering supplies, principally carbon and regular maintenance of the system over a 20-year period of estimated operation starting in 2023.

Accordingly, as discussed above, in the three months ended June 30, 2021, we revised in accordance with AsASC 250 – Accounting Changes and Error Corrections, its estimated liability to comply with the CO and Addendum, and an incremental $49 million was accrued related to the construction of the barrier wall and an additional $60 million related to the future operation of the groundwater extraction and treatment system. In accordance with ASC 410 – Asset Retirement and Environmental Obligations, these amounts were recorded as a component of cost of goods sold as we only capitalize environmental costs if the costs extend the useful life of the property, increase the property’s capacity, and/or reduce or prevent contamination from future operations.

Pre-construction site preparation activities are in progress and construction of the water treatment facility is expected to commence before the end of 2021. Construction of the barrier wall is expected to commence in 2022 with completion planned in the first quarter of 2023. At June 30, 2021, several significant uncertainties remain, principally related to an extension of the barrier wall along Willis Creek at the northern end of the site, additional wetlands mitigation fees, finalization of the volume of water to be treated, contract negotiations with key construction and water treatment vendors and the estimated future time period of OM&M. We believe that extension of the barrier wall along the Willis Creek is technically impracticable and not necessary to comply with the terms of the CO and Addendum. Accordingly, we have increased the upper range of our cost estimates for the barrier wall and groundwater OM&M from $111 million at December 31, 2020 to $303 million at June 30, 2021, of which $173 million is already accrued. We have not accrued for the incremental costs in the upper range, including the extension of the barrier wall. Estimated costs for the barrier wall extension included in the upper range of the cost estimates is approximately $30 million.

The final cost of the on-site groundwater treatment system primarily depends on receiving timely NC DEQ design and permit approvals and thus the timely finalization of certain significant design details, notably the actual barrier wall location, depth, and length, number and configuration of extraction wells, water extraction rates and estimated carbon usage. The engineering design is expected to be approximately 60% complete in the third quarter of 2021, which will form the basis of a submission for the first approval by NC DEQ which we are required to be submit no later than August 15, 2021. Per the Addendum, the NC DEQ shall use best efforts to complete its review and notify us whether the design is approved within 30 days after submittal. If not approved within 30 days, subsequent deadlines shall be extended by the time required for NC DEQ approval in excess of 30 days. Unanticipated schedule delays or other factors beyond our control could lead to further increases in the cost of the barrier wall and groundwater treatment system, which could be material. Changes in estimates are recorded in results of operations in the period that the events and circumstances giving rise to such changes occur. If we do not achieve project completion of the barrier wall and groundwater treatment system by March 15, 2023, the Addendum specifies penalties of $0.15 million plus an additional $0.02 million per week until installation is completed.

Accordingly, based on the CO, the Addendum, the CAP, and management’s plans, which are based on current regulations and technology, we have accrued $301 million and $140 million at June 30, 2021 and December 31, 2020, respectively, related to the estimated cost of on-site remediation, which is within the existing estimated range of potential outcomes, based on current potential remedial options, and projected to be paid over a period of approximately 20 years. The final costs of any selected remediation will depend primarily on the final approved design and actual labor and material costs.

As of June 30, 2021, based on the CO, the Addendum, the CAP, and our plans, which are based on current regulations and technology, we have accrued ~~$142~~$301 million and ~~$57~~$54 million related to the estimated cost of on-site and off-site remediation, respectively. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, we accrued an additional $181 million and $192 million, respectively, of which $5 million and $10 million ~~and $31 million, respectively, which~~ was ~~largely~~ attributable to off-site groundwater testing and water treatment system installations at additional qualifying third-party properties in the vicinity surrounding Fayetteville. The amounts accrued during the three and nine months ended September 30, 2020 are net of $3 million and $7 million, respectively, of changes in estimates related to the cost of installing, maintaining, and monitoring certain water treatment systems. During most of the second quarter of 2020, testing of drinking water wells and water treatment system installations were temporarily suspended in connection with health and safety precautions taken during the COVID-19 pandemic. ~~We resumed residential sampling and installation of water treatment systems in June 2020.~~ Off-site installation, maintenance, and monitoring may be impacted by additional changes in estimates as actual experience may differ from management’s estimates. Specific to our on-site and plant remediation at Fayetteville, we accrued $176 million and $182 million during the three and six months ended June 30, 2021, respectively.

During the 20th century, blasting caps, fuses, and related materials were manufactured at Pompton Lakes, Passaic County, New Jersey. Operating activities at the site were ceased in the mid-1990s. The primary contaminants in the soil and sediments are lead and mercury. Groundwater contaminants include volatile organic compounds. Under the authority of the EPA and the New Jersey Department of Environmental Protection (“NJ DEP”), remedial actions at the site are focused on investigating and cleaning-up the area. Groundwater monitoring at the site is ongoing, and we have installed and continue to install vapor mitigation systems at residences within the groundwater plume. In addition, we are further assessing groundwater conditions. In September 2015, the EPA issued a modification to the site’s RCRA permit that requires us to dredge mercury contamination from a 36-acre area of the lake and remove sediment from two other areas of the lake near the shoreline. The remediation activities commenced when permits and implementation plans were approved in May 2016, and work on the lake dredging project is now complete. In April 2019, we submitted a revised Corrective Measures Study (“CMS”) proposing actions to address on-site soils impacted from past operations that exceed applicable clean-up criteria. We received comments on the CMS from the EPA and NJ DEP in March 2020, and we responded to their comments in June 2020.

The U.S. Smelter and Lead Refinery, Inc. (“USS Lead”) Superfund site is located in the Calumet neighborhood of East Chicago, Lake County, Indiana. The site includes the former USS Lead facility along with nearby commercial, municipal, and residential areas. The primary compounds of interest are lead and arsenic which may be found in soils within the impacted area. The EPA is directing and organizing remediation on this site, and we are one of a number of parties working cooperatively with the EPA on the safe and timely completion of this work. ~~DuPont’s~~EID’s former East Chicago manufacturing facility was located adjacent to the site, and ~~DuPont~~EID assigned responsibility for the site to us in the Separation agreement.

The USS Lead Superfund site was listed on the National Priorities List in 2009. To facilitate negotiations with PRPs, the EPA divided the residential part of the USS Lead Superfund site into three zones, referred to as Zone 1, Zone 2, and Zone 3. The division into three zones resulted in Atlantic Richfield Co. (“Atlantic Richfield”) and ~~DuPont~~EID entering into an agreement in 2014 with the EPA and the State of Indiana to reimburse the EPA’s costs to implement clean-up in Zone 1 and Zone 3. More recently, in March 2017, we and three other parties – Atlantic Richfield, ~~DuPont,~~EID, and the U.S. Metals Refining Co. (“U.S. Metals”) – entered into an administrative order on consent to reimburse the EPA’s costs to clean-up a portion of Zone 2. In March 2018, the EPA issued a Unilateral Administrative Order for the remainder of the Zone 2 work to five parties, including us, Atlantic Richfield, ~~DuPont,~~EID, U.S. Metals, and USS Lead Muller Group, and these parties entered into an interim allocation agreement to perform that work. As of the end of 2019, the required work in Zone 3 has been completed, and Zone 2 iswas nearly ~~complete. There is uncertainty as to whether these parties will be able to agree on~~complete by the end of 2020. The determination of a final allocation for Zone 2 and/or the other Zones is ongoing, and ~~whether any~~ additional PRPs may be identified.

The environmental accrual for USS Lead continues to include completion of the remaining obligations under the 2012 Record of Decision (“ROD”) and Statement of Work, which principally encompasses completion of Zone 1. The EPA released a proposed amendment to the 2012 ROD (the “ROD Amendment”) for a portion of Zone 1 in December 2018 (following its August 2018 Feasibility Study Addendum), with its recommended option based on future residential use. The EPA’s ROD Amendment for modified Zone 1 was released in March 2020, and selects as the preferred remedy one which requires a clean-up to residential standards based on the current applicable residential zoning. The ROD Amendment for modified Zone 1 also sets forth a selected contingent remedy which requires clean-up to commercial/industrial standards if the future land use becomes commercial/industrial. In November 2019, a Letter of Intent was executed by the City of East Chicago, Indiana and Industrial Development Advantage, LLC, relating to modified Zone 1 development, and the EPA has indicated that it is “more likely” that future land use in this area will be commercial/industrial and not residential. During the three months ended June 30, 2021, we accrued an additional $3 million based on a remediation estimate provided by Industrial Development Advantage, LLC. We expect that our future costs for modified Zone 1 will be further contingent on the development of this area and implementation under the ROD Amendment, as well as any final allocation between PRPs.

In March 2019, the NJ DEP issued two Directives and filed four lawsuits against Chemours and other defendants. Further discussion related to these matters is included in “Note 1715 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

In 2018, we issued our inaugural Corporate Responsibility Commitment Report, which expresses our Corporate Responsibility Commitment – an extension of our growth strategy – asthrough 10 ambitious goals targeted for completion by 2030. In April 2021, we announced an update to our climate goals to better align our climate commitment with the Paris Accord and set us on a path to achieve net zero greenhouse gas emissions from our operations by 2050. Built on the principles of inspired people, shared planet, and an evolved portfolio, our shared planet principle underlines our commitment to deliver essential solutions responsibly, without causing harm to the Earth. With a focus on the responsible treatment of climate, water, and waste, our shared planet 2030 goals are comprised of the following:

WeThese goals are ~~committed~~designed to ~~improving~~promote accountability to our ~~resource efficiency, acting on opportunities to reduce our GHG emissions, enhancing the eco-efficiency of our supply chain,~~commitment and ~~encouraging our employees to reduce their own environmental footprints.~~position us for sustainable, long-term earnings growth. We understand that maintaining safe, sustainable operations has an impact on us, our communities, the environment, and our collective future. WeWith this focus, we continue to enhance emission control technologies at our manufacturing sites, drive energy efficiency improvements across our operations, and pursue opportunities to power our operations with low carbon or renewable energy sources. We invest in research and development in order to develop safer, cleaner, and more efficient products and processes that ~~help~~enable our operations, customers, and consumers to reduce both their ~~GHGs~~GHG emissions, carbon footprint, and ~~their~~ overall environmental footprint. We value collaboration to drive change and commit to working with policymakers, our value chain, and other organizations to encourage collective action to reduce GHG emissions and encourage lower-carbon forms of energy.

Consistent with our Corporate Responsibility Commitment, we believe that climate change is an important global issue that presents both opportunities and challenges for ~~reducing GHGs.~~our company, our partners, and our communities. Climate change matters for our company are likely to be driven by changes in physical climate parameters, regulations and/or public policy, and changes in technology and product demand. Our operations and business results are increasingly subject to evolving climate-related legislation and regulations. Our business segments conduct market trend impact assessments, continuously evaluate opportunities for existing and new products and offerings, and are well-positioned to take advantage of opportunities that may arise from increased consumer demand for and/or legislation mandating or incentivizing the use of products and technologies necessary to achieve a low-carbon economy.

As an energy and emissions intensive company, our costs of complying with complex environmental laws, regulations, and enforcements, as well as internal and external voluntary programs, are significant and will continue to be significant for the foreseeable future. These laws, regulations, and enforcements may change and could become more stringent over time. Additionally, significant regional or national differences in approaches to the imposition of such regulations and restrictions could present competitive challenges in a global marketplace. Furthermore, the recent change in the U.S. political administration could lead to additional federal regulation with respect to GHG emissions limits and/or other legislation that could impact our operations. By tracking and taking action to reduce our GHG emissions footprint through energy efficiency programs and focused GHG management efforts, we can decrease the potential future impact of these regulatory matters.

See our discussion under the heading “PFOA” in “Note 1715 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

OnIn June ~~26,~~ 2019, the Member States Committee of the European Chemicals Agency (“ECHA”) voted to list HFPO Dimer Acid as a Substance of Very High Concern. The vote was based on Article 57(f) – equivalent level of concern having probable serious effects to the environment. This identification does not impose immediate regulatory restriction or obligations, but may lead to a future authorization or restriction of the substance. On September 24, 2019, Chemours filed an application with the EU Court of Justice for the annulment of the decision of ECHA to list HFPO Dimer Acid as a Substance of Very High Concern.

OnIn May ~~11,~~ 2020, ECHA announced that five Member States (Germany, the Netherlands, Norway, Sweden, and Denmark) launched a call for evidence to inform a PFAS restriction proposal. Companies producing or using PFAS, as well as selling mixture or products containing PFAS, were invited to provide input. This call for evidence closed July 31, 2020. Thousands of substances meet the definition of PFAS as outlined in the call for evidence. This very broad definition covers substances with a variety of physical and chemical properties, health and environmental profiles, uses, and benefits. We submitted information on the substances covered by the call for evidence to the Member State competent authority for Germany, which is the Federal Institute for Occupational Safety and Health (“BAuA”).

In May 2020, five European countries began an initiative to restrict the manufacture, placing on the market and use of PFAS in the EU. In this regulatory process, more than 4,000 substances, including F-gases and fluoropolymers are being considered as part of this broad regulatory action. On July 15, 2021, the countries submitted their restriction proposal, which informs ECHA of the intent to prepare a PFAS restriction dossier for fluorinated substances within a defined structural formula scope, including branched fluoroalkyl groups and substances containing ether linkages, fluoropolymers and side chain fluorinated polymers. The restriction dossier will include information on hazards and risks, available information on alternatives and an analysis of the risk management instrument for addressing the identified risks. The submitting countries indicate that they expect to submit the restriction dossier to ECHA in July 2022. As part of the preparation of the restriction dossier, stakeholders were requested to provide relevant information and, based on risk and socio-economic information, derogations from the proposed restriction may be proposed by the submitting countries. If a derogation is not proposed by the submitting countries, the relevant stakeholders may do so during a consultation process. The draft dossier will be reviewed by the ECHA committees RAC (Risk Assessment Committee) and SEAC (Socio-economic Analysis Committees) and proposals submitted to the EU Commission in 2023. The estimated entry into force of restrictions is 2025. The impacts of restrictions and regulatory measures could lead to adverse effects on our results of operations, financial condition, and cash flows.

In May 2019, we filed a lawsuit in Delaware Chancery Court (“Chancery Court”) against ~~DowDuPont, Inc.,~~Dupont, Corteva, ~~Inc.,~~ and ~~DuPont~~EID concerning ~~DuPont’s~~EID’s contention that it is entitled to unlimited indemnity from us for specified liabilities that ~~DuPont~~EID assigned to us in the spin-off. The lawsuit ~~requests that the Chancery Court enter~~requested a declaratory ~~judgment~~judgement limiting ~~DuPont’s~~EID’s indemnification rights against us and the transfer of liabilities to us to the actual “high-end (maximum) realistic exposures” it stated in connection with the spin-off, or, in the alternative, requiring the return of the approximate $4$4.0 billion dividend ~~DuPont~~EID extracted from us in connection with the spin-off. In March 2020, the Chancery Court granted ~~DuPont’s~~EID’s Motion to Dismiss, placing the matter in non-public binding arbitration. ~~We have appealed the ruling to~~The dismissal was affirmed by the Delaware Supreme ~~Court, which has set argument~~ ~~en banc~~ ~~for December 2, 2020. Pending~~Court. In January 2021, the ~~result of~~parties entered into a binding MOU, addressing the ~~appeal,~~allegations in the ~~matter is proceeding concurrently in~~lawsuit and arbitration. ~~DuPont has asserted a counterclaim for breach of the Master Separation Agreement. Management believes that the probability of loss as~~Pursuant to the ~~counterclaim is remote.~~MOU, the parties have agreed to dismiss the arbitration. Many of the potential litigation liabilities discussed in ~~“Note 17~~“Note 15 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statementsare ~~at issue~~included in the ~~matter.~~

We prepare our interim consolidated financial statements in accordance with generally accepted accounting principles in the U.S. (“GAAP”). To supplement our financial information presented in accordance with GAAP, we provide the following non-GAAP financial measures – Adjusted EBITDA, Adjusted Net Income, Adjusted Earnings per Share (“EPS”), Free Cash Flows (“FCF”), ~~and~~ Return on Invested Capital (“ROIC”), and Net Leverage Ratio – in order to clarify and provide investors with a better understanding of our performance when analyzing changes in our underlying business between reporting periods and provide for greater transparency with respect to supplemental information used by management in its financial and operational decision-making. We utilize Adjusted EBITDA as the primary measure of segment profitability used by our CODM.

Adjusted EBITDA is defined as income (loss) before income taxes, excluding the following:

Adjusted Net Income is defined as our net income (loss), adjusted for items excluded from Adjusted EBITDA, except interest expense, depreciation, amortization, and certain provision for (benefit from) income tax amounts. Adjusted EPS is calculated by dividing Adjusted Net Income by the weighted-average number of our common shares outstanding. Diluted Adjusted EPS accounts for the dilutive impact of our stock-based compensation awards, which includes unvested restricted shares. FCF is defined as our cash flows provided by (used for) operating activities, less purchases of property, plant, and equipment as shown in our consolidated statements of cash flows. ROIC is defined as Adjusted Earnings before Interest and Taxes (“EBIT”), divided by the average of our invested capital, which amounts to our net debt, or debt less cash and cash equivalents, plus equity. Net Leverage Ratio is defined as our total debt principal, net, or our total debt principal outstanding less cash and cash equivalents, divided by Adjusted EBITDA.

We believe the presentation of these non-GAAP financial measures, when used in conjunction with GAAP financial measures, is a useful financial analysis tool that can assist investors in assessing our operating performance and underlying prospects. This analysis should not be considered in isolation or as a substitute for analysis of our results as reported under GAAP. In the future, we may incur expenses similar to those eliminated in this presentation. Our presentation of Adjusted EBITDA, Adjusted Net Income, Adjusted EPS, FCF, ROIC, and ~~ROIC~~Net Leverage Ratio should not be construed as an inference that our future results will be unaffected by unusual or infrequently occurring items. The non-GAAP financial measures we use may be defined differently from measures with the same or similar names used by other companies. This analysis, as well as the other information provided in this Quarterly Report on Form 10-Q, should be read in conjunction with the Interim Consolidated Financial Statements and notes thereto included in this report, as well as the Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~

The following table sets forth a reconciliation of ~~Adjusted EBITDA,~~our net income (loss) attributable to Chemours to Adjusted Net Income, Adjusted EBITDA, and Adjusted EPS ~~to our net income attributable to Chemours~~ for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Three Months Ended September 30,						Nine Months Ended September 30,						Three Months Ended June 30,						Six Months Ended June 30,
(Dollars in millions, except per share amounts)	2020			2019			2020			2019			2021			2020			2021			2020
Net income attributable to Chemours	$	76		$	76		$	200		$	265		$	66		$	24		$	161		$	124
Non-operating pension and other post-retirement employee benefit (income) cost		(1	)		1			(2	)		(5	)
Exchange losses (gains), net		9			(5	)		28			(2	)
Non-operating pension and other post-retirement employee benefit income														(2	)		(1	)		(5	)		(1	)
Exchange (gains) losses, net														(3	)		(6	)		5			19
Restructuring, asset-related, and other charges (1)		9			34			37			49			5			17			—			28
Gain on sales of assets and businesses ~~(2)~~		—			(9	)		—			(11	)		(2	)		—			(2	)		—
Natural disasters and catastrophic events (2)														3			—			19			—
Transaction costs		—			—			2			1			—			—			5			2
Legal and environmental charges (3)		1			5			12			43
Adjustments made to income taxes (4)		(10	)		3			(32	)		5
Benefit from income taxes relating to reconciling items (5)		(6	)		(7	)		(19	)		(18	)
Legal and environmental charges (3,4)														195			1			208			12
Adjustments made to income taxes (5)														(10	)		(2	)		(10	)		(22	)
Benefit from income taxes relating to reconciling items (6)														(47	)		(3	)		(58	)		(13	)
Adjusted Net Income		78			98			226			327			205			30			323			149
Interest expense, net		53			53			160			156			47			53			97			107
Depreciation and amortization		79			78			240			232			79			82			163			160
All remaining provision for income taxes		—			19			7			78			35			1			51			7
Adjusted EBITDA	$	210		$	248		$	633		$	793		$	366		$	166		$	634		$	423

Weighted-average number of common shares outstanding - basic		164,762,621			163,815,483			164,556,139			165,254,084			166,168,550			164,648,103			165,912,089			164,448,226
Dilutive effect of our employee compensation plans		1,851,050			1,325,380			1,209,143			2,780,874			3,989,453			765,838			3,693,498			888,190
Weighted-average number of common shares outstanding - diluted		166,613,671			165,140,863			165,765,282			168,034,958			170,158,003			165,413,941			169,605,587			165,336,416

Per share data
Basic earnings per share of common stock	$	0.46		$	0.46		$	1.22		$	1.60		$	0.40		$	0.15		$	0.97		$	0.75
Diluted earnings per share of common stock		0.46			0.46			1.21			1.58			0.39			0.15			0.95			0.75
Adjusted basic earnings per share of common stock		0.47			0.60			1.37			1.97			1.23			0.18			1.95			0.91
Adjusted diluted earnings per share of common stock		0.47			0.59			1.36			1.94			1.20			0.18			1.90			0.90

The following table sets forth a reconciliation of ~~FCF to~~ our cash flows provided by (used for) operating activities to FCF for the ~~nine~~six months ended ~~September~~June 30, ~~2020~~2021 and ~~2019.~~2020.

	Nine Months Ended September 30,						Six Months Ended June 30,
(Dollars in millions)	2020			2019			2021			2020
Cash provided by operating activities	$	454		$	250		$	295		$	155
Less: Purchases of property, plant, and equipment(1)		(214	)		(385	)		(127	)		(167	)
Free Cash Flows	$	240		$	(135	)	$	168		$	(12	)

The following table sets forth a reconciliation of ~~ROIC to~~ Adjusted EBIT and average invested capital, and their nearest respective GAAP measures, to ROIC for the periods presented.

	Twelve Months Ended September 30,						Twelve months Ended June 30,
(Dollars in millions)	2020			2019			2021			2020
Adjusted EBITDA (1)	$	860		$	1,134		$	1,090		$	898
Less: Depreciation and amortization (1)		(318	)		(303	)		(321	)		(315	)
Adjusted EBIT	$	542		$	831		$	769		$	583

	As of September 30,						As of June 30,
(Dollars in millions)	2020			2019			2021			2020
Total debt	$	4,095		$	4,156		$	3,989		$	4,346
Total equity		734			843			900			659
Less: Cash and cash equivalents		(956	)		(694	)		(1,139	)		(1,031	)
Invested capital, net	$	3,873		$	4,305		$	3,750		$	3,974
Average invested capital (2)	$	4,009		$	4,094		$	3,834		$	4,116

Return on Invested Capital		14	%		20	%		20	%		14	%

The following table sets forth a reconciliation of our total debt principal, cash and cash equivalents, and Adjusted EBITDA to Net Leverage Ratio.

We are exposed to changes in foreign currency exchange rates because of our global operations. As a result, we have assets, liabilities, and cash flows denominated in a variety of foreign currencies. We also have variable rate indebtedness, which subjects us to interest rate risk. Additionally, we are also exposed to changes in the prices of certain commodities that we use in production. Changes in these rates and commodity prices, which may be further exacerbated by the impacts of COVID-19 and the associated volatility in the broader financial markets, may have an impact on our future cash flows and earnings. We manage these risks through our normal operating and financing activities and, when deemed appropriate, through the use of derivative financial instruments. We do not enter into derivative financial instruments for trading or speculative purposes.

By using derivative financial instruments, we are subject to credit and market risk. The fair values of the derivative financial instruments are determined by using valuation models whose inputs are derived using market observable inputs, and reflect the asset or liability position as of the end of each reporting period. When the fair value of a derivative contract is positive, the counterparty owes us, thus creating a receivable risk for us. We are exposed to counterparty credit risk in the event of non-performance by counterparties to our derivative agreements. We minimize counterparty credit (or repayment) risk by entering into transactions with major financial institutions of investment grade credit ratings.

Our risk management programs and the underlying exposures are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the changes in the value of the underlying exposures. See “Note 19 – Financial Instruments” to the Interim Consolidated Financial Statements for further information.

We enter into foreign currency forward contracts to minimize the volatility in our earnings related to foreign exchange gains and losses resulting from remeasuring our monetary assets and liabilities that are denominated in non-functional currencies, and any gains and losses from the foreign currency forward contracts are intended to be offset by any gains or losses from the remeasurement of the underlying monetary assets and liabilities. These derivatives are stand-alone and, except as described below, have not been designated as a hedge. At ~~September~~June 30, ~~2020,~~2021, we had 2014 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of ~~$528~~$350 million, the fair value of which amounted to ~~less than~~negative $1 million. At December 31, ~~2019,~~2020, we had 1625 foreign currency forward contracts outstanding with an aggregate gross notional U.S. dollar equivalent of ~~$530~~$688 million, the fair value of which amounted to ~~less than $1~~$3 million. We recognized a net gain of $9 million and a net loss of $11 million for the three and six months ended June 30, 2021, respectively, and net gains of $10 million and ~~$14~~$4 million for the three and ~~nine~~six months ended ~~September~~June 30, 2020, ~~respectively, and net gains of $1 million and less than $1 million for the three and nine months ended September 30, 2019,~~ respectively, within other income (expense), net related to our non-designated foreign currency forward contracts.

We enter into certain qualifying foreign currency forward contracts under a cash flow hedge program to mitigate the risks associated with fluctuations in the euro against the U.S. dollar for forecasted U.S. dollar-denominated inventory purchases in certain of our international subsidiaries that use the euro as their functional currency. At ~~September~~June 30, ~~2020,~~2021, we had ~~117~~156 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of ~~$86~~$119 million, the fair value of which amounted to ~~negative $2~~$1 million. At December 31, ~~2019,~~2020, we had ~~150~~144 foreign currency forward contracts outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of ~~$124~~$101 million, the fair value of which amounted to $1negative $4 million. We recognized a pre-tax ~~losses~~loss of $2$1 million and a pre-tax gain of $3 million for the three and six months ended June 30, 2021, respectively, and pre-tax loss of $1 million and a pre-tax gain of $1 million for the three and ~~nine~~six months ended ~~September~~June 30, 2020, ~~respectively, and pre-tax gains of $5 million and $7 million for the three and nine months ended September 30, 2019,~~ respectively, within accumulated other comprehensive loss. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, $1 million and $5$3 million of ~~gain~~loss was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively. For the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, $2 million and $8$3 million of gain was reclassified to the cost of goods sold from accumulated other comprehensive loss, respectively.

~~Beginning in the second quarter of 2020, we elected to expand our cash flow hedge program and enter into interest rate swaps,~~ ~~which are used to mitigate the volatility in our cash payments for interest due to fluctuations in the~~ ~~London Interbank Offered Rate (“LIBOR”), as is applicable to the portion of our senior secured term loan facility denominated in U.S. dollars~~. At September 30, 2020, we had three interest rate swaps outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of $400 million, the fair value of which amounted to negative $3 million. We recognized pre-tax losses of less than $1 million and $3 million for the three and nine months ended September 30, 2020, respectively, within accumulated other comprehensive loss. For the three and nine months ended September 30, 2020, less than $1 million of loss was reclassified to interest expense, net from accumulated other comprehensive loss.

We designated our euro-denominated debt as a hedge of our net investment in certain of our international subsidiaries that use the euro as their functional currency in order to reduce the volatility in stockholders’ equity caused by changes in foreign currency exchange rates of the euro with respect to the U.S. dollar. We recognized a pre-tax ~~losses~~loss of ~~$32~~$13 million and ~~$40~~a pre-tax gain of $24 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2020,~~2021, respectively, and pre-tax ~~gains~~losses of ~~$33~~$18 million and ~~$36~~$8 million for the three and ~~nine~~six months ended ~~September~~June 30, ~~2019,~~2020, respectively, on our net investment hedge within accumulated other comprehensive loss.

Our risk management programs and the underlying exposures are closely correlated, such that the potential loss in value for the risk management portfolio described above would be largely offset by the changes in the value of the underlying exposures. See “Note 19 – Financial Instruments” to the ~~Interim Consolidated Financial Statements~~ ~~for further information.~~

We enter into interest rate swaps under our cash flow hedge program, which are used to mitigate the volatility in our cash payments for interest due to fluctuations in the London Interbank Offered Rate (“LIBOR”), as is applicable to the portion of our senior secured term loan facility denominated in U.S. dollars. At June 30, 2021, we had three interest rate swaps outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of $400 million, the fair value of which amounted to negative $2 million. At December 31, 2020, we had three interest rate swaps outstanding under our cash flow hedge program with an aggregate notional U.S. dollar equivalent of $400 million, the fair value of which amounted to negative $3 million. We recognized a pre-tax loss of less than $1 million and a pre-tax gain of less than $1 million for the three and six months ended June 30, 2021, and pre-tax losses of $3 million for the three and six months ended June 30, 2020, within accumulated other comprehensive loss. For the three and six months ended June 30, 2021, $1 million of loss was reclassified to interest expense, net from accumulated other comprehensive loss. No amounts were reclassified from accumulated other comprehensive loss for interest rate swaps during the three and six months ended June 30, 2020.

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Securities Exchange Act of 1934 (“Exchange Act”) is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the U.S. Securities and Exchange Commission (“SEC”). These controls and procedures also provide reasonable assurance that information required to be disclosed in such reports is accumulated and communicated to management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), to allow timely decisions regarding required disclosures.

As of ~~September~~June 30, ~~2020,~~2021, our CEO and CFO, together with management, conducted an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rule 13a-15(e) under the Exchange Act. Based on that evaluation, the CEO and CFO have concluded that these disclosure controls and procedures are effective at the reasonable assurance level.

There have been no changes in our internal control over financial reporting that occurred during the quarter ended ~~September~~June 30, ~~2020~~2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

We are subject to various legal proceedings, including, but not limited to, product liability, intellectual property, personal injury, commercial, contractual, employment, governmental, environmental, anti-trust, and other such matters that arise in the ordinary course of business. Information regarding certain of these matters is set forth below and in “Note 1715 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements. We have excluded matters that we expect to result in sanctions of less than $1 million, if any.

For purposes of this report, the term “PFOA” means, collectively, perfluorooctanoic acid and its salts, including the ammonium salt, and does not distinguish between the two forms. The term “PFAS” means per- and polyfluoroalkyl substances. Information related to ~~this~~these and other litigation matters is included in “Note 1715 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

Actions related to our Fayetteville Works site in Fayetteville, North Carolina (“Fayetteville”), as discussed in “Note 1715 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements, other than those by the State of North Carolina, are shown below.

The U.S. Environmental Protection Agency (“EPA”) conducted a multimedia inspection at the DuPont LaPorte, Texas facility in January 2008. DuPont, the EPA, and the U.S. Department of Justice began discussions in the fall of 2011 relating to the management of certain materials in the facility’s waste water treatment system, hazardous waste management, flare, and air emissions. These negotiations continue. We operate a fluoroproducts production facility at this site.

~~A Proposed Consent Agreement and Final Order (“CAFO”) was received from the EPA in January 2020, alleging Clean Air Act (“CAA”) Section 112(r) violations at the LaPorte, Texas site.The alleged violations are under the CAA’s chemical accident prevention provisions (40 CFR Part 68), and the EPA states that it is seeking a civil penalty of $0.6 million for negotiation purposes.We have reviewed the draft CAFO and the alleged violations, and have responded to the EPA. At this time, we believe a loss is probable and is currently estimated at $0.2 million.~~

We have complied with requests from the local environmental agency (“DCMR”, formerly under the jurisdiction of “OZHZ”), the Labor Inspectorate (“iSZW”), the Inspectorate for Environment and Transportation (“ILT”), and the Water Authority (“RWS”) in the Netherlands for information and documents regarding the Dordrecht site’s operations. We have complied with the requests, and the agencies have published several reports between 2016 and 2019, all of them publicly available. The National Institute for Public Health and the Environment (“RIVM”) has also published several reports with respect to PFOA and the polymerization processing aid hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid”, sometimes referred to as “GenX” or “C3 Dimer Acid”). InBetween December 2018 and March 2019, DCMR imposed ~~a €1~~several fines, aggregating to an amount of €1.75 million, ~~fine~~ after ~~undertaking~~performing waste water tests ~~which~~that detected low levels of legacy PFOA. ~~DCMR continued taking samples and has imposed three additional fines between January and May 2019, each of which was €0.25 million.~~ We have appealed ~~all~~ the fines, and ~~we believe~~judgement was rendered on December 16, 2020. The court stated that ~~we have valid defenses to prevail. We continue to cooperate with all authorities in responding to information requests.~~Chemours did not deliberately discharge waste water containing PFOA and ruled that DCMR must reimburse Chemours for 50% of the collected fines, plus court and legal fees.

In May 2020, we were notified of an alleged criminal offense related to the Netherlands’ Environmental Management Act and the Working Conditions Decree, regarding the use of PFOA during the pre-spin time period of June 1, 2008 to December 31, 2012. The investigation was initiated in the first quarter of 2016 by a public prosecutor. We believe that the Company has complied with all relevant laws, and we are in contact with the prosecutor.

In October 2019, we received a $0.15 million fine from the Federal Rail Administration (“FRA”) based on the results of an investigation of our Antimony Pentachloride railcar shipments, fleet, commodity code accuracy, and condition of valves. We are continuing to investigate this matter and have submitted a response to the FRA in December 2019.

In February 2019, we received a Notice of Violation (“NOV”) from the EPA, alleging certain Toxic Substances Control Act (“TSCA”) violations at Fayetteville. Matters raised in the NOV could have the potential to affect operations at Fayetteville. For this NOV, we responded to the EPA in March 2019, asserting that we have not violated environmental laws. We also received an NOV in April 2020 from the North Carolina Department of Environmental Quality (“NC DEQ”), alleging an air permit violation under the North Carolina Administrative Code. At this time, management does not believe that a loss is probable related to the matters in these NOVs. Further discussion related to these matters is included in “Note 1715 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements.

Except for the updated risk factor set forth below, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the year ended December 31, ~~2019.~~2020.

~~A pandemic, epidemic,~~We are subject to extensive environmental health and safety laws and regulations that may result in unanticipated loss or ~~other outbreak of infectious disease~~liability related to our current or past operations, and that may ~~have a material adverse effect on~~result in significant additional compliance costs or obligations, which in either case, could reduce our ~~business operations, results of operations, financial condition, and cash flows.~~profitability.

Our ~~operational~~operations and ~~financial condition may be negatively impacted by the widespread outbreak~~production facilities are dependent upon attainment and renewal of ~~any illnesses or communicable diseases, as well as any associated public~~requisite operating permits and are subject to extensive environmental and health ~~crises that may ensue. In December 2019, a novel coronavirus disease (“COVID-19”) was identified~~and safety laws, regulations, and enforcements at national, international, and local levels in ~~Wuhan, China. COVID-19 has continued~~numerous jurisdictions, relating to ~~spread globally, including areas in which we operate and sell our products. In March 2020, the World Health Organization declared COVID-19 a global pandemic, and the President~~pollution, protection of the ~~United States declared the COVID-19 outbreak a national emergency. Since the initial stages~~environment, climate change, transporting and storing raw materials and finished products, storing and disposing of ~~the pandemic, certain economies in regions throughout the world have started to reopen; however, certain of these regions have also seen further spread~~hazardous wastes, and ~~even resurgences in the number of positively identified infections. Particularly in the Americas~~product content and ~~Europe, infections have continued to spread, leading to health-related concerns in regions where we have several key manufacturing facilities.~~ In an attempt to minimize the transmission of COVID-19, significant social and economic restrictions have been imposed throughout the U.S. and abroad, including travel bans, quarantines, restrictions on public gatherings, shelter-in-place orders, and/or safer-at-home orders. These restrictions, while necessary and important for public health, have negative business-related implications for the Company and the U.S. and global economies.

~~Throughout 2020,~~ the COVID-19 pandemic has negatively impacted the global economy, disrupting global supply chains and creating significant uncertainty and volatility in financial markets. As of the filing of this Quarterly Report on Form 10-Q, we continue to experience minimal disruption in our operations and business-related processes. However, due to reduced consumer demand for certain of our customers’ end-products, we have experienced the negative impact of COVID-19 in our results of operations, and we anticipate that this weakened consumer demand will continue to have a negative impact on our financial results. ~~See~~ ~~Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations~~ ~~in this Quarterly Report on Form 10-Q for further information.~~ ~~We are closely monitoring the effects of the COVID-19~~pandemic on all aspects of our business, including its adverse impacts on our employees, customers, suppliers, vendors, business partners, and supply and distribution channels, as well as our ability to execute our business strategies and objectives. As a multi-national corporation, we are also closely monitoring the operational and financial impacts of recently introduced restrictive local and nationalother safety concerns. Such laws ~~and regulations, as well as recommendations set forth by public health organizations and governmental organizations to impede the spread of COVID-19.~~

~~The extent to which the COVID-19~~pandemic will continue to adversely impact our Company depends on currently evolving factors, as well as future developments that we are not able to predict with certainty. Such factors and potential developments may include, but are not limited to:

If we are found to be in violation of these laws, regulations, or enforcements, which may be subject to change based on legislative, scientific, or other factors, we may incur substantial costs, including fines, damages, criminal or civil sanctions, remediation costs, reputational harm, loss of sales or market access, or experience interruptions in our operations. We also may be subject to changes in our operations and production based on increased regulation or other changes to, or restrictions imposed by, any such additional regulations. Any operational interruptions or plant shutdowns may result in delays in production or may cause us to incur additional costs to develop redundancies in order to avoid interruptions in our production cycles. In addition, the manner in which adopted regulations (including environmental and safety regulations) are ultimately implemented may affect our products, the demand for and public perception of our products, the reputation of our brands, our market access, and our results of operations. In the event of a catastrophic incident involving any of the raw materials we use or chemicals we produce, we could incur material costs as a result of addressing the consequences of such event and future reputational costs associated with any such event.

Our costs of ~~any illness or communicable disease~~complying with complex environmental laws, regulations, and enforcements, as well as internal and external voluntary programs, are significant and will continue to be significant for the foreseeable future. These laws, regulations, and enforcements may change and could become more stringent over time, which could result in significant additional compliance costs, increased costs of purchased energy or other raw materials, increased transportation costs, investments in, or restrictions on, our operations, installation or modification of GHG-emitting equipment, or additional costs associated with GHG emissions. As a result of our current and historic operations, including the operations of divested businesses and certain discontinued operations, we also expect to continue to incur costs for environmental investigation and remediation activities at a number of our current or former sites and third-party disposal locations. However, the ultimate costs under environmental laws and the timing of these costs are difficult to accurately predict. While we establish accruals in accordance with U.S. generally accepted accounting principles (“GAAP”), the ultimate actual costs and liabilities may vary from the accruals because the estimates on which the accruals are based depend on a number of factors (many of which are outside of our control), including the nature of the matter and any associated third-party claims, the complexity of the site, site geology, the nature and extent of contamination, the type of remedy, the outcome of discussions with regulatory agencies and other Potentially Responsible Parties (“PRPs”) at multi-party sites, and the number and financial viability of other PRPs. Refer to “Environmental Matters” within Item 2 – Management’s Discussion and Analysis of Financial Condition and Results of Operations and “Note 15 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements for further information. We also could incur significant additional costs as a result of additional contamination that is discovered or remedial obligations imposed in the ~~instance~~future.

As discussed in “Note 15 – Commitments and Contingent Liabilities” to the Interim Consolidated Financial Statements, we continue to have active dialogue with the North Carolina Department of Environmental Quality (“NC DEQ”) and other stakeholders regarding potential remedies that are both economically and technologically feasible to achieve the objectives of the ~~COVID-19 pandemic has resulted in, a significant health crisis that adversely affects local~~Consent Order (“CO”) and ~~global economies and financial markets, including the companies that operate within these conditions. Each of the above considerations~~Addendum (“Addendum”) related to the ~~COVID-19 pandemic remain highly uncertain~~discharge of hexafluoropropylene oxide dimer acid (“HFPO Dimer Acid,” sometimes referred to as “GenX” or “C3 Dimer Acid”) and ~~subject~~other per- and polyfluoroalkyl substances (“PFAS”) from our Fayetteville Works site in North Carolina (“Fayetteville”) into the Cape Fear River, site surface water, groundwater, and air emissions. The Addendum establishes the procedure to implement specified remedial measures for reducing PFAS loadings from Fayetteville to the Cape Fear River, including construction of a barrier wall with a groundwater extraction system to be completed by March 15, 2023. The estimated liabilities of achieving the CO and Addendum objectives consist of several components, each of which may vary significantly and may exceed the current estimates. The final cost of the on-site barrier wall and groundwater treatment system primarily depends on receiving timely NC DEQ design and permit approvals and thus the timely finalization of certain significant design details, notably the actual barrier wall location, depth, and length, number and configuration of extraction wells, water extraction rates and estimated carbon usage. Unanticipated schedule delays or other factors beyond our control could lead to further increases in the cost of the barrier wall, which could be material. Changes in estimates are recorded in results of operations in the period that the events and circumstances giving rise to such changes occur.

There is also a risk that one or more of our manufacturing processes, key raw materials, or products may be found to have, or be characterized or perceived as having, a toxicological or health-related impact on the environment or on our customers or employees or unregulated emissions, which could potentially result in our incurring liability in connection with such characterization and the associated effects of any toxicological or health-related impact. If such a discovery or characterization occurs, we may incur increased costs in order to comply with new regulatory requirements or as a result of litigation. In addition, the relevant materials or products, including products of our customers incorporating our materials or products, may be recalled, phased-out, or banned. Changes in laws, science, or regulations, or their interpretations, and our customers’ perception of such changes or interpretations may also affect the marketability of certain of our products.

For example, in May 2016, the European Chemicals Agency (“ECHA”) accepted a proposal from France’s competent authority under REACH to change ~~continue~~the classification of TiO₂. ECHA’s Committee for Risk Action (“RAC”) provided the opinion that the evidence meets the criteria under the EU’s Classification, Labeling and Packaging (“CLP”) Regulation to ~~evolve,~~classify TiO₂ as a Category 2 Carcinogen (suspected human carcinogen) by inhalation. To implement this opinion, the EU Commission (“EC”) presented a draft of the full 14^th Adaptation to Technical Progress (“ATP”), including a proposed classification (with notes) for the powder form of TiO₂ as a Category 2 Carcinogen by inhalation, as a delegated act for scrutiny by EU Council and Parliament. The scrutiny period ended in February 2020, with publication to the Official Journal on February 18, 2020. The publication initiated an implementation period, and the act will come into enforcement on October 1, 2021. The impacts of the additional regulatory measures will include increased requirements for TiO₂ product labeling and importing operations. This could increase our costs associated with our TiO₂ manufacturing and handling processes.

In June 2019, the Member States Committee of ECHA also voted to list HFPO Dimer Acid as a Substance of Very High Concern. The vote was based on Article 57(f) – equivalent level of concern having probable serious effects to the environment. This identification does not impose immediate regulatory restriction or obligations, but may lead to a future authorization or restriction of the substance, which could have ~~the potential to have a material~~an adverse ~~impact~~effect on our ~~business operations,~~ results of operations, financial condition, and cash flows. ~~However,~~In September 2019, we ~~cannot predict~~filed an application with ~~certainty~~ the ~~magnitude~~EU Court of ~~such impacts at this time. The impact of COVID-19may also exacerbate our other risks, as described in~~ ~~Item 1A – Risk Factors~~ ~~included in our Annual Report on Form 10-K~~Justice for the ~~year ended December 31, 2019, any~~annulment of the decision of ECHA to list HFPO Dimer Acid as a Substance of Very High Concern.

In May 2020, five European countries began an initiative to restrict the manufacture, placing on the market and use of PFAS in the EU. In this regulatory process, more than 4,000 substances, including F-gases and fluoropolymers are being considered as part of this broad regulatory action. On July 15, 2021, the countries submitted their restriction proposal, which ~~could have~~informs ECHA of the intent to prepare a ~~material effect~~PFAS restriction dossier for fluorinated substances within a defined structural formula scope, including branched fluoroalkyl groups and substances containing ether linkages, fluoropolymers and side chain fluorinated polymers. The restriction dossier will include information on ~~us.~~hazards and risks, available information on alternatives and an analysis of the risk management instrument for addressing the identified risks. The ~~situation continues~~submitting countries indicate that they expect to ~~evolve at~~submit the restriction dossier to ECHA in July 2022. As part of the preparation of the restriction dossier, stakeholders were requested to provide relevant information and, based on risk and socio-economic information, derogations from the proposed restriction may be proposed by the submitting countries. If a ~~rapid pace,~~derogation is not proposed by the submitting countries, the relevant stakeholders may do so during a consultation process. The draft dossier will be reviewed by the ECHA committees RAC (Risk Assessment Committee) and ~~additional~~SEAC (Socio-economic Analysis Committees) and proposals submitted to the EU Commission in 2023. The estimated entry into force of restrictions is 2025. The impacts of ~~which we are not currently aware may also arise.~~

restrictions and regulatory measures could lead to adverse effects on our results of operations, financial condition, and cash flows.

On August 1, 2018, our board of directors approved a share repurchase program authorizing the purchase of shares of our issued and outstanding common stock in an aggregate amount not to exceed $750 million, plus any associated fees or costs in connection with our share repurchase activity (“2018 Share Repurchase Program”). On February 13, 2019, our board of directors increased the authorization amount of the 2018 Share Repurchase Program from $750 million to $1.0 billion. Under the 2018 Share Repurchase Program, shares of our common stock can be purchased on the open market from time to time, subject to management’s discretion, as well as general business and market conditions. Our 2018 Share Repurchase Program became effective on August 1, 2018, was announced to the public on August 2, 2018, and ~~will~~was originally scheduled to continue through the earlier of its expiration on December 31, 2020, or the completion of repurchases up to the approved amount. On December 8, 2020, our board of directors approved the extension of the 2018 Share Repurchase Program through December 31, 2022. The program may be suspended or discontinued at any time. All common shares purchased under the 2018 Share Repurchase Program are expected to be held as treasury stock and accounted for using the cost method.

The following table sets forth the purchases of our issued and outstanding common stock under the 2018 Share Repurchase Program for the three months ended June 30, 2021.

As of ~~September~~June 30, ~~2020,~~2021, under the 2018 Share Repurchase Program, we have purchased a cumulative ~~15,245,999~~15,669,272 shares of our issued and outstanding common stock, which amounted to ~~$572~~$587 million at an average share price of ~~$37.52~~$37.46 per share. ~~There were no share repurchases under the 2018 Share Repurchase Program for the three months ended September 30, 2020.~~ The aggregate amount of our common stock that remained available for purchase under the 2018 Share Repurchase Program at ~~September~~June 30, ~~2020~~2021 was ~~$428~~$413 million.

Information regarding mine safety and other regulatory actions at our surface mines in Starke, Florida, Jesup, Georgia, and ~~Folkston,~~Nahunta, Georgia, as well as our mineral sands separation facility in Offerman, Georgia, is included in Exhibit 95 to this Quarterly Report on Form 10-Q.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Title of Each Class		Trading Symbol(s)		Name of Exchange on Which Registered
Common Stock ($0.01 par value)		CC		New York Stock Exchange

Large Accelerated Filer ☒	Accelerated Filer ☐
Non-Accelerated Filer ☐	Smaller reporting company ☐
	Emerging growth company ☐

		Page
Part I	Financial Information
Item 1.	Interim Consolidated Financial Statements
	Interim Consolidated Statements of Operations (Unaudited)	2
	Interim Consolidated Statements of Comprehensive Income (Unaudited)	3
	Interim Consolidated Balance Sheets (Unaudited)	4
	Interim Consolidated Statements of Stockholders’ Equity (Unaudited)	5
	Interim Consolidated Statements of Cash Flows (Unaudited)	6
	Notes to the Interim Consolidated Financial Statements (Unaudited)	7
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	4148
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	6579
Item 4.	Controls and Procedures	6680

Part II	Other Information
Item 1.	Legal Proceedings	6781
Item 1A.	Risk Factors	6983
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	7186
Item 3.	Defaults Upon Senior Securities	7186
Item 4.	Mine Safety Disclosures	7186
Item 5.	Other Information	7186
Item 6.	Exhibits	7287
Signature		7388


☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934


☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	June 30, 2021		December 31, 2020
Capitalized repair and maintenance costs	$	158	$	198
Pension assets (1)		83		79
Deferred income taxes		145		95
Miscellaneous		28		33
Total other assets	$	414	$	405

	September 30, 2020		December 31, 2019
Asbestos	$	34	$	34
PFOA		21	20
All other matters		4	6
Total accrued litigation	$	59	$	60

	Net Investment Hedge			Cash Flow Hedge			Cumulative Translation Adjustment			Defined Benefit Plans			Total
Balance at January 1, 2021	$	(76	)	$	(8	)	$	(120	)	$	(106	)	$	(310	)
Other comprehensive loss		18			5			(34	)		3			(8	)
Balance at June 30, 2021	$	(58	)	$	(3	)	$	(154	)	$	(103	)	$	(318	)

Balance at January 1, 2020	$	(10	)	$	2		$	(231	)	$	(110	)	$	(349	)
Other comprehensive loss		(6	)		(4	)		(78	)		2			(86	)
Balance at June 30, 2020	$	(16	)	$	(2	)	$	(309	)	$	(108	)	$	(435	)

Three Months Ended September 30,	Fluoroproducts		Chemical Solutions		Titanium Technologies		Segment Total
2020
Net sales to external customers	$	533	$	88	$	612	$	1,233
Adjusted EBITDA		112		12		129		253
Depreciation and amortization		35		6		32		73

2019
Net sales to external customers	$	636	$	140	$	614	$	1,390
Adjusted EBITDA		122		23		137		282
Depreciation and amortization		34		5		30		69

Nine Months Ended September 30,	Fluoroproducts		Chemical Solutions		Titanium Technologies		Segment Total
2020
Net sales to external customers	$	1,657	$	263	$	1,711	$	3,631
Adjusted EBITDA		350		45		361		756
Depreciation and amortization		106		16		95		217

2019
Net sales to external customers	$	2,034	$	404	$	1,735	$	4,173
Adjusted EBITDA		461		55		390		906
Depreciation and amortization		100		18		90		208

(Dollars in millions, except per share amounts)							Approximate Dollar
					Total Number		Value of Shares
	Total Number				of Shares		That May Yet be
	of Shares		Average Price		Purchased as Part of		Purchased Under the
	Purchased		Paid per Share		Publicly Announced		Plans or Programs
Period	(1)		(2)		Plans or Programs		(2)
Month ended April 30, 2021		-	$	-		-	$	428
Month ended May 31, 2021		-		-		-		428
Month ended June 30, 2021		423,273		35.08		423,273		413
Total		423,273	$	35.08		423,273	$	413

Exhibit Number		Description
2.1		Purchase and Sale Agreement, dated as of July 26, 2021, by and between The Chemours Company and Manchester Acquisition Sub LLC (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 26, 2021).

3.1		Company’s Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).

3.2		Company’s Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 1, 2015).

10.1		Employment Transition Agreement between Mark Vergnano and the Company, dated as of June 2, 2021 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on June 3, 2021).

10.2		Settlement Agreement, Limited Release, Waiver and Covenant Not to Sue, dated July 13, 2021, by and among The Chemours Company, Corteva, Inc., E.I. du Pont De Nemours and Company, DuPont de Nemours, Inc, and the State of Delaware (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K, as filed with the U.S. Securities and Exchange Commission on July 13, 2021).

22		List of Guarantor Subsidiaries.

31.1		Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Executive Officer.

31.2		Rule 13a-14(a)/15d-14(a) Certification of the Company’s Principal Financial Officer.

32.1		Section 1350 Certification of the Company’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
32.2		Section 1350 Certification of the Company’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.

95		Mine Safety Disclosures.

101		The following financial statements from the Company’s Quarterly Report on Form 10-Q for the period ended ~~September~~June 30, ~~2020~~2021 have been formatted in Inline XBRL: (i) the Interim Consolidated Statements of Operations (Unaudited); (ii) the Interim Consolidated Statements of Comprehensive Income (Unaudited); (iii) the Interim Consolidated Balance Sheets (Unaudited); (iv) the Interim Consolidated Statements of Stockholders’ Equity (Unaudited); (v) the Interim Consolidated Statements of Cash Flows (Unaudited); and, (vi) the Notes to the Interim Consolidated Financial Statements (Unaudited). These financial statements have been tagged as blocks of text and include detailed tags.

104		The cover page from the Company’s Quarterly Report on Form 10-Q for the period ended ~~September~~June 30, ~~2020,~~2021, which has been formatted in Inline XBRL and included within Exhibit 101.

THE CHEMOURS COMPANY
(Registrant)

Date:	~~November 4, 2020~~July 30, 2021


By:	/s/ Sameer Ralhan

	Sameer Ralhan
	Senior Vice President, Chief Financial Officer
	(As Duly Authorized Officer and Principal Financial Officer)